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Part A. Structure Determination of Bioactive Metabolites from Marine-
Derived Fungi 
Marine natural products have been proven to be a prolific source 
of novel therapeutic agents that have demonstrated significant activities in 
various pathological conditions including cancer, viral infection, 
inflammation, analgesia, and immune modulation. The marine-derived 
fungi is one of the three dominated phylogenetic groups, have shown great 
diversity of their secondary metabolites and a wide range novel secondary 
 II 
metabolites have been isolated since 1980s. Marine-derived fungi alone 
have produced more than 400 novel compounds, of which several have 
exhibited potent and diverse bioactivities. The purpose of this study is to 
investigate new marine natural products from marine-derived fungi and 
study their biological activities. During the course of searching for 
bioactive metabolites from marine-derived fungi, two strains Penicillium 
sp. and Aspergillus sp. were selected for chemical investigation based on 
LC-ESIMS analysis and bioassay screening of the crude extracts. 
Secondary metabolites from the selected fungi were isolated and structure 
determination based on 1D, 2D NMR, and IR, UV, OR and MS. As a 
result, 9 novel compounds and 9 known compounds were structurally 
determined using integrated spectroscopic analysis and chemical 
approaches. These compounds belonged to various structural classes: 
meroterpenoids, alkaloids, anthroquinones, and lipopeptides. The 
biological activities of the isolated compounds were studied on various 
bioactivity tests: cytotoxicity, antimicrobial activities, inhibition against 
the enzymes isocitrate lyase (ICL), sortase A (SrtA) and Na+/K+-ATPase, 
and quinone reductase. Structure-activity relationships were also deduced. 
Part B. Simultaneous Analysis of Herbal Medicines by HPLC-DAD-ELSD-
MS 
 III 
Traditional herbal medicines have been practiced to maintain health 
and treat diseases especially in the Asia communities for more than 2,000 
years. Increment of worldwide attention and concomitant pharmaceutical 
research has made it essential to carry out the quality control measurement 
for the herbal medicines. However, serious hindrance has been attributed to 
the lack of recognition and regulation of professions, qualified practitioners, 
quality-controlled herbal medicines, and evidence-based clinical studies. 
Thus it is urgently needed to establish a comprehensive qualified evaluation 
method that could accurately reflect the quality of herbal medicines. The 
purpose of this study is developing simultaneous analysis methods of 
bioactive compounds in herbal medicines. Two herbal medicines, which are 
Kalopanacis Cortex and Semen Ziziphus jujuba were subjected to the 
current study. In herbal medicines, it is hard to consider that single or a few 
compounds would determine the overall pharmacological activities. Rather, 
it is more likely that multiple compounds act simultaneously and attribute to 
the therapeutic function of the herbal medicine. For this reason, most 
bioactive metabolite in the selected herbal medicines were analyzed and 
determined. In particular, three phenolics and nine hedergenin saponins 
were selected for the analysis of Kalopanacis Cortex. Moreover, one 
alkaloid, five flavonoid saponins and three jujuboside saponins from Semen 
 IV 
Ziziphus jujuba were also analyzed. The methods based on HPLC-DAD-
ELSD-MS was established for the quantitative and qualitative analysis of 
a selected folk medicine. Various validation parameters, such as linearity, 
limit of detection, limit of quantification, recovery, accuracy, and precision, 
were successfully obtained. In addition, the efficiencies of diverse 
extraction methods were compared for the development of a standard 
analytic method. The verified methods were successfully applied to the 
quantitative determination of representative metabolites in commercial 
samples from Korea, Myanmar and China. 
 
Keywords: marine natural products, marine-derived fungi, structure 
determination, herbal medicines, simultaneous analysis 
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Structure Determination of Bioactive Metabolites 





Marine microorganisms are tiny, single-celled organisms that live in 
the ocean and account for more than 98% of ocean biomass. In contrast to the 
terrestrial microorganisms, the environment of marine microorganisms is 
extreme and changeable with the high salinity, high pressure, low oxygen, 
and insufficient light, which made them produce bioactive and structurally 
unique secondary metabolites.1-6 Since late 1990s, the numbers of new 
compounds isolated from the marine microbes increased steeply.7 This trend 
has accelerated in recent years due to both the demand of mass bioactive 
compounds and the technical progress in related field, such as microbial 
genetics and bioinformatics.8 Marine microbes, particularly actinomycete 
bacteria and fungi, produce a wide variety of biologically active and 
structurally unique metabolites.2-6 Hundreds of novel compounds are isolated 
from these organisms annually.7 A wide range of pharmacological activities 
of these compounds as antitumor/anticancer, antimicrobial, antiviral, and 
cytotoxic activities against several cell lines have been reported.6, 10-12 Until 
2010, several compounds from marine microbes are in clinical or preclinical 
studies.13-16  
Marine-derived fungi, as one of the major marine microbes, which is 
 
3 
comprised of marine fungi and facultative species that are found in terrestrial 
ecosystem as well but grow well in the marine environment. Based on the 
sources of the marine-derived fungi, the distribution of taxonomic diversity 
and all compounds isolated has been graphically summarized in Figures 1 and 
2.3, 17 The greatest taxonomic diversity and the largest number compounds 
come from strains derived from sponges (33%). The highest number of novel 
metabolites also come from those isolated from sponges. Marine algae and 
drifting woods come next that is reminiscent of abundance of algaecolous and 












Figure 1. The distribution of compounds from marine-derived fungi by their 







































Figure 2. The distribution of new compounds from marine-derived fungi by 
their sources (or origins).  
 
The marine-derived fungi that have shown great diversity of their 
secondary metabolites and a wide range novel secondary metabolites have 
been isolated since 1980s. The diverse novel bioactive metabolites have been 
reported which show anticancer, antibacterial, antifungal, antiviral, 
antiplasmodial, anti-inflammatory could be beneficial for pharmaceutical 
therapeutics.18  
The representative examples of novel bioactive secondary 




















































Figure 3. Examples of novel bioactive secondary metabolites from marine-
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Figure 3. Examples of novel bioactive secondary metabolites from marine-











Figure 3. Examples of novel bioactive secondary metabolites from marine-
derived fungi.36-38 
The purpose of this thesis is to investigate new marine natural 
products from the marine-derived fungi which were isolated from the marine 
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sediment and marine organisms that mostly were sponges collected from off 
the coast of Korea. 
In this research, several media were used for the isolation of fungi. 
Those media are follows: 
YMM : Mannitol 2 g, malt extract 4 g, yeast extract 2 g, agar 16 g, 
artificial seawater 1 L. 
YPMBFe : Yeast extract 2 g, peptone 2 g, mannitol 4 g, KBr 5 mL/L of 
20 g/L in purified H2O, FePO4 5 mL/L of 8 g/L in purified 
H2O, agar 16 g, artificial seawater 1 L. 
YPM : Yeast extract 2 g, peptone 2 g, mannitol 4 g, crab meal 2 g, 
agar 16 g, artificial seawater 1 L. 
YPM2 : Yeast extract 2 g, peptone 2 g, mannitol 4 g, crab meal 2 
g, calcium carbonate 1 g, agar 16 g, artificial seawater 1 L 
YPG : Yeast extract 5 g, peptone 5 g, glucose 10 g, agar 16 g, 
artificial seawater 1 L. 
MB 2216 : Marine broth 2216 37.4 g, glycerol 20 g, agar 16 g, purified 
H2O 1 L. 
The bacterial inhibitors, penicillin G sodium salt and streptomycin 




During my research for bioactive compounds from marine fungi, in 
total more than 200 fungal strains were isolated from marine sediment and 
marine organisms that mostly isolated from sponges. 
The pure strains were further investigated by performing small scale 
cultivation and extraction for screenings. Strains selection was conducted by 
LC-ESIMS based on the chemical constituents and cytotoxicity towards 
K562 and A549. The selected strains were chosen for a large cultivation and 
isolation of the new compounds. The first strain is F446 which was isolated 
from marine sediment, the LC-ESIMS profile of the extract revealed the 
presence of novel compounds which prompted us to investigate its 
metabolites in detail (Figure 4). And the organic extract showed a mild 
cytotoxicity (LC50 = 192 μg/mL) against the K562 human leukemia cell line. 
The F446 was identified to be Penicillium sp.. The second strain was F452 
which was isolated from marine-submerged decaying wood from Korea, the 
LC-ESIMS profile of the extract revealed the presence of diverse secondary 





[M+ H]+ = 347 
[M- H]- = 345 
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Figure 4. LC-MS profile of the broth extract of strain F446. 
HPLC with C18 (Phenomenex, 5 m, 4.6 x 100 mm), elution by 
H2O-MeCN, gradient (90:10 to 0:100 in 20 min, then 0:100 in 5 








Figure 5. LC-MS profile of the broth extract of strain F452. 
HPLC with C18 (Phenomenex, 5 m, 4.6 x 100 mm), elution by 
H2O-MeCN, gradient (90:10 to 0:100 in 20 min, then 0:100 in 5 
min), 0.7 mL/min, UV detection at 254 nm. 
The large scale cultivation, extraction and separation using diverse 
chromatographic methods were conducted to yield 9 new compounds and 9 
known compounds from F466 and F452 in total. Structure elucidation was 
performed mainly using 1D and 2D NMR techniques and chemical 
characterization of the isolated metabolites.  
The biological activity assays were performed for antimicrobioal, 
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and cytotoxic activities, inhibition against the enzymes isocitrate lyase (ICL) 
and reduction of quinone reductase, sortase A (SrtA) and Na+/K+-ATPase. 
The cytotoxicity of the test compounds were conducted on A549, K562, 
HCT116, MDA-MB231, SNU638, and SK-HEP1 cancer cell lines.39-41 
Quinone reductase was conducted on murine Hepa 1c1c7 cells.42 Sortase A 
(SrtA) and isocitrate lyase (ICL),43,44 which are not found in mammalian 
species, were selected as target enzyme since they play crucial roles in the 
virulence or survival of various human-pathogenic bacteria and fungi. In 
addition, the inhibitory activity against Na+/K+-ATPase, which plays a crucial 














II. Penicillipyrones A and B, Meroterpenoids from the 
Marine-derived Fungus Penicillium sp. 
Two novel meroterpenoids, Penicillipyrones A (1) and B (2), together with 
methyl 8-hydroxy-6-methyl-9-oxo-9H-xanthene-1-carboxylate (3) and 
coniochaetone B (4) were isolated from the marine-derived fungus 
Penicillium sp.. Based upon the results of combined spectroscopic analyses, 
these compounds were structurally elucidated to be triprenyl γ-lactones from 
a new skeletal class derived from a unique pattern of linkage between the 
prenyl and pyrone moieties. The new compounds exhibited weak 
cytotoxicities against K562 and A549 cell lines. Compound 2 also elicited a 
significant induction of quinone reductase. 
2-1. Introduction 
Fungi from marine environments are widely recognized as very 
prolific sources of biologically active and structurally unique secondary 
metabolites.2-6 Although studies on these organisms began much later than 
their counterparts in terrestrial environments, more than a hundred novel 
compounds have been found annually since the late 1990s.7 Consequently, 
fungi, along with actinomycete bacteria, from marine environments are 
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regarded as a new frontier for research into natural products. 
In our search for novel bioactive compounds from marine fungi, we 
reported acremostrictin, a highly oxygenated metabolite of a new structural 
class from Acremonium strictum.36 In addition, there have recent reports of 
novel polyaromatic compounds and hydroxybenzolactones from marine-
derived Penicillium sp.37 and Chrysosporium articulatum, respectively.38 In 
our continued search, a strain of Penicillium sp. was collected from a marine 
sediment from Korea, whose organic extract showed a mild cytotoxicity 
(LC50 = 192 μg/mL) against the K562 human leukemia cell line. More 
importantly the LC-ESIMS profile of the Penicillium sp. extract revealed the 
presence of novel compounds which prompted us to investigate its 
metabolites in detail. Large-scale culture of the strain followed by the 
extraction of the broth and chromatographic separation led to the isolation of 
two new meroterpenoids. Here, we report the structural determinations of the 
penicillipyrones A (1) and B (2) (Figure 1), triprenyl γ-pyrones of a novel 
skeletal class. These compounds exhibited weak inhibition against K562 and 
A549 cell lines as well as significant induction (compound 2) of quinone 




Figure 6. The chemical structures of compounds 1 - 4. 
2-2. Results and discussion 
The molecular formula of penicillipyrone A (1) was deduced to be 
C21H30O4 by HRFABMS analysis. The 
13C NMR data of this compound 
showed signals from a carbonyl carbon at a δC value of 180.2 and four olefinic 
carbons at δC values of 163.3, 160.6, 111.8, and 98.0 (Table 1). The highly 
differentiated chemical shifts of the olefinic carbons, in conjunction with the 
seven degrees of unsaturation inherent in the molecular formula, suggested 
the presence of a conjugated cyclic lactone or ketone moiety, such as an α- or 
γ-pyrone. The strong absorption band at 1665 cm‒1 in the IR data as well as 
the absorption maxima at 210, 243 and 257 nm in the UV data were indicative 
of the latter, a γ-pyrone moiety. 46 
In addition to the downfield carbon signals, the 13C NMR data also 
showed signals of two oxygenated carbons at δC values of 89.5 and 78.6 and 
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fourteen upfield carbon atoms: 2 x C, 2 x CH, 5 x CH2, and 5 x CH3. The high 
occurrence of methyl groups in the NMR data revealed the polyprenyl-
containing meroterpenoid nature of this compound. 
Given this information, the planar structure of compound 1 was 
determined by a combination of the 1H COSY, HSQC and HMBC 
experiments. In particular, the HMBC correlations between the upfield 
methyl protons and their neighboring carbons were crucial to defining the 
triprenyl portion of compound 1 (Figure 7). The two singlet methyl protons 
at δH values of 1.00 and 0.84 showed long-range correlations to the 
neighboring carbons at δC values of 78.6, 39.1 and 47.6 as well as the mutual 
correlations with their carbons at δC values of 15.3 and 28.4, revealed that 
these are the terminal isopropyl head of the triprenyl-derived ring system. 
Starting from the methine protons at δH values of 3.22 and 1.23, which are 
attached at the carbons at δC values of 78.6 (C-3) and 39.1 (C-5), respectively, 
and are also neighbors to the isopropyl moiety, the 1H COSY NMR data 
revealed the presence of two linear proton spin systems (Figure 7). The C-1 
and C-5 carbons at δC values of 29.7 and 47.6, which contained the protons 
belonging to each of the spin systems, showed long-range correlations with a 
singlet methyl proton at a δH value of 1.08 (H-13) in the HMBC data. Thus, a 
six-membered carbocycle was constructed from these data and an additional 
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correlation between H-13 and a quaternary carbon at a δC value of 41.8 (C-
10). 
 
Figure 7. The COSY (bold line) and selected gHMBC (arrows) correlations 
of compound 1. 
Meanwhile, an oxygen-containing carbon at a δC value of 89.5 was 
placed at the neighboring C-9 position by its HMBC correlation with the H-
13 methyl proton. Another six-membered ring was also established by the 
HMBC correlations of a singlet methyl proton at a δH value of 1.22 (H-12) 
with the prepositioned C-9 and C-10 atoms as well as a methine carbon at a 
δC value of 33.5 (C-8) whose proton at a δH value of 2.01 was determined to 
belonged to a linear spin system starting from the H-5 methine proton. 
The terminus of the triprenyl portion was deduced to be the C-11 
methylene whose carbon and proton signals were assigned to be those at a δC 
value of 22.0 and δH values of 2.53 and 1.93 by the 
1H COSY data of the 
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linear proton spin system starting from H-5 as well as from the carbon-proton 
correlations of H-8/C-11, H-11/C-7 and H-11/C-9 in the HMBC data (Figure 
7). The characteristic shifts of the carbon atom and protons of this methylene 
group indicated the direct attachment of an aromatic moiety, γ-pyrone, at this 
position that was confirmed by the long-range correlations of the methylene 
protons with the carbons at δC values of 180.2 (C-3′), 163.3 (C-1′) and 98.0 
(C-2′). The remaining three carbons at δC values of 160.6 (C-5′), 111.8 (C-4′) 
and 19.2 (C-6′) were also placed on this methylpyrone by a series of HMBC 
correlations between H-4′/C-2′, H-4′/C-3′, H-4′/C-5′, H-4′/C-6′, H-6′/C-4′, 
and H-6′/C-5′. Meanwhile, 2-D NMR based carbon assignments, in 
conjunction with the molecular formula, confirmed the presence of a γ-pyrone 
moiety by the downfield shifts of the C-1′ and C-5′ carbons at δC values of 
163.3 and 160.6, respectively.46 Although the lack of protons at these 
positions prohibited direct evidences, the downfield shift of C-9 at a δC value 
of 89.5 showed an ether bridge between this and carbon atom C-1′.46, 47 Thus, 
the planar structure of penicillipyrone A (1) was unambiguously determined. 
Penicillipyrone A possesses asymmetric carbon centers at C-3, C-5, 
C-8, C-9, and C-10. The relative configurations at these centers were 
determined by a combination of 1-D NMR data and NOESY analysis (Figure 
8). First, the H-3 and H-5 protons were placed at the axial orientation by the 
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large vicinal proton-proton couplings (10.0 and 12.9 Hz). Starting from these 
protons, those axially oriented to same side of the rings were found by 
NOESY cross-peaks to be: H-1α (δH 1.67)/H-5, H-1α/H-12, H-3/H-14, H-
5/H-14, H-6α (δH 1.64)/H-14, H-7α (δH 1.14)/H-11α (δH 1.93), and H-7α/H-
12. Those axially oriented to the opposite side of H-3 and H-5 were also 
determined by the NOESY data to be: H-2β (δH 1.66)/H-13, H-2β/H-15, H-
6β (δH 1.47)/H-13, H-6β/H-15, H-6/H-8, H-8/H-13, and H-13/H-15. Overall 
these data determined that the orientations for both the A/B and B/C ring 
junctures were trans, which was supported by the characteristic upfield shifts 
of the bridgehead methyl groups and the downfield shifts of the ring juncture 
methines in the 13C NMR data.  
 
Figure 8. The selected NOE correlations of compound 1. 
Having the relative configurations through the NMR data, the 
absolute configurations were assigned by Mosher analysis in which the S 
configuration at the hydroxy-bearing C-3 was deduced from δ values 
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between the MTPA esters (Figure 9). Therefore, the overall absolute 
configurations were assigned as 3S, 5S, 8S, 9S, and 10S. Thus the structure of 
penicillipyrone A (1) was determined to be that of a triprenyl-γ-pyrone 
meroterpenoid from a new skeletal class. 
 
Figure 9. The δ (δ(S-ester)-δ(R-ester)) values of MTPA esterification for 
compound 1. 
The structure of penicillipyrone A (1) was found to be a 
meroterpenoid of cyclic triterpenyl-γ-pyrone. A literature survey showed that 
structurally related prenylated α- and/or γ-pyrones are found from diverse 
organisms,48-52 such as sponges, fungi and plants, and have also been 
synthetically prepared.53 However, the cyclization pattern of the prenyl 
portion of 1 significantly differed from the other known meroterpenoids. As 
depicted in Scheme 1, using pyripyrone E whose biosynthesis has been 
proven experimentally as an example,54 the removal of the pyrophosphate 
group generally induced the attack of pyrone moiety at the terminal isoprene 
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unit. Then sequential epoxidation, ring opening and cyclization occurred in 
the carbon framework of pyrone-containing meroterpenoids. However, the 
unique framework of 1 required an alternative biosynthetic pathway because 
the vinyl methyl group (C-11) of the third isoprene unit was directly linked to 
the pyrone moiety in 1 instead of the terminal methylene carbon (C-12) of the 
prenyl portion as seen in the ordinary linkage. A plausible mechanism is, after 
the preliminary removal of pyrophosphate and the formation of a linear 
sesquiterpene alcohol, epoxidation and cyclization may occur prior to the 
attachment of the pyrone moiety that may be driven by the cation generated 
by a cyclization of the prenyl moiety. To the best of our knowledge, this is an 




Schem 1. Comparison of bioynthetic pathyways of meroterpenoids. 
The molecular formula of penicillipyrone B (2) was deduced to be 
C21H28O4 by HRFABMS analysis. The NMR data of this compound was very 
similar to that of 1, with the most noticeable difference being the replacement 
of the C-3 oxymethine, which had signals at a δC value of 78.6 and a δH value 
of 3.22 with a carbonyl carbon having a signal at a δC value of 215.5. This 
interpretation was readily confirmed by a combination of 2-D NMR 
experiments, in which all of the proton-proton and carbon-proton correlations 
obtained supported the placement of a ketone group at C-3. NOESY data 
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showed the same cross-peaks among the ring juncture protons as 1, allowing 
the assignment of the 5R, 8S, 9S, and 10S configurations, which were also 
supported by the comparison of the optical rotations ([]25D  = +51.4 and +25.7 
for 1 and 2, respectively). Thus penicillipyrone B (2) was structurally 
elucidated to be a 3-keto derivative of 1.  
In our bioactivity measurements, compounds 1 and 2 exhibited weak 
cytotoxicities toward the K562 (LC50 = 27.84 and 50.16 μM for 1 and 2, 
respectively, doxorubicin was uesd as a positive control with a LC50 = 0.99 
μM) and A549 (LC50 = 15.43, 17.25 and 1.18 μM for 1, 2 and doxorubicin, 
respectively) cell lines. However, compounds 1 and 2 were inactive (MIC > 
100 μg/mL) against various Gram-positive and Gram-negative bacteria and 
pathogenic fungi. 
Compound 2 also exhibited a significant induction of QR in a dosage-
dependent manner in murine Hepa 1c1c7 cells over the concentration range 
of 5‒40 μM. At a concentration of 40 μM, the induction was 1.9-times that of 
blank control (0.1% DMSO), which was comparable with that of β-NF (2 
μM), a positive control (Figure 10). Contrastingly, compound 1, which 
possessed the 3-hydroxy group, failed to show a noticeable induction in the 
given concentration, implying that the ketone moiety at C-3 of 2 plays a 
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crucial role in its QR inducing activity. QR, a representative detoxification 
enzyme, is known to play an important anticancer role through the reduction 
of electrophilic quinones.55 Therefore, the significant induction of 
penicillipyrone B (2) with significant induction of QR may be suggestive of 
a potential role in cancer prevention. 
Figure 10. Effects of penicillipyrone B (2) on induction of quinone reductase 
in murine Hepa 1c1c7 cells. Cells were grown for 24 h and then exposed to 
penicillipyrone B (2) for 24 h. Quinone reductase activity were measured in 
cell lysates by reduction of a tetrazolium dye and expressed a nmol/min/mg 
protein. Values represent the mean ± SD of four determinanats. Asterisks (*) 
 
 

























denote significant differences between the penicillipyrone B (2) treated group 
and the control group (P < 0.05). 
2-3. Experimental section 
General Experimental Procedures. Optical rotations were 
measured on a JASCO P-1020 polarimeter using a 1 cm cell. IR spectra were 
recorded on a Jasco 4200 FT-IR spectrometer, using a ZnSe cell. UV spectra 
were acquired with a Hitachi U-3010 spectrophotometer. NMR spectra were 
recorded on Bruker Avance 500 spectrometer. Proton and carbon NMR 
spectra were measured in CDCl3 solution at 500 and 125 MHz, respectively. 
High-resolution fast-atom bombardment mass spectrometry (HRFABMS) 
data were acquired using Jeol JMS 700 mass spectrometer with meta-
nitrobenzyl alcohol (NBA) as a matrix in the Korea Basic Science Institute 
(Daegu, Korea). HPLC were performed on a Spectrasystem p2000 equipped 
with a refractive index detector (Spectrasystem RI-150). All solvents used 
were spectroscopic grade or distilled from glass prior to use. 
Isolation and Identification of Fungal Strain. The fungal strain 
Penicillium sp. (strain number F446) was isolated from marine sediments at 
the depth of ‒25 m collected from Geomun-do (Island), Korea, in October 
2011. F446 was identified using standard molecular biological protocols by 
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DNA amplification and sequencing of the ITS region. Genomic DNA 
extraction was performed using Intron’s i-genomic BYF DNA Extraction 
Mini Kit according to the manufacturer’s protocol. The nucleotide sequence 
of F446 has been deposited in the GenBank database under the accession 
number JF901804. The 18S rDNA sequence of this strain showed 99% 
identity with Penicillium citrinum a2s6-6 (GenBank accession number 
KF146984). 
Fermentation and Isolation. The isolated strain was cultured on 
marine broth agar plate (37.4 g Difco marine broth 2216, 20.0 g glycerol, 16.0 
g agar in 1 L artificial seawater) for 7 days. Agar plugs (1 cm × 1 cm, 10 
pieces for 1 L) were inoculated into 2.8 L Glass Fernbach Flask, 24 flasks in 
all, containing MB media (37.4 g Difco marine broth 2216 and 20.0 g glycerol 
in 1 L artificial seawater). The fermentation was conducted at 28 oC on a 
rotary shaker at 150 rpm for 3 weeks. The mycelia and culture broth were 
separated by filtration, and the broth was extracted with EtOAc. The solvent 
was evaporated to obtain an organic extract (1.4 g). The extract was separated 
by C18 reversed-phase vacuum flash chromatography using a sequential 
mixture of MeOH and H2O as eluents (seven fractions in gradient, H2O‒
MeOH, from 60:40 to 0:100), acetone, and finally EtOAc. On the basis of the 
results of 1H-NMR analysis, the fractions eluted with H2O‒MeOH (30:70) 
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(96 mg) was chosen for separation. The fraction eluted with H2O‒MeOH 
(30:70) was separated by semipreparative reversed-phase HPLC (H2O‒
MeCN, 70:30, 1.0 mL/min) to afford compound 1 (8.9 mg), compound 2 (4.5 
mg). 
Penicillipyrone A (1): pale yellow amorphous solid, []25D  +51.4 (c 
0.5, acetone); UV (MeOH) max (log ) 210 (3.83), 243 (3.83), 257 (3.85) nm; 
IR (ZnSe) max 3394 (br), 2942, 2874, 1665, 1572, 1449 cm
‒1; HRFABMS, 
m/z 347.2224 [M+H]+ (Calcd for C21H31O4, 347.2222). 
Penicillipyrone B (2): pale yellow amorphous solid, []25D  +25.7 (c 
0.5, acetone); UV (MeOH) max (log ) 210 (3.80), 243 (3.81), 256 (3.82) nm; 
IR (ZnSe) max 2944, 2876, 1666, 1579, 1431 cm
‒1; HRFABMS, m/z 
345.2064 [M+H]+ (Calcd for C21H29O4, 345.2066). 
MTPA Esterifications of 1. To a solution of 1 (2.0 mg) in 1.0 mL of 
pyridine (distilled over CaH2), were added 10 μL of triethylamine and 20 μL 
of (-)-(R)-MTPA chloride. The mixture was stirred under N2 for 1 h at room 
temperature. After the consumption of the starting material was confirmed by 
thin-layer chromatography, the solvent was removed under vacuum and the 
residue was purified by analytical HPLC (YMC-ODS column, 4.6 × 250 mm; 
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H2O‒MeOH, 15:85, 1.0 mL/min) to afford the (S)-MTPA ester of 1, 1S. The 
corresponding (R)-MTPA ester of 1, 1R was also obtained from the same 
esterification reaction with (+)-(S)-MTPA chloride. 1H NMR (CDCl3, 600 
MHz) of 1S: δH 7.533‒7.417 (5 H, m, aromatic), 6.143 (1 H, s, H-4’), 4.708 
(1 H, dd, J = 11.2, 4.4 Hz, H-3), 3.521 (3 H, s, OMe), 2.567 (1 H, dd, J = 15.9, 
4.7 Hz, H-11), 2.234 (3 H, s, H-6’), 2.031 (1 H, dddd, J = 11.7, 9.0, 4.7, 4.7 
Hz, H-8), 1.971 (1 H, dd, J = 15.9, 11.7 Hz, H-11), 1.910 (1 H, m, H-7), 1.885 
(1 H, m, H-2), 1.783 (1 H, m, H-1), 1.730 (1 H, m, H-1), 1.711 (1 H, m, H-2), 
1.662 (1 H, m, H-6), 1.490 (1 H, dq, J = 12.9, 4.7 Hz, H-6), 1.347 (1 H, dd, J 
= 12.9, 3.2 Hz, H-5), 1.260 (3 H, s, H-12), 1.181 (1 H, m, H-7), 1.103 (3 H, 
s, H-13), 0.921 (3 H, s, H-15), 0.871 (3 H, s, H-14); ESI-MS m/z 563.2, 
[M+H]+ (calcd for C31H38F3O6, 563.3). 
1H NMR (CDCl3, 600 MHz) of 1R: 
δH 7.554‒7.410 (5 H, m, aromatic), 6.113 (1 H, s, H-4’), 4.737 (1 H, dd, J = 
11.0, 4.4 Hz, H-3), 3.576 (3 H, s, OMe), 2.562 (1 H, dd, J = 15.9, 4.6 Hz, H-
11), 2.230 (3 H, s, H-6’), 2.030 (1 H, dddd, J = 11.7, 9.0, 4.6, 4.6 Hz, H-8), 
1.965 (1 H, dd, J = 15.9, 11.7 Hz, H-11), 1.938 (1 H, m, H-2), 1.905 (1 H, m, 
H-7), 1.835 (1 H, m, H-2), 1.805 (1 H, m, H-1), 1.788 (1 H, m, H-1), 1.656 
(1 H, m, H-6), 1.484 (1 H, dq, J = 12.9, 4.7 Hz, H-6), 1.343 (1 H, dd, J = 12.9, 
3.2 Hz, H-5), 1.259 (3 H, s, H-12), 1.175 (1 H, m, H-7), 1.128 (3 H, s, H-13), 
0.866 (3 H, s, H-15), 0.840 (3 H, s, H-14); ESI-MS m/z 563.2, [M+H]+ (calcd 
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for C31H38F3O6, 563.3). 
Biological Assays. Quinone reductase (QR) activity in Hepa 1c1c7 
murine hepatoma cells was performed in accordance with literature 
protocols.42 Anti-microbial and cytotoxicities assays were also carried out in 














Table 1. 13C and 1H NMR assignment for compound 1 in CDCl3 
 Position δC δH   
 1 29.7, CH2 1.67, m; 1.75, m 
 2 27.1, CH2 1.73, m; 1.66, m 
 3 78.6, CH 3.22, dd (10.0, 3.0) 
 4 39.1, C  
 5 47.6, CH 1.23, dd (12.9, 3.2) 
 6 20.9, CH2 1.64, m; 1.47, m 
 7 28.9, CH2 1.14, dq (12.9, 4.7); 1.88, m 
 8 33.5, CH 2.01, dddd (11.7, 9.0, 4.7, 4.7) 
 9 89.5, C  
 10 41.8, C  
 11 22.0, CH2 1.93, dd (15.9, 11.7); 2.53, dd (15.9, 4.7) 
 12 13.1, CH3 1.22, s 
 13 14.5, CH3 1.08, s 
 14 28.4, CH3 1.00, s 
 15 15.3, CH3 0.84, s 
 1’ 163.3, C  
 2’ 98.0, C  
 3’ 180.2, C 
 4’ 111.8, CH 5.96, brs 
 5’ 160.6, C  




Table 2. 13C and 1H NMR assignment for compound 2 in CDCl3 
 Position δC δH   
 1 30.8, CH2 2.02, m; 2.03, m 
 2 34.5, CH2 2.42, dt (15.6, 4.5); 2.70, ddd (15.6, 12.1, 7.3) 
 3 215.5, C 
 4 47.8, C  
 5 48.8, CH 1.70, dd (10.8, 5.1) 
 6 22.1, CH2 1.62, m; 1.61, m 
 7 28.7, CH2 1.21, dq (12.9, 4.4); 1.94, m 
 8 28.7, CH 2.10, dddd (12.0, 9.3, 5.2, 4.4) 
 9 88.8, C  
 10 41.5, C  
 11 22.0, CH2 1.95, dd (16.4, 12.0); 2.58, dd (16.4, 5.2) 
 12 13.2, CH3 1.27, s 
 13 14.1, CH3 1.29, s 
 14 26.2, CH3 1.11, s 
 15 21.8, CH3 1.09, s 
 1’ 163.0, C  
 2’ 98.1, C  
 3’ 180.1, C 
 4’ 111.9, CH 5.98, brs 
 5’ 160.7, C  
 6’ 19.3, CH3 2.21, brs 
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III. Alkaloidal Metabolites from a Marine-Derived 
Aspergillus sp. Fungus 
Fumiquinazoline S (5), a new quinazoline-containing alkaloid, and the known 
fumiquinazolines F (10) and L (11) of the same structural class were isolated 
from the solid-substrate culture of an Aspergillus sp. fungus collected from 
marine-submerged wood. In addition, isochaetominines A-C (6-8) and 14-
epi-isochaetominine C (9), new alkaloids possessing an unusual amino acid-
based tetracyclic core framework related to the fumiquinazolines, and 
together with nidurufin (12), versiconol (13), sterigmatocystin (14), 7-
deoxysterigmatocystin (15), and isobenzofuranone (16) were isolated from 
the same fungal strain. The structures of these compounds were determined 
by combined spectroscopic methods, and the absolute configurations were 
assigned by NOESY, ROESY and advanced Marfey’s analyses along with 
biogenetic considerations. The new compounds exhibited weak inhibition 
against Na+/K+-ATPase. 
3-1. Introduction  
 Microorganisms in marine environments have been widely 
recognized as emerging sources of biologically active and structurally unique 
secondary metabolites.2-6 Dominated by three major phylogenetic groups, 
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actinomycete and non-actinomycete bacteria and fungi, the novel natural 
products from marine microorganisms have shown a noticeable increase since 
1997.3 Marine fungi alone have produced more than 400 novel compounds, 
of which several have exhibited potent and diverse bioactivities.7,8 
In our search for bioactive metabolites from the fungi of marine 
environments, we have recently reported novel compounds, such as 
acremostrictin, chrysoarticulins, herqueiazoles, herqueidiketal, and 
penicillipyrones, possessing unusual carbon frameworks and/or 
functionalities, thus contributing to the chemical library from marine-derived 
fungi.36-38,58 Several of these compounds have exhibited moderate to 
significant inhibition of sortase A (chrysoarticulin C and herqueidiketal),37,38 
significant induction of quinone reductase (penicillipyrone B),58 and 
moderate antioxidant activity (acremostrictin).36 During our search, a strain 
of Aspergillus was collected from marine-submerged decaying wood from 
Korea, with an organic extract that showed moderate cytotoxicity (IC50 170 
μg/mL) against the K562 human leukemia cell line. Furthermore, the LC-
ESIMS profile of the extract revealed the presence of diverse secondary 




A solid-substrate culture of the strain followed by an extraction and 
chromatographic separation led to the isolation of several new alkaloids. In 
this study, we report the structure determinations of fumiquinazoline S (5), 
isochaetominines A-C (6-8) and 14-epi-isochaetominine C (9), and the known 
congeners, fumiquinazolines F (10) and L (11) based on combined 
spectroscopic and chemical analyses (Figure 11). Fumiquinazoline S is a new 
member of the fumiquinazoline class of alkaloids, which has been reported in 
a number of marine-derived Aspergillus, Acremonium and Scopulariopsis 
fungal strains. Fumiquinazolines A-P have been reported in the literature. 
However, fumiquinazolines K and L were doubly designated.59-61 
Accordingly, our new compound was designated fumiquinazoline S instead 
of either Q or R.59-66 The isochaetominines are structurally related to the 
recently reported chaetominine from the terrestrial endophytic fungus 
Chaetomium sp.67 Our isolation of the fumiquinazolines and the 
isochaetominines from a common fungal strain provides insight into the 
biogenetic relationships of these quinazoline-containing natural products. 
Although these compounds were not significantly active against the K562 and 





Figure 11. The chemical structrues of compounds 5-16. 
3-2. Results and discussion  
The molecular formula of fumiquinazoline S (5) was deduced as 
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C26H27N5O4 by the HRFABMS analysis. The spectroscopic data of this 
compound revealed the characteristic features of fumiquinazolines. That is, 
the presence of 12 carbon signals in the aromatic region (C 150-110) in the 
13C NMR data, along with the corresponding proton signals (H 8.2-7.0) in 
the 1H NMR data and aromatic E bands in the UV spectrum, was indicative 
of two benzene rings in 5 (Table 3). Four carbon signals at C 172.1, 168.9, 
160.2, and 153.3 in the 13C NMR data were thought to represent either 
carbonyl or imine carbons, which was implied by the molecular formula and 
the strong absorption bands at 1730 and 1681 cm-1 in the IR spectrum.  
The gross structure of compound 5 was determined by a combination 
of 2D NMR analyses as well as comparison with the congeners 10 and 11. 
First, the COSY data showed a linear spin system of four aromatic protons 
resonating at H 8.12, 7.82, 7.66, and 7.53, thus revealing the presence of a 
1,2-disubstituted benzene whose carbons were also assigned by the HSQC 
and HMBC data. The attachment of a carbonyl carbon at C 160.2 to the ring 
quaternary carbon at C 120.0 was secured by its HMBC correlation with a 
ring proton at H 8.12, designating a benzamide for this portion (C-6~C-12) 
(Figure 12). The COSY and HSQC data also defined two spin systems 
consisting of a methine (C 51.8, H 5.58; C-14) and a methylene (C 35.4, H 
2.58 and 1.82; C-15), and a methyl (C 16.6, H 1.58; C-16) and a methine 
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group (C 48.6, H 4.95; C-3), respectively. The HMBC correlations of these 
protons and an exchangeable one at H 8.61 (2-NH) with the neighboring 
carbons accomplished a 4-oxo-quinazoline--lactam system found in several 
fumiquinazolines.61,63  
 
Figure 12. The COSY (bold line) and selected HMBC (arrows) correlations 
of compounds 5 and 6. 
The combined 2D NMR data also revealed the presence of another 
1,2-disubstituted benzene (C-23~C-28) in 5 (Table 3). The extension of this 
ring to a 3-alkylindole-3-ol moiety as well as its connection to the upper 
portion of the molecule via a methylene (C-15) was accomplished by the 
HMBC correlations of an oxygenated carbon at C 80.1 (C-17) and a methine 
carbon at C 88.2 (C-18) with neighboring protons and carbons (Figure 12). 
The remaining portion of the molecule was also found to have a valine (Val)-
 
38 
derived residue by the COSY data which showed a long spin system 
consisting of protons at H 5.26 (H-18), 3.51 (19-NH), 3.54 (H-20), 1.98 (H-
29), 0.96 (H-30), and 0.93 (H-31). The HMBC correlations of several of these 
protons with a carbonyl carbon at C 172.1 (C-21) allowed the construction 
of an imidazolidinone moiety (Figure 12). Thus, the planar structure of 
fumiquinazoline S (5) was determined as a new derivative of the 
fumiquinazoline class possessing a Val-derived residue.  
A structural comparison of the congeners revealed a biogenetic 
relationship between 5 and 11, whose absolute configurations were assigned 
by X-ray crystallographic analysis.61 Although several biosynthetic 
postulations would be plausible for the structural conversion between these 
compounds, the configurations at C-14, C-17, C-18, and C-20 are likely to be 
the same in these two compounds, whereas the configuration at the reaction 
center C-3 in 5 may be either intact or reversed, depending on the reaction 
pathway. This hypothesis was supported by the ROESY data for 5 in which a 
conspicuous cross-peak was found at H-18/H-29 (Figure 13). Although the 
desired cross-peak at 17-OH/H-18 was not found, it was compensated by 
another cross-peak at H-15 (H 2.58)/H-20 because a DFT model calculation 
(Supporting Information) revealed a spatial proximity between these protons 
only by the β-orientation of the 17-OH proton at the tetracyclic frame. 
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Similarly, H-14 was placed at the β-orientation based on the cross-peaks at 
H-3/H-15 (H 2.58), H-3/H-15 (H 1.82), and H-14/H-27. 
 
Figure 13. Selected ROESY correlations of compound 5. 
The significant ROESY correlations of H-3 with both of the H-15 
methylene protons coupled with the lack of a ROESY correlation of H-16 
with the latter protons assigned an α-orientation for the H-3 to the quinazoline 
plane, which was supported by the 13C NMR data. A literature study showed 
that the C-3 asymmetric center significantly influences the chemical shifts of 
the C-16 methyl carbon (cis C ~24.9, trans C ~16.8), possibly due to the 
spatial crowding of the substituents at C-14 (cis C ~52.7 and trans C 
~49.2).62-64 The chemical shifts of C-16 and C-14 at C 16.9 and 49.1 in CDCl3, 
respectively, in the 13C NMR data fit well with the α-orientation (trans 
orientation of C-15 with C-16) of H-3 (Supporting Information). Thus, the 
relative configurations of the stereogenic carbon centers of 5 were 
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unambiguously assigned throughout the molecule. Compound 5 has a Val-
derived unit at C-21. The absolute configuration of this unit was determined 
to be L by advanced Marfey’s analysis (Experimental Section).68 Therefore, 
the overall absolute configuration of 5 was assigned as 3S, 14R, 17R, 18R, 
and 20S. 
The molecular formula of isochaetominine A (6) was deduced as 
C22H18N4O4 by the HRFABMS analysis. The gross NMR features of this 
compound were highly reminiscent of 5, indicating the presence of a 
quinazoline and a 3-alkylindolin-3-ol as substructures. The replacement of 
the Val-derived residue with an alanine (Ala)-derived one was also found by 
the NMR data (C 174.4, 59.7, and 13.8, H 4.58 and 1.57). However, a 
detailed examination of the 13C and 1H NMR data revealed that the signals of 
the several carbons and protons, particularly those near the -lactam C-14, 
noticeably differ from those of 5 in the chemical shifts and the multiplicities, 
which prompted an extensive interpretation of the full spectroscopic data 
(Table 4). 
First, a combination of the COSY, HSQC and HMBC data secured 
the presence of a 1,2-disubstituted benzene in 6 and assigned all of the 
carbons and protons in this moiety. A three-bond HMBC correlation with an 
 
41 
aromatic proton at H 8.14 (H-19) placed a carbonyl carbon at C 159.9 as a 
substituent (C-17) (Figure 12). Interestingly, this carbon showed an additional 
correlation with an isolated singlet proton at H 8.25, which correlated with 
the aromatic carbon at C 127.2 (C-22). The downfield chemical shift of this 
proton-bearing carbon at C 146.7 defined it as an amidine methine carbon 
(C-25), corresponding to the C-4 carbon in 5. Therefore, unlike the additional 
6-membered lactam system present in 5 and other fumiquinazoline 
metabolites, the 4-oxo-quinazoline moiety of 6 was directly attached to the 
remaining portion of the compound through a single bond at N-26, which is 
discussed later.  
A combination of 2D NMR data revealed the presence of another 1,2-
disubstituted benzene moiety. Despite the noticeable shifts of the protons and 
the carbons in the NMR data, the extension to a 3-alkylindolin-3-ol, identical 
to 5, was accomplished by the HMBC analysis (H-2/C-3, H-2/C-4, H-2/C-9, 
and H-5/C-3, Figure 12). The connection of the Ala-derived residue to the 
indolinol moiety through the construction of an imidazolidinone ring was also 
accomplished long-range correlations at H-11/C-2 and H-11/C-10 and H-
11/C-15. Thus, 6 was found to possess the same indolinol-imidazolidinone 
tricyclic substructure as found in 5.  
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Compound 6 possessed a three-carbon moiety (C-13, C-14 and C-15) 
connecting the indolinol and quinazoline moieties. The 13C NMR data for 6 
also showed signals of three carbons at C 164.2 (C), 55.6 (CH) and 34.7 (CH2) 
having corresponding multiplicities to those of 5. Although the chemical 
shifts of these carbons and their attached protons at H 4.88, 2.92 and 2.65 in 
the 1H NMR data were significantly shifted compared with those of 5, the 
COSY and HMBC data showed the same linear assembly of these groups in 
6. In addition, the HMBC data showed the key correlations at H-2/C-15, H-
13/C-2, H-13/C-3, H-13/C-4, and H-14/C-3, constructing a -lactam moiety 
consisting of indolinol-imidazolidinone and three carbons at C-13, C-14 and 
C-15 (Figure 12). As previously mentioned, the connection between this 
lactam and 4-oxo-quinazoline via a C-N single bond was also accomplished 
by the long-range correlations at H-14/C-17, H-14/C-25 and H-25/C-14 in the 
HMBC data. Thus, the planar structure of isochaetominine A (6) was defined 
as a 4-oxo-quinazoline-containing alkaloid, identical to chaetominine.67  
A comparison of the main framework of this compound with that of 
fumiquinazolines 5, 10 and 11 indicated that 6 and the fumiquinazolines are 
biogenetically related, but that the exact relationship is unclear at this time. A 
literature study revealed that the hexacyclic framework of 6 is unusual; the 
only previous example is the recently found chaetominine from the terrestrial 
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endophytic Chaetomium sp. fungus whose planar structure is identical to 6. 
However, the NMR chemical shifts of several carbons and protons of these 
compounds significantly differ from each other, suggesting a diastereomeric 
relationship between them. 
Compound 6 possessed four asymmetric carbon centers at C-2, C-3, 
C-11, and C-14 with configurations assigned by NOESY (Figure 14) and the 
chemical analyses. The H-2 methine proton showed strong cross-peaks with 
the 3-OH and H-12 in the NOESY data, placing all of these protons on the 
same face of the tetracyclic plane. In contrast, the H-14 methine proton did 
not exhibit cross-peaks with any of these protons but showed strong cross-
peaks with both of the neighboring H-13 methylenes, matching the gauche 
conformation based on the proton coupling constants (J11,12 = 7.0 and 5.1 Hz) 
on the pseudo boat form of the lactam ring deduced by DFT model study 
(Supporting Information). Therefore, H-14 must be oriented on the opposite 
face of the tetracyclic plane, which coincided well with the cross-peak at H-
2/H-25. For compound 6, the absolute configuration of the Ala-derived 
residue at C-10 was determined as L by advanced Marfey’s analysis 
(Supporting Information). These results assigned the 2R, 3R, 11S, and 14R 
absolute configuration, which was distinguished from the 2S, 3S, 11S, and 
14R configuration of chaetominine based on X-ray crystallographic 
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Figure 14. Selected NOESY and ROESY correlations of compounds 6 and 9. 
Isochaetominine B (7) was isolated as a pale yellow solid, which was 
determined as C23H20N4O4 by HRFABMS analysis. The NMR data for this 
compound were similar to those of 6, and all of the key structural features 
were intact in 7. In the 13C NMR data, the only significant difference was the 
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addition of a methylene carbon at C 21.7 (Table 5). A corresponding 
difference was found in the 1H NMR data in which the signals of the new 
methylene protons were observed at H 2.06 and 2.00. In addition, the 
multiplicity of a doublet methyl proton was changed to a triplet (J = 7.3 Hz) 
(Table 5). These spectroscopic differences were readily accommodated by the 
replacement of the C-12 methyl with an ethyl group, which was confirmed by 
combined 2D NMR methods. Therefore, the Ala-derived residue must be 
replaced with a 2-amino-butanoic acid-derived residue. The ROESY data 
showed the same cross-peaks as 7, which along with the L configuration for 
the newly appeared 2-amino-butanoic acid residue by advanced Marfey’s 
analysis, assigned the same absolute configuration as 6. Thus, the structure of 
isochaetominine B (7) was defined as a new alkaloid possessing an unusual 
L-2-amino-butanoic acid-derived lactam moiety. 
The molecular formula of isochaetominine C (8) was deduced as 
C24H22N4O4 by HRFABMS analysis. The NMR data for this compound were 
similar to those of 7, with the replacement of signals of the C-12 group to an 
isopropyl group (C 28.2, 20.2 and 18.7, H 2.44, 1.15 and 1.12) (Table 6). 
This replacement of an Ala-derived residue in 6 with a valine (Val)-derived 
one was confirmed by the combined 2D NMR data. The NOESY cross-peaks 
at H-2/3-OH, H-2/H-12 and H-13/H-14 along with the L configuration of the 
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newly appeared Val-derived residue by advanced Marfey’s analysis assigned 
the same 2R, 3R, 11S, and 14R configuration as 6 and 7. Thus, the structure 
of isochaetominine C (8) was determined as a new alkaloid, possessing an L-
Val-derived lactam moiety.  
Finally, the molecular formula of 14-epi-isochaetominine C (9) was 
deduced as C24H22N4O4, which is identical to 8, by HRFABMS analysis. 
Despite the noticeable shifts of several carbons, the 13C NMR data for this 
compound showed the same signal distribution and multiplicities as 8 (Table 
7). The same trend was also found in the 1H NMR data in which most of the 
signals showed similar chemical shifts and coupling constants as 9 (Table 7). 
Accordingly, 8 and 9 must be diastereomeric to each other, which was 
supported by the combined COSY, HSQC and HMBC analyses in which the 
identical proton-proton and carbon-proton correlations were found between 
these compounds. The ROESY data showed cross-peaks at H-2/3-OH and H-
2/H-12, confirming the same syn orientations for these protons as for the other 
isochaetominines (Figure 14). However, additional cross-peaks were found at 
H-2/H-14 and 3-OH/H-14, adding the H-14 methine proton in a syn 
orientation to the other key protons. Furthermore, the 4-oxo-quinazoline 
moiety was spatially close to the main framework by the cross-peaks at H-
13/H-25 and H-14/H-25. Because the L-configuration was found for the Val-
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derived moiety (C-10, C-11, C-12, C-27, C-28) by advanced Marfey’s 
analysis, the overall ROESY data confidently assigned the 2R, 3R, 11S, and 
14S configuration for 9, reversed at C-14 from 6-8. This interpretation 
coincides well with the 13C and 1H NMR data in which the conspicuous 
differences were concentrated at the signals of the carbons and the protons 
near C-14 (Table 7). This conclusion was further supported by the opposite 
sign of the specific rotation of 9 compared with the other isochaetominines. 
Thus, the structure of 9 was determined as the 14-epi-derivative of 
isochaetominine C (8). 
Certain fumiquinazoline metabolites have been reported to exhibit 
weak activities against cancer cell lines,62,63 proliferation of cancer cell 
lines,66 and/or fungal strains,64 whereas chaetominine exhibited cytotoxicity 
against K562 leukemia and SW1116 colon cancer cell lines comparable to 5-
fluorouracil.67 In our measurement of cytotoxicity, however, 5-11 were 
inactive (5-9: IC50 > 13-50 μM, 10 and 11: IC50 > 100 μΜ) against the K562 
and A549 cell lines.39 In the antimicrobial activity tests against selected 
strains of Gram-positive and Gram-negative bacteria and pathogenic fungi, 
only compound 10 displayed weak inhibition (MIC 50 μΜ) against Bacillus 
subtilis.57 These alkaloids also exhibited a weak inhibition (IC50 were 34, 78, 
20, 38, 57, 17, and 20 M for 5-11, respectively) against Na+/K+-ATPase.41 
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None of these compounds were active against the enzymes sortase A or 
isocitrate lyase.  
In conclusion, five new alkaloidal metabolites, fumiquinazoline S (5), 
isochaetominines A-C (6-8) and 14-epi-isochaetominine C (9), along with the 
known fumiquinazolines F (10) and L (11), were isolated from a marine-
derived Aspergillus sp. fungus. Compound 5 is a new member of the 
fumiquinazoline alkaloids, whereas 6-9 had a structural similarity only with 
chaetominine, which has been recently isolated from a terrestrial endophytic 
fungus. Furthermore, the differences in the relative and absolute 
configurations among these compounds provide additional structural novelty 
to the isochaetomines. These compounds exhibited weak inhibition against 
Na+/K+-ATPase. 
3-3. Experimental section 
General Experimental Procedures. The optical rotations were 
measured on a JASCO P-1020 polarimeter using a 1 cm cell. The UV spectra 
were acquired with a Hitachi U-3010 spectrophotometer. The CD spectra 
were obtained on a Chirascan-plus CD spectrometer. The IR spectra were 
recorded on a JASCO 4200 FT-IR spectrometer, using a ZnSe cell. The NMR 
spectra were recorded on Bruker Avance 400, 500 and 600 spectrometers. The 
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proton and carbon NMR spectra were measured in a DMSO-d6 solution at 
400 and 100 MHz (5), 600 and 150 MHz (6), and 500 and 125 MHz (7-9), 
respectively. HRFABMS data were acquired using a Jeol JMS 700 mass 
spectrometer with meta-nitrobenzyl alcohol (NBA) as the matrix at the Korea 
Basic Science Institute (Daegu, Korea). The HPLC analyses were performed 
on a Spectrasystem p2000 equipped with a refractive index detector 
(Spectrasystem RI-150). All of the solvents used were spectroscopic grade or 
distilled from glass prior to use. 
Isolation and Identification of the Fungal Strain. The fungal strain 
Aspergillus sp. (strain number F452) was isolated from submerged decaying 
wood off of the shore of Jeju Island, Korea, in November 2011. The strain was 
identified using standard molecular biological protocols by DNA 
amplification and sequencing of the ITS region. The genomic DNA extraction 
was performed using Intron’s i-genomic BYF DNA Extraction Mini Kit 
according to the manufacturer’s protocol. The nucleotide sequence of F452 
has been deposited in the GenBank database under the accession number 
KF384188. The 18S rDNA sequence of this strain showed a 99% identity with 
Aspergillus versicolor Ppf48 (GenBank accession number GU586852). 
Fermentation and Isolation. The isolated strain was cultivated on a 
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YPG agar plate (5 g yeast extract, 5 g peptone, 10 g glucose, and 16.0 g agar, 
24.8 g artificial sea salt; Instant Ocean in 1 L distilled H2O) for 7 days. The 
agar plugs (1 cm × 1 cm, 5 pieces each) were inoculated into 100 mL of the 
YPG media in a 250 mL Erlenmeyer flask for 7 days, then separately 
transferred to 2.8 L glass Fernbach flasks with rice media (1 g peptone, 1 g 
yeast extract, 200 g rice, 5 g artificial sea salt; Instant Ocean in 200 mL 
distilled H2O in each flask, boiled in an autoclave for 20 min at 120 °C; 8 
flasks total). The fermentation in the rice media was conducted under static 
conditions for 6 weeks and then was extracted by EtOAc (1 L × 3). The 
solvent was evaporated to obtain a brown organic extract (5.8 g). The extract 
was separated by C18 reversed-phase vacuum flash chromatography using a 
sequential mixture of MeOH and H2O as the eluents (seven fractions in the 
gradient, H2OMeOH, from 60:40 to 0:100), acetone, and, finally, EtOAc. 
Based on the results of the 1H-NMR analysis, the fractions that eluted with 
H2OMeOH (40:60) (1010 mg) and (30:70) (1019 mg) were chosen for the 
separation. The fraction that eluted with H2OMeOH (40:60) was separated 
by semi-preparative reversed-phase HPLC (H2OMeOH, 50:50, 2.0 mL/min) 
to afford compounds 5 and 9. The fraction that eluted with H2OMeOH 
(30:70) was separated by semi-preparative reversed-phase HPLC 
(H2OMeOH, 40:60, 2.0 mL/min) to yield, in order of elution, compounds 6, 
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7, 8, 10 and 11. The purified metabolites were isolated in the following 
amounts: 6.4, 10.0, 9.4, 4.0, 8.9, 3.2, and 5.5 mg for 5-11, respectively. 
Fumiquinazoline S (5): pale yellow amorphous solid, []25D  -105 (c 
0.5, MeOH), -151 (c 0.25, CHCl3); UV (MeOH) max (log ) 205 (4.37), 226 
(4.14), 257 (3.80), 266 (3.62), 279 (3.36), 304 (3.05), 317 (2.93) nm; CD 
(MeOH) λ (∆) 210 (+13.64), 233 (-12.88), 287 (-1.33) nm; IR (ZnSe) max 
3395, 1730, 1681, 1605 cm-1; 1H and 13C NMR data, Table 3; HRFABMS m/z 
474.2143 [M+H]+ (calcd for C26H28N5O4, 474.2141). 
Isochaetominine A (6): pale yellow amorphous solid, []25D  -63 (c 
0.5, MeOH); UV (MeOH) max (log ) 204 (4.60), 225 (4.44), 275(4.07), 305 
(3.35) nm; CD (MeOH) λ (∆) 204 (-15.10), 219 (+5.78), 247 (-3.24), 285 
(+0.52), 304 (-1.57) nm; IR (ZnSe) max 3364 (br), 1725, 1673, 1607 cm
-1; 1H 
and 13C NMR data, Table 4, respectively; HRFABMS m/z 403.1404 [M+H]+ 
(calcd for C22H19N4O4, 403.1406). 
Isochaetominine B (7): pale yellow amorphous solid, []25D  -73 (c 
0.6, MeOH); UV (MeOH) max (log ) 208 (4.60), 226 (4.45), 275 (4.09), 305 
(3.34) nm; CD (MeOH) λ (∆) 203 (-18.11), 218 (+8.17), 243 (-13.14), 286 




and 13C NMR data, Table 5, respectively; HRFABMS m/z 417.1566 [M+H]+ 
(calcd for C23H21N4O4, 417.1563). 
Isochaetominine C (8): pale yellow amorphous solid, []25D  -90 (c 
0.6, MeOH); UV (MeOH) max (log ) 204 (4.58), 224 (4.42), 274 (4.03), 303 
(3.33) nm; CD (MeOH) λ (∆) 201 (-19.25), 217 (+9.06), 244 (-6.53), 274 
(+0.29), 303 (-2.28) nm; IR (ZnSe) max 3362 (br), 1723, 1676, 1610 cm
-1; 1H 
and 13C NMR data, Table 6, respectively; HRFABMS m/z 431.1721 [M+H]+ 
(calcd for C24H23N4O4, 431.1719). 
14-epi-Isochaetominine C (9): pale yellow amorphous solid, []25D  
+33 (c 0.7, MeOH); UV (MeOH) max (log ) 204 (4.58), 224 (4.42), 274 
(4.03), 302 (3.30) nm; CD (MeOH) λ (∆) 204 (-15.10), 219 (+5.78), 247 (-
3.24), 285 (+0.52), 305 (+0.85) nm; IR (ZnSe) max 3370 (br), 1726, 1677, 
1609 cm-1; 1H and 13C NMR data, Table 7, respectively; HRFABMS m/z 
431.1720 [M+H]+ (calcd for C24H23N4O4, 431.1719). 
Advanced Marfey’s Analysis of Compounds 5-9.68 Compound 5 
(0.4 mg) was dissolved in 0.5 mL of 6 N HCl and heated to 110 °C for 1 h. 
The solution was evaporated with distilled H2O three times to remove the 
trace HCl under vacuum. The divided hydrolysate (0.2 mg each) was treated 
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with 100 μL of 1 N NaHCO3 followed by 50 μL of 1% L- or D- FDAA in 
acetone. The mixture was stirred at 80 °C for 15 min. After quenching by the 
addition of 50 μL 2 N HCl, the mixture was analyzed by ESI-LC/MS to assign 
the chirality of the amino acids. The retention times of the L- and D-FDAA-
derivatized hydrolysates were 19.0 and 22.9 min, respectively. Compounds 
6-9 were prepared and analyzed using the same procedure. The results 
demonstrated that all of the amino acids in compounds 5-9 were in the L- 
form. 
Biological Assays. The cytotoxicity assays were performed in 
accordance with protocols reported in the literature.39 Antimicrobial assays 











Table 3. 13C and 1H NMR assignment for compound 5 in DMSO-d6 
No. δC δH    
1 168.9, C   
3 48.6, C 4.95, q (6.5)   
4 153.3, C   
6 146.6, C  
7 126.9, CH 7.66, dd (8.3, 0.8)  
8 134.5, CH 7.82, ddd (8.3, 7.5, 1.3)  
9 126.7, CH 8.12, dd (8.1, 1.3)  
10 126.5, CH 7.53, ddd (8.1, 7.5, 0.8)  
11 120.0, C   
12 160.2, C   
14 51.8, CH 5.58, d (9.6, 4.5)  
15 35.4, CH2 2.58, dd (14.9, 9.6); 1.82, dd (14.9, 4.5) 
  
16 16.6, CH3 1.58, d (6.5)  
17 80.1, C   
18 88.2, CH 5.26, dd (6.8, 1.7)  
20 69.2, CH 3.54, m  
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21 172.1, C   
23 137.2, C    
24 115.1, CH 7.34, dd (7.9, 1.0) 
25 128.8, CH 7.25, ddd (7.9, 7.5, 1.3) 
26 124.6, CH 7.09, ddd (7.5, 7.5, 1.0) 
27 125.5, CH 7.80, dd (7.5, 1.3) 
28 138.7, C 
29 31.1, CH 1.98, m 
30 18.6, CH3 0.96, d (6.9) 
31 17.6, CH3 0.93, d (6.9) 
2-NH  8.61, s 
17-OH  5.70, brs 













Table 4. 13C and 1H NMR assignment for compound 6 in DMSO-d6 
No. δC δH    
2 82.9, CH 5.88, s  
3 74.1, C    
4 135.8, C   
5 124.6, CH 7.40, dd (8.0, 1.0) 
6 125.2, CH 7.20, ddd (8.0, 8.0, 1.3)  
7 130.1, CH 7.38, ddd (8.0, 8.0, 1.0)  
8 114.1, CH 7.47, dd (8.0, 1.3)  
9 139.7, C   
10 174.4, C   
11 59.7, CH 4.58, q (7.3)  
12 13.8, CH3 1.57, d (7.3)  
13 34.7, CH2 2.92, dd (14.3, 7.0); 2.65, dd (14.3, 5.1)  
14 55.6, CH 4.88, dd (7.0, 5.1)  
15 164.2, C   
17 159.9, C   
18 121.4, C   
19 126.2, CH 8.14, dd (8.0, 1.3)  
20 127.4, CH 7.56, ddd (8.0, 8.0, 1.0)  
21 134.7, CH 7.84, ddd (8.0, 8.0, 1.3) 
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22 127.2, CH 7.67, dd (8.0, 1.0) 
23 147.5, C  
25 146.7, CH 8.25, s 


















Table 5. 13C and 1H NMR assignment for compound 7 in DMSO-d6 
No. δC δH    
2 83.3, CH 5.85, s  
3 74.0, C    
4 135.4, C   
5 124.6, CH 7.52, dd (7.4, 1.0) 
6 125.2, CH 7.24, ddd (7.5, 7.4, 1.4)  
7 130.0, CH 7.42, ddd (7.6, 7.5, 1.0)  
8 114.1, CH 7.43, dd (7.6, 1.4)  
9 139.9, C   
10 175.2, C   
11 65.3, CH 4.45, dd (9.4, 5.9)  
12 21.7, CH2 2.06, m; 2.00, m  
13 34.4, CH2 2.97, dd (14.2, 7.2); 2.72, dd (14.2, 5.2)  
14 55.7, CH 4.89, dd (7.2, 5.2)  
15 164.6, C   
17 159.8, C   
18 121.5, C   
19 126.2, CH 8.17, dd (7.9, 1.2)  
20 127.4, CH 7.59, ddd (7.9, 7.9, 1.0)  
21 134.7, CH 7.87, ddd (7.9, 7.9, 1.2) 
22 127.2, CH 7.71, dd (7.9, 1.0) 
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23 147.5, C  
25 146.7, CH 8.29, s 
27 10.9, CH3 1.11, t (7.3) 

















Table 6. 13C and 1H NMR assignment for compound 8 in DMSO-d6 
No. δC δH    
2 83.7, CH 5.81, s  
3 73.9, C    
4 134.9, C   
5 124.6, CH 7.54, dd (7.5, 1.3) 
6 125.2, CH 7.26, ddd (7.8, 7.5, 1.3)  
7 130.1, CH 7.43, ddd (7.8, 7.5, 1.3)  
8 114.2, CH 7.46, dd (7.5, 1.3)  
9 140.3, C   
10 173.9, C   
11 69.4, CH 4.21, d (9.3)  
12 28.2, CH 2.44, m  
13 34.1, CH2 3.01, dd (14.0, 7.9); 2.77, dd (14.0, 5.3)  
14 55.7, CH 4.86, dd (7.9, 5.3)  
15 164.9, C   
17 159.8, C   
18 121.5, C   
19 126.2, CH 8.18, dd (7.9, 1.3)  
20 127.4, CH 7.59, ddd (7.9, 7.5, 1.0)  
21 134.7, CH 7.87, ddd (7.7, 7.5, 1.3) 
22 127.2, CH 7.71, dd (7.7, 1.0) 
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23 147.5, C  
25 146.9, CH 8.30, s 
27 20.2, CH3 1.12, d (6.7) 
28 18.7, CH3 1.15, d (6.7) 















Table 7. 13C and 1H NMR assignment for compound 9 in DMSO-d6 
No. δC δH    
2 84.5, CH 5.78, s  
3 76.7, C    
4 137.5, C   
5 124.6, CH 7.47, dd (7.4, 0.9) 
6 125.5, CH 7.24, ddd (7.4, 7.4, 1.2)  
7 129.7, CH 7.41, ddd (7.8, 7.4, 0.9)  
8 114.7, CH 7.49, dd (7.8, 1.2)  
9 137.6, C   
10 169.7, C   
11 69.6, CH 4.37, d (6.7)  
12 30.3, CH 2.26, m  
13 38.2, CH2 2.93, dd (13.0, 13.0); 2.49, dd (13.0, 3.5)  
14 49.1, CH 5.98, dd (13.0, 3.5)  
15 167.2, C   
17 159.9, C   
18 121.0, C   
19 126.4, CH 8.20, dd (7.9, 1.3)  
20 127.2, CH 7.58, ddd (7.9, 7.6, 0.9)  
21 134.7, CH 7.86, ddd (7.8, 7.6, 1.3) 
22 127.1, CH 7.70, dd (7.8, 0.9) 
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23 147.2, C  
25 146.7, CH 8.23, s 
27 19.1, CH3 1.09, d (6.7) 
28 19.0, CH3 1.05, d (6.7) 

















IV. Asperphenins A and B, as anticancer agents from a Marine-
Derived Aspergillus sp. Fungus  
Asperphenins A (17) and B (18), two new lipopeptide containing aromatic 
compounds were isolated from the marine-derived fungus Aspergillus sp.. 
Based upon the results of combined spectroscopic analyses, these compounds 
were structurally elucidated to be lipopeptide containing the benzophenone 
function group, the first example of this type. The new compounds were 
significantly active toward HCT116, and moderately avtive against SNU638 
SK-HEP1, MDA-MB 231, and weak toward the A549 cell line. Compound 
18 also was studied the vivo test and elicited a significant antitumor on RKO 
cell-implanted xenografts. 
4-1. Introduction 
Marine microorganism has been widely recognized as the prolific 
sources of natural products with biological activities and unique structures.2-
6 Marine-derived fungi, as one of the three major dominated phylogenetic 
groups, have produed more than 400 novel compounds since 1997, of which 
exhibited potent and diverse bioactivities.3,7-8  
During the course of searching for bioactive metabolites from 
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marine-derived fungi, one strain Aspergillus sp. was isolated from marine-
submerged decaying wood from Korea based on the LC-ESIMS profile of 
crude extract, from which several fumiquinazoline-related and chatominine 
derivatives were isolated and structural determination as previous report.69 
Recently, another twe new compounds were isolated and structural 
determinated as lipopeptide type containing the benzophenone functional 
group. These two new compounds have the similar character with 
fellutamides possessing 3-hydroxydodecanoic acid, aspergine, and glutamine 
which have been reported in the literature.70-72 However this is the first 
example of the lipoppeptide connected with the benzophenone functional 
group.73 Both compounds possessed the significantly bioactivity toward the 
HCT116, moderately active toward the SNU638, SK-HEP1, and MDA-MB 
231, and weak activity toward the A549. Compound 18 was studied the vivo 





Figure 15. The chemical structures of compounds 17-18 
4-2. Results and discussion 
The molecular formula of asperphenin A (17) was deduced as 
C42H61N5O11 by the HRFABMS analysis. The 
13C NMR data of this 
compound showed two ketones signals at C 201.8 and 198.3, four carbonyl 
carbons at C 171.8, 171.2, 170.9, and 170.2, respectively (Table 8). 
Additionly, two NH2 groups were observed as two pairs of broad singlets at 
H 7.14 and 6.70, 7.39 and 6.91 (Table 8) implied two units of primary amines. 
In 1H NMR data three amine protons were observed as doublets using DMSO-
d6 as solvent at H 8.04, 7.92, and 7.66, and three α-NH protons were detected 
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at H 4.44, 4.13, and 4.02 as well. This information revealed the presence of 
three amino units in compound 17, which was implied by the resonances at 
H 52.6, 49.8, and 43.4 in 
13C NMR. The overlapped signals (H 1.19-1.30) in 
1H NMR and methylenes (C 37.0-22.1) in 
13C NMR indicated the fatty acid 
chain. And the presence of 12 carbon signals in the aromatic region (C 161.6-
106.8) in 13C NMR data, along with the corresponding proton signals (H 
6.19-7.21) in the 1H NMR data and aromatic absorptions (322 and 268 nm) 
in UV spectrum, was indicative of two benzene rings in 17. Hence, the 
compound 17 was a system including fatty acid, three units of peptide, and 
two aromatic rings. The IR strong absorption at 3309 and 1671 cm-1 also 
supported it.   
 





The planar structure of compound 17 was determined by the 
combination of 1H-1H COSY, HSQC, and HMBC experiments. First, two 
aromatic protons (H 7.21, H-2, and 6.84, H-4) appeared as broad siglets, and 
the 1H-1H COSY correlations between these two protons and the methyl 
group (C 20.8 and H 2.29) indicated the H-2 and H-4 had to be in the meta-
positon to one another (Figure 16). The linear spin system of three aromatic 
protons resonating at H 7.15, 6.19, and 6.19 implied three protons were 
adjacent in the other aromatic ring. All the carbons were assigned by the 
HSQC and HMBC data. Three downfield carbon signals at C 161.6 (C-9, 13) 
and 153.4 (C-5) indicated the oxygenated ones.Two aromatic rings were 
connected with each other via the 15-keone at C 198.3 based on the long-
range correlation in the HMBC data, which was identical as 
monodictyphenone except the 7-ketone substitute in 17 instead of 1-
carboxylic acid in monodictyphenone.70 From the TOCSY, 1H-1H COSY, 
HSQC, and HMBC correlations, the fatty acid was determined as 
hydroxytetradecanoic acid and three amino uints were defined as aspergine, 
glutamine, and 1-methlene-3-methylbutyl-amine, which is quite similar to 
that of fellutamide C.71 The linkage of these segments were deduced by the 
long-range HMBC (H-17/C-22, NH-17/C-22, NH-23/C-27, and NH-28/C-
31). And the 1-methlene-3-methylbutyl-amine was connected to the 
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monodictyphenone via the 7-ketone at C 201.8 in the long-range HMBC data 
(H-17/C-7 and H-16/C-7) (Figure 17). Thus, the planar structure of 





Figure 17. The selective HMBC (arrows) correlations of compound 17. 
Asperphenin A possesses asymmetric carbon centers at C-17, C-23, 
C-28, and C-33. The absolte configuration of the Gln-derived and Asn-
derived residues at the C-23 and C-28 were determined as L by advanced 
Marfey’s analysis as described in the references reported.70-72 And the 
absolute chemistry of hydroxyl in C-33 was determined as R by Mosher 
method from the Δδ values between the MTPA esters (Figure 18). Dued to the 
unstability of compound 17 in basic condition, the cyclization of compound 
17 was designed between C-7 and C-16 to make five member ring based on 
the aldol condensation mechanism74 and compound 19 was obtained. And 
then all the phenolic hydroxyl group were protected by acetylation using 
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(Ac)2O as the reagent. R/S-MTPA ester of compound 19 (19S and 19R) were 
obtained (schem 2). And the absolute chemistry of C-33 was unambiguously 
assigned as R. 
 
Schem 2. a. DMF, K2CO3; b. (Ac)2O in pyridine; c. MTPA-Cl in pyridine 
 
 
Figure 18. The ∆δ (δ(S-ester)-δ(R-ester)) values of MTPA esterification for 
compound 19 acetylation. 
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To figure out the relative stereochemsity of C-17, we designed the 
ketone reduction of asperphenin A. As the 7-ketone located between two 
aromatic ring, it played more active character than 15-ketone. To get the 15-
ketone reduction, 7-ketone was reduced firstly and produed two reduction 
products (comounds 21 and 22). As the reduction went further, the 15-ketone 
of compound 21 was reduced and produced two products, compounds 25 and 
26, respectively. However, the compound 22 was decomposed during the 
reduction procedure. As a result, two products (compounds 25 and 26) of 
7,15-diketone reduction of asperphenin A were produced using the NaBH4 as 
reduction reagent (schem 3). Then we utilized J-based configuration75 
analysis with vicinal 1H-1H and 3-bond 1H-13C coupling constants and 
ROESY corrlations.  
 
Schem 3. Reagent: NaBH4, dry MeOH 
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The 1H-1H coupling constants were measured in the 1H and 1H 
homodecoupling NMR spectra, and long-range heteronuclear coupling 
constants were acquired via a hetero half-filtered TOCSY (HETLOC) NMR 
experiment.75 For compound 25, the 3JH15/H16b value (10.0 Hz) suggested an 
anti relationship between H-15 and H-16b. The small value of 3JC17/H15 (2.2 
Hz) indicated a relative gauche relationship between C-17 and H-15. The 
small value of 2JC15/H16a (-1.8 Hz) implied an anti relationship between 15-
OH and H-16a. Futher analysis of the 1H-1H and 1H-13C coupling constants 
strongly suggested the rotamer depicted in Figure 19. The ROESY 
correlations of H-15 to H-16a and H-17 completely supported the 
configuration shown in Figure 19. 
 
Figure 19. J-based configuration analysis of 7,15-diketone reduction of 




The intermediate value of 3JH17/H16a (7.3 Hz) and 
3JH17/H16b (6.9 Hz) 
indicated the rotational changes occurred between two rotamers as the Figure 
20b. The large value of 2JC17/H16b (-5.1 Hz) implied the gauche relationship 
between 17-NH and H-16b. The relative stereochemistry of C-15 and C-17 
were assigned as 15S*, 17R*. For compound 26, the relative stereochemistry 
between C-15 and C-17 were assigned as 15R*, 17R* based on the 1H-1H and 
1H-13C coupling constants as shown in Figure 21, respectively.  
   
Figure 20. J-based configuration analysis of 7,15-diketone reduction of 




    
Figure 21. J-based configuration analysis of 7,15-diketone reduction of 
asperphenin A (26) at (a) C-15 and C-16, and (b) C-16 and C-17.  
The molecular formula of asperphenin B (18) was deduced as 
C42H61N5O11 by the HRFABMS analysis, the same molecular formula with 
asperphenin A. The IR, UV spectrum were identical with asperphenin A. And 
the 1D and 2D NMR were quite similar with asperphenin A as well (Table 9). 
However, these two compounds eluted in different retension time in HPLC.  
Futher analysis of asperphenin B, we found both compounds 
possessed the same planar structure and identical chirality in C-23, C-28, and 
C-33 using the same method as decribed in asperphenin A. Compound 20 was 
the cylization product of asperphenin B. To determine the stereochemistry of 
C-17 in asperphenin B, 7,15-diketone reduction products (compounds 27 and 
28) were designed and HETLOC analysis was applied for the products as 
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shown in the Figures 22, 23 and 24. The relative chemistry of C-15 and C-17 
were assigned 15R* and 17S*, 15S* and 17S* in 27 and 28, respectively. 
Asperphenins A and B possess the different chirality in C-17. This conclusion 
explained well the different retension time for these two compounds in the 
HPLC with the same condition. Unfortunately, the absolute chemistry of C-
15 couldn’t be assigned due to the decomposition of MTPA esterification of 
compounds 25, 26, 27, and 28 using the MTPA-chloride as reagent in 
pyridine. 
 
Figure 22. J-based configuration analysis of 7,15-diketone reduction of 
asperphenin B (27) at C-15 and C-16. 
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Figure 23. J-based configuration analysis of 7,15-diketone reduction of 
asperphenin B (27) at C-16 and C-17. 
       
Figure 24. J-based configuration analysis of 7,15-diketone reduction of 
asperphenin B (28) at (a) C-15 and C-16, and (b) C-16 and C-17. 
Then the recently proposed CD and ECD calculation was employed, 
which has been used to unambiguously assign both relative and absolute 
configurations for many natural products76. The first CD spectrum of 
asperphenins A and B is asymmetric and the similar optical rotation with -
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24.7 and -18.4 for A and B, maybe due to the conjugated system is far away 
from the C-17 and free rotation with linear side chain. Interestingly, the 
cylization products of asperphenins A and B (comounds 19 and 20) showed 
the symmetric CD spectrum and opposite optical rotation with +56.5 and -
85.5 for 19 and 20, repectively. Then the unit of C-1~C-21~17-NH was 
selected as unit to be applied the ECD calculation. From the ECD spectrum, 
we assigned the absolute chemistry of C-17 as R for asperphenin A and S for 
asperphenin B, respectively (Figure 25). Thus, all the stereochemistry were 
successfully determined as 17R, 23S, 28S, and 33R for asperphenin A, 17S, 
23S, 28S, and 33R for asperphenin B.  
 
Figure 25. The CD spectrum of cycloasperphenins A and B, ECD spectrum 
of cyclo-ASP-partial_17R and cyclo-ASP-partial_17S. 
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In our bioactivity measurement, compounds 17-28 were studied 
toward the A549, HCT116, SNU638, SK-HEP1, and MDA-MB 231. 
Asperphenins A (17) and B (18) were significantly ative against HCT116, 
moderately active toward the SNU638, SK-HEP1, and MDA-MB 231, and 
weak activity toward the A549 (Table 10). However, the cycloasperphenins 
A (19) and B (20) were inactive toward all the cell lines, and 7-ketone 
reduction of asperphenins A (21, 22) and B (23) were inactive toward the 
A549 and MDA-MB 231, and weak toward HCT116, SNU638 and SK-
HEP1. And 7-ketone reduction of asperphenin B (24) and 7,15-diketone 
reduction of asperphenins A (26) and B (27, 28) were inactive toward all the 
cell lines. The results implied that the 7-ketone and 15-ketone played the 
important role for activities against A549, HCT116, SNU638, SK-HEP1, and 
MDA-MB 231 (Table 10). Morever, the asperphenin B (18) was studied as 
the antitumor agent on RKO cell-implated xenografts. Asperphenin B 
exhibited significant inhibition of colon cancer. At a concentration of 8mg/kg, 
the inhibition rate was 68.7%, which was approached the inhibition rate of 
irinotecan with the 4 mg/kg. And the combination of asperphenin B and 
irinotecan improved the inhibition to 86.9% (Figure 26). Therefore, the 
significant inhibition toward the colon cancer by asperphenin B may be 
suggestive of a potential role in anticancer drug. The mechanism of anti-colon 
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Inhibition rate (%) 38.9 68.7 70.0 86.9 
FTV 
Asperphenin B (4 mg/kg) 
 
FTV 
Irinotecan (4 mg/kg) 
Expected FTV Observed FTV 
Combination 
ratio 
0.61 0.30 0.18 0.13 1.39 
Figure 26. The antitumor effects of asperphenin B (18) on RKO cell-implated 
xenografts. 
4-3. Experimental section 
General Experimental Procedures. The optical rotations were 
measured on a JASCO P-2000 polarimeter using a 1 cm cell. The UV spectra 
were acquired with a Hitachi U-3010 spectrophotometer. ECD spectra were 
recorded using an Applied Photophysic Chirasscan-plus circular dichroism 
detector. The IR spectra were recorded on a JASCO 4200 FT-IR spectrometer, 
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using a ZnSe cell. The NMR spectra were recorded on Bruker Avance 600 
MHz spectrometer at the NCIRF (National Center for Interuniversity 
Research Facilities at Seoul National University), and on Bruker Avance II 
800 MHz and 900 MHz at the KBSI (Korea Basic Science Institute at 
Ochang). HRFABMS data were acquired using a Jeol JMS 700 mass 
spectrometer with meta-nitrobenzyl alcohol (NBA) as the matrix at the Korea 
Basic Science Institute (Daegu, Korea). The HPLC analyses were performed 
on a Spectrasystem p2000 equipped with a refractive index detector 
(Spectrasystem RI-150). All of the solvents used were spectroscopic grade or 
distilled from glass prior to use.  
Isolation and Identification of the Fungal Strain. The fungal strain 
Aspergillus sp. (strain number F452) was isolated from submerged decaying 
wood off of the shore of Jeju Island, Korea, in November 2011. The strain was 
identified using standard molecular biological protocols by DNA 
amplification and sequencing of the ITS region. The genomic DNA extraction 
was performed using Intron’s i-genomic BYF DNA Extraction Mini Kit 
according to the manufacturer’s protocol. The nucleotide sequence of F452 
has been deposited in the GenBank database under the accession number 
KF384188. The 18S rDNA sequence of this strain showed a 99% identity with 
Aspergillus versicolor Ppf48 (GenBank accession number GU586852). 
 
81 
Fermentation and Isolation. The isolated strain was cultivated on a 
YPG agar plate (5 g yeast extract, 5 g peptone, 10 g glucose, and 16.0 g agar 
in 1 L artificial seawater) for 4 days. The agar plugs (1 cm × 1 cm, 5 pieces 
each) were inoculated into 100 mL of the YPG media in a 250 mL Erlenmeyer 
flask for 5 days, then separately transferred to 2.8 L glass Fernbach flasks 
with rice media (2 g peptone, 2 g yeast extract, 200 g rice with 200 mL 
artificial seawater in each flask, boiled in an autoclave for 20 min at 120 °C; 
24 flasks in total). The fermentation in the rice media was conducted under 
static conditions for 6 weeks and then was extracted by MeOH (1 L × 3) and 
CH2Cl2 (1 L × 3). The solvent was evaporated to obtain an organic extract. 
The combined extracts (102.6 g) were successively partitioned between n-
BuOH (72.5 g) and H2O (30.1 g); the former fraction was repartitioned using 
H2O-MeOH (15:85) (44.3 g) and n-hexane (31.2 g). The fraction of H2O-
MeOH (15:85) was separated by C18 reversed-phase vacuum flash 
chromatography using a sequential mixture of MeCN and H2O as eluents 
(five fractions in gradient, H2O‒MeCN, from 80:20 to 0:100), MeOH, 
acetone, and finally EtOAc. On the basis of the results of LC-MS analysis, 
the fractions eluted with H2O‒MeCN (40:60) (11.3 g) was separated by C18 
reversed-phase vacuum flash chromatography again using a sequential 
mixture of MeCN and H2O as eluents (six fractions in gradient, H2O‒MeCN, 
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from 50:50 to 0:100), and 100% MeOH. The fraction eluted with H2O‒MeCN 
(40:60) (2.1 g) was separated by semi-preparative reversed-phase HPLC 
(H2O‒MeOH, 30:70, 2.0 mL/min) to afford compound 17 (103.2 mg) and 
compound 18 (106.7 mg). 
Asperphenin A (17): pale yellow amorphous solid, []25D  ‒24.7 (c 
0.1, MeOH); UV (MeOH) max (log ) 211 (4.65), 268 (4.25), 322 (3.95) nm; 
CD (MeOH) λ (∆ε) 217 (+2.26), 235 (-1.79), 331 (-0.30) nm; IR (ZnSe) max 
3309, 1671 cm‒1; 1H and 13C NMR data, see Table 8; HRFABMS, m/z 
812.4430 [M+H]+ (Calcd for C42H62N5O11, 812.4440). 
Asperphenin B (18): pale yellow amorphous solid, []25D  ‒18.4 (c 
0.1, MeOH); UV (MeOH) max (log ) 211 (4.65), 268 (4.25), 322 (3.95) nm; 
CD (MeOH) λ (∆ε) 224 (-0.80), 242 (-1.10), 280 (+0.66), 337 (-0.08), 448 
(+0.10) nm; IR (ZnSe) max 3309, 1670 cm
‒1; 1H and 13C NMR data, see Table 
8; HRFABMS, m/z 812.4431 [M+H]+ (Calcd for C42H62N5O11, 812.4440). 
Cyclization of Compounds 17 and 18. Compound 17 (21.2 mg) was 
dissolved in DMF (3 ml) containing K2CO3 (4.3 mg) and was stirred for 7 h. 
The solution was extracted by EA and evaporated under vacuum and the 
residue of the reaction was purified by reverse-phase HPLC (YMC-ODS 
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column, 4.6 × 250 mm; H2O‒MeCN, 50:50, 1.0 mL/min) to afford 19 (4.2 
mg) (retention time in HPLC: 17.5min). 20 (4.3 mg) was prepared in the same 
procedure from the compound 18 (22.8 mg).  
Compound 19 (19): 1H NMR (600 MHz, MeOD-d4) δ 7.03 (1 H, t, 
J = 8.3 Hz, H-11), 6.77 (1 H, s, H-2), 6.57 (1 H, s, H-4), 6.45 (1 H, J = 8.3 
Hz, H-10), 6.41 (1 H, J = 8.3 Hz, H-12), 4.70 (1 H, dd, J = 7.2, 5.4 Hz, H-28), 
4.65 (1 H, t, J = 7.8 Hz, H-17), 4.25 (1 H, dd, J = 9.5, 4.4 Hz, H-23), 3.97 (1 
H, m, H-33), 2.81 (1 H, dd, J = 15.4, 5.4 Hz, H-29), 2.75 (1 H, dd, J = 15.4, 
7.2 Hz, H-29), 2.45 (1 H, dd, J = 14.3, 4.1 Hz, H-32), 2.32 (1 H, dd, J = 14.3, 
8.4 Hz, H-32), 2.26 (2 H, overlap, H-25), 2.23 (3 H, s, H-14), 2.10 (1 H, m, 
H-24), 1.84 (1 H, m, H-24), 1.56 (1 H, m, H-19), 1.47 (3 H, m, H-18, H-34), 
1.28 (15 H, m, H-34‒H-41), 0.88 (3 H, t, J = 6.8 Hz, H-42), 0.71 (3 H, d, J = 
6.8 Hz, H-20), 0.70 (3 H, d, J = 6.8 Hz, H-21); 13C NMR (600 MHz, MeOD-
d4) δ 199.3 (C-15), 178.2 (C-26), 175.2 (C-27), 174.7 (C-4), 173.4 (C-5), 
172.0 (C-22), 156.7 (C-9), 156.4 9C-13), 156.1 (C-5), 153.4 (C-7), 141.7 (C-
3), 134.3 (C-1), 132.9 (C-16), 131.0 (C-11), 126.8 (C-6), 125.2 (C-4), 116.5 
(C-2), 111.5 (C-8), 108.4 (C-12), 108.0 (C-10), 69.8 (C-33), 54.4 (C-23), 51.7 
(C-28), 45.5 (C-17), 44.6 (C-32), 43.5 (C-18), 38.3 (C-34), 37.3 (C-29), 33.1 
(C-40), 32.5 (C-25), 30.8 (C-36), 30.7 (C-37), 30.7 (C-38), 30.5 (C-39), 28.9 
(C-24), 26.8 (C-35), 25.6 (C-19), 23.8 (C-41), 23.2 (C-21), 22.5 (C-20), 21.2 
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(C-14), 14.5 (C-42); []25D  +56.5 (c 1.0, MeOH); CD (MeOH) λ (∆ε) 248 
(+1.99), 334 (-0.44), 448 (+0.10) nm (Figure 20); LRESIMS m/z 794.4, [M-
H2O+H]
+ (Calcd for C42H60N5O10).  
Compound 20 (20): 1H NMR (600 MHz, MeOD-d4) δ 7.03 (1 H, t, 
J = 8.3 Hz, H-11), 6.77 (1 H, s, H-2), 6.57 (1 H, s, H-4), 6.46 (1 H, J = 8.3 
Hz, H-10), 6.40 (1 H, J = 8.3 Hz, H-12), 4.71 (1 H, dd, J = 5.6, 6.4 Hz, H-28), 
4.65 (1 H, t, J = 7.8 Hz, H-17), 4.26 (1 H, dd, J = 9.5, 4.5 Hz, H-23), 3.98 (1 
H, m, H-33), 2.75 (2 H, overlap, H-29), 2.47 (1 H, dd, J = 14.3, 4.1 Hz, H-
32), 2.34 (1 H, dd, J = 14.3, 8.7 Hz, H-32), 2.26 (2 H, overlap, H-25), 2.23 (3 
H, s, H-14), 2.14 (1 H, m, H-24), 1.85 (1 H, m, H-24), 1.56 (1 H, m, H-19), 
1.49 (3 H, m, H-18, H-34), 1.28 (15 H, m, H-34‒H-41), 0.89 (3 H, t, J = 6.8 
Hz, H-42), 0.71 (3 H, d, J = 6.8 Hz, H-20), 0.69 (3 H, d, J = 6.8 Hz, H-21); 
13C NMR (600 MHz, MeOD-d4) δ 199.4 (C-15), 178.1 (C-26), 175.1 (C-27), 
174.8 (C-4), 173.5 (C-5), 172.1 (C-22), 156.8 (C-9), 156.4 (C-13), 156.1 (C-
5), 153.4 (C-7), 141.7 (C-3), 134.3 (C-1), 132.9 (C-16), 131.0 (C-11), 126.8 
(C-6), 125.3 (C-4), 116.6 (C-2), 111.6 (C-8), 108.4 (C-12), 108.0 (C-10), 69.8 
(C-33), 54.5 (C-23), 51.9 (C-28), 45.7 (C-17), 44.6 (C-32), 43.5 (C-18), 38.3 
(C-34), 37.4 (C-29), 33.1 (C-40), 32.5 (C-25), 30.8 (C-36), 30.7 (C-37), 30.7 
(C-38), 30.5 (C-39), 28.9 (C-24), 26.7 (C-35), 25.7 (C-19), 23.8 (C-41), 23.1 
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(C-21), 22.5 (C-20), 21.2 (C-14), 14.5 (C-42); []25D  ‒85.5 (c 1.0, MeOH); 
CD (MeOH) λ (∆ε) 241 (-2.53), 318 (+0.18), 470 (-0.47) nm (Figure 20); 
LRESIMS m/z 794.3, [M-H2O+H]
+ (Calcd for C42H60N5O10). 
Esterifications of Compounds 19 and 20. Compound 19 (2.5 mg) 
was dissolved in pyridine (0.5 ml), then acetic anhydride (3 µl) was added in 
ice cooling water bath. After 2 h in room temperature, the reaction was 
quenched by adding ice water and evaporated the solvent using evaporator. 
And the residue was divided to 1.5 mg and 1.4 mg, respectively. To a solution 
of 1.5 mg in 1.0 mL of pyridine (distilled over CaH2), were added 0.5 mg 
DMAP, and 10 μL of (-)-(R)-MTPA chloride. The mixture was stirred under 
N2 for 2 h at room temperature. After the consumption of the starting material 
was confirmed by HPLC-DAD, the solvent was removed under vacuum and 
the residue was purified by reverse-phase HPLC (YMC-ODS column, 4.6 × 
250 mm; H2O‒MeCN, 20:80, 1.0 mL/min) to afford 19S, the (S)-MTPA ester 
of 19 acetylation (S of 19 acetylation). 19R, the corresponding (R)-MTPA 
ester of 19 acetylation (R of 19 acetylation) was also obtained from the same 
esterification reaction with (+)-(S)-MTPA chloride. 20S (S of 20 acetylation) 




Compound 19S (21): 1H NMR (600 MHz, MeOD-d4) δ 7.53 (1 H, t, 
J = 8.3 Hz, H-11), 7.53-7.42 (5 H, m, aromatic, MPTA), 7.30 (1 H, d, J = 8.3 
Hz, H-12), 7.29 (1 H, d, J = 8.3 Hz, H-10), 7.18 (1 H, s, H-2), 6.96 (1 H, s, 
H-4), 5.55 (1 H, dddd, J = 12.4, 6.2, 6.2, 6.2 Hz, H-33), 4.65 (1 H, dd, J = 
10.2, 4.3 Hz, H-17), 4.49 (1 H, dd, J = 6.8, 6.0 Hz, H-28), 4.32 (1 H, dd, J = 
9.6, 4.2 Hz, H-23), 3.51 (3 H, s, OMe, MTPA), 2.76 (1 H, dd, J = 16.9, 6.0 
Hz, H-29), 2.72 (1 H, dd, J = 16.9, 6.0 Hz, H-29), 2.65 (2 H, t, J = 6.2 Hz, H-
32), 2.46 (2 H, t, J = 7.9 Hz, H-25), 2.34 (3 H, s, H-14), 2.15 (1 H, m, H-24), 
2.04 (3 H, s, 9-OAc), 2.02 (3 H, s, 13-OAc), 1.85 (1 H, m, H-24), 1.76 (1 H, 
m, H-18), 1.73 (2 H, overlap, H-34), 1.55 (3 H, s, 5-OAc), 1.50 (1 H, m, H-
19), 1.36 (2 H, overlap, H-35), 1.32 (1 H, m, H-18), 1.30-1.25 (12 H, overlap, 
H-36─H-41), 0.89 (3 H, t, J = 7.1 Hz, H-42), 0.79 (3 H, d, J = 6.9 Hz, H-20), 
0.73 (3 H, d, J = 6.5 Hz, H-21); ESI-MS m/z 1136.40, [M+H]+ (Calcd for 
C58H73F3N5O15 1136.50).  
Compound 19R (22): 1H NMR (600 MHz, MeOD-d4) δ 7.53 (1 H, 
t, J = 8.3 Hz, H-11), 7.53-7.42 (5 H, m, aromatic, MPTA), 7.30 (1 H, d, J = 
8.3 Hz, H-12), 7.29 (1 H, d, J = 8.3 Hz, H-10), 7.18 (1 H, s, H-2), 6.96 (1 H, 
s, H-4), 5.53 (1 H, dddd, J = 12.4, 6.4, 6.4, 6.3 Hz, H-33), 4.65 (1 H, dd, J = 
10.2, 4.3 Hz, H-17), 4.63 (1 H, dd, J = 7.6, 5.6 Hz, H-28), 4.33 (1 H, dd, J = 
9.6, 4.2 Hz, H-23), 3.55 (3 H, s, OMe, MTPA), 2.95 (1 H, dd, J = 17.2, 5.6 
 
87 
Hz, H-29), 2.88 (1 H, dd, J = 17.2, 7.6 Hz, H-29), 2.70 (2 H, t, J = 6.4 Hz, H-
32), 2.47 (2 H, t, J = 7.9 Hz, H-25), 2.34 (3 H, s, H-14), 2.15 (1 H, m, H-24), 
2.04 (3 H, s, 9-OAc), 2.02 (3 H, s, 13-OAc), 1.86 (1 H, m, H-24), 1.76 (1 H, 
m, H-18), 1.63 (2 H, overlap, H-34), 1.55 (3 H, s, 5-OAc), 1.50 (1 H, m, H-
19), 1.32 (1 H, m, H-18), 1.28-1.21 (12 H, overlap, H-36─H-41), 1.19 (2 H, 
overlap, H-35), 0.89 (3 H, t, J = 7.1 Hz, H-42), 0.79 (3 H, d, J = 6.9 Hz, H-
20), 0.73 (3 H, d, J = 6.5 Hz, H-21); LRESIMS m/z 1136.4, [M+H]+ (Calcd 
for C58H73F3N5O15 1136.4). 
Compound 20S (23): 1H NMR (600 MHz, MeOD-d4) δ 7.53 (1 H, t, 
J = 8.3 Hz, H-11), 7.53-7.42 (5 H, m, aromatic, MPTA), 7.30 (1 H, d, J = 8.3 
Hz, H-12), 7.30 (1 H, d, J = 8.3 Hz, H-10), 7.19 (1 H, s, H-2), 6.96 (1 H, s, 
H-4), 5.55 (1 H, m, H-33), 4.64 (1 H, dd, J = 10.1, 4.4 Hz, H-17), 4.50 (1 H, 
dd, J = 7.2, 5.9 Hz, H-28), 4.31 (1 H, dd, J = 9.7, 4.6 Hz, H-23), 3.50 (3 H, s, 
OMe, MTPA), 2.74 (1 H, dd, J = 17.0, 5.9 Hz, H-29), 2.67 (1 H, dd, J = 17.0, 
7.2 Hz, H-29), 2.64 (1 H, dd, J = 15.2, 5.0 Hz, H-32), 2.58 (1 H, dd, J = 15.2, 
8.4 Hz, H-32), 2.46 (2 H, m, H-25), 2.34 (3 H, s, H-14), 2.13 (1 H, m, H-24), 
2.05 (3 H, s, 9-OAc), 2.03 (3 H, s, 13-OAc), 1.86 (1 H, m, H-24), 1.73 (1 H, 
m, H-18), 1.73 (2 H, overlap, H-34), 1.56 (3 H, s, 5-OAc), 1.50 (1 H, m, H-
19), 1.35 (2 H, overlap, H-35), 1.33 (1 H, m, H-18), 1.35-1.28 (12 H, overlap, 
H-36─H-41), 0.89 (3 H, t, J = 7.0 Hz, H-42), 0.77 (3 H, d, J = 6.8 Hz, H-20), 
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0.73 (3 H, d, J = 6.6 Hz, H-21); ESI-MS m/z 1136.41, [M+H]+ (Calcd for 
C58H73F3N5O15 1136.50). 
Compound 20R (24): 1H NMR (600 MHz, MeOD-d4) δ 7.53 (1 H, 
t, J = 8.3 Hz, H-11), 7.53-7.42 (5 H, m, aromatic, MPTA), 7.30 (1 H, d, J = 
8.3 Hz, H-12), 7.30 (1 H, d, J = 8.3 Hz, H-10), 7.19 (1 H, s, H-2), 6.96 (1 H, 
s, H-4), 5.51 (1 H, m, H-33), 4.65 (1 H, dd, J = 10.1, 4.4 Hz, H-17), 4.63 (1 
H, dd, J = 8.0, 5.6 Hz, H-28), 4.31 (1 H, dd, J = 9.7, 4.6 Hz, H-23), 3.56 (3 
H, s, OMe, MTPA), 2.91 (1 H, dd, J = 17.2, 5.6 Hz, H-29), 2.82 (1 H, dd, J = 
17.2, 8.0 Hz, H-29), 2.69 (1 H, dd, J = 15.4, 8.4 Hz, H-32), 2.62 (1 H, dd, J = 
15.4, 5.0 Hz, H-32), 2.47 (2 H, m, H-25), 2.33 (3 H, s, H-14), 2.14 (1 H, m, 
H-24), 2.05 (3 H, s, 9-OAc), 2.03 (3 H, s, 13-OAc), 1.87 (1 H, m, H-24), 1.73 
(1 H, m, H-18), 1.62 (2 H, overlap, H-34), 1.56 (3 H, s, 5-OAc), 1.50 (1 H, 
m, H-19), 1.32 (1 H, m, H-18), 1.30-1.18 (12 H, overlap, H-36─H-41), 1.18 
(2 H, overlap, H-35), 0.89 (3 H, t, J = 7.0 Hz, H-42), 0.77 (3 H, d, J = 6.8 Hz, 
H-20), 0.72 (3 H, d, J = 6.6 Hz, H-21); LRESIMS m/z 1136.4, [M+H]+ (Calcd 
for C58H73F3N5O15 1136.5). 
Advanced Marfey’s Analysis of Compounds 17 and 18. 
Compound 17 (1.0 mg) was dissolved in 6 N HCl (0.5 ml) and heated at 110 
oC for 12 h. The solution was evaporated with distilled water three times to 
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remove the trace of HCl under vacuum. The divided hydrolysate (0.5 mg) was 
treated with 100 μL of 1N NaHCO3 followed by 50 μL of 1% L- or D- FDAA 
in acetone. The mixture was stirred at 80 oC for 5 min. After the reaction was 
quenched by the addition of 50 μL 2N HCl, the mixture was analyzed by ESI-
LC/MS to assign the chirality of the amino acids. The retention times of the 
L- and D-FDAA-derivatized hydrolysates were 10.8 and 11.4 min for L- and 
D-aspartic acid, respectively; and the retention times of the L- and D-FDAA-
derivatized hydrolysates were 12.0 and 13.2 min for L- and D-glutamic acid, 
respectively. Compound 18 was prepared and analyzed using the same 
procedure. The results demonstrated that all the amino acids in compounds 
17 and 18 were L-form. 
7-ketone reduction of Compounds 17 and 18. Compound 17 (22.1 
mg) was dissolved in MeOH (2 ml) and NaBH4 (1.2 mg) was added to the 
solution in 0 oC. Then the reaction was stirred for 30 min and quenched by 
adding 1 N HCl, the solution was purified by reverse-phase HPLC (YMC-
ODS column, 4.6 × 250 mm; H2O‒MeOH, 45:55, 1.0 mL/min) to afford 
compounds 21 (8.1 mg) and 22 (8.7 mg). Compounds 23 (8.2 mg) and 24 (8.0 
mg) were prepared in the same procedure from compound 18 (24.5 mg). 
Compound 21 (25): 1H NMR (600 MHz, MeOD-d4) δ 6.75 (1 H, t, 
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J = 8.0 Hz, H-11), 6.67 (1 H, s, H-2), 6.63 (1 H, s, H-4), 6.43 (1 H, s, H-7), 
6.21 (1 H, d, J = 7.9 Hz, H-12), 6.07 (1 H, d, J = 7.9 Hz, H-10), 4.61 (1 H, t, 
J = 6.4 Hz, H-28), 4.44 (1 H, dd, J = 10.2, 3.7 Hz, H-17), 4.27 (1 H, dd, J = 
9.6, 4.3 Hz, H-23), 3.94 (1 H, m, H-33), 2.74 (1 H, dd, J = 15.7, 6.4 Hz, H-
29), 2.70 (1 H, dd, J = 15.7, 6.4 Hz, H-29), 2.40 (1 H, dd, J = 14.4, 4.3 Hz, 
H-32), 2.31 (2 H, m, H-25), 2.29 (1 H, dd, J = 14.4, 6.8 Hz, H-32), 2.21 (3 H, 
s, H-14), 2.17 (1 H, m, H-24), 1.92 (1 H, m, H-24), 1.68 (1 H, m, H-16), 1.60 
(1 H, m, H-16), 1.49 (1 H, m, H-19 ), 1.44 (3 H, m, H-18, H-34), 1.29 (1 H, 
overlap, H-34), 1.34-1.23 (14 H, overlap, H-35─H-41), 0.96 (3 H, d, J = 6.9 
Hz, H-20), 0.93 (3 H, d, J = 6.9 Hz, H-21), 0.88 (3 H, t, J = 7.1 Hz, H-42); 
LRESIMS m/z 796.2, [M-H2O+H]
+ (Calcd for C42H62N5O10 796.4).  
Compound 22 (26): 1H NMR (600 MHz, MeOD-d4) δ 6.83 (1 H, s, 
H-4), 6.75 (1 H, t, J = 8.0 Hz, H-11), 6.67 (1 H, s, H-2), 6.44 (1 H, s, H-7), 
6.22 (1 H, d, J = 7.9 Hz, H-12), 6.09 (1 H, d, J = 7.9 Hz, H-10), 4.62 (1 H, t, 
J = 6.4 Hz, H-28), 4.52 (1 H, dd, J = 10.2, 3.7 Hz, H-17), 4.26 (1 H, dd, J = 
9.6, 4.3 Hz, H-23), 3.94 (1 H, m, H-33), 2.75 (1 H, dd, J = 15.7, 6.4 Hz, H-
29), 2.66 (1 H, dd, J = 15.7, 6.4 Hz, H-29), 2.38 (1 H, dd, J = 14.4, 4.3 Hz, 
H-32), 2.31 (2 H, m, H-25), 2.29 (1 H, dd, J = 14.4, 6.8 Hz, H-32), 2.24 (3 H, 
s, H-14), 2.18 (1 H, m, H-24), 1.94 (1 H, m, H-24), 1.64 (1 H, m, H-16), 1.60 
(1 H, m, H-16), 1.44 (3 H, m, H-18, H-34), 1.36 (1 H, m, H-19 ), 1.29 (1 H, 
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overlap, H-34), 1.34-1.23 (14 H, overlap, H-35─H-41), 0.96 (3 H, d, J = 6.9 
Hz, H-20), 0.94 (3 H, d, J = 6.9 Hz, H-21), 0.82 (3 H, t, J = 7.1 Hz, H-42); 
LRESIMS m/z 796.2, [M-H2O+H]
+ (Calcd for C42H62N5O10 796.4). 
Compound 23 (27): 1H NMR (600 MHz, MeOD-d4) δ 6.74 (1 H, t, 
J = 8.0 Hz, H-11), 6.65 (1 H, s, H-2), 6.63 (1 H, s, H-4), 6.43 (1 H, s, H-7), 
6.21 (1 H, d, J = 7.9 Hz, H-12), 6.08 (1 H, d, J = 7.9 Hz, H-10), 4.64 (1 H, t, 
J = 6.4 Hz, H-28), 4.45 (1 H, dd, J = 10.2, 3.7 Hz, H-17), 4.25 (1 H, dd, J = 
9.6, 4.3 Hz, H-23), 3.96 (1 H, m, H-33), 2.78 (1 H, dd, J = 15.7, 6.4 Hz, H-
29), 2.70 (1 H, dd, J = 15.7, 6.4 Hz, H-29), 2.41 (1 H, dd, J = 14.4, 4.3 Hz, 
H-32), 2.32 (1 H, dd, J = 14.4, 6.8 Hz, H-32), 2.30 (2 H, m, H-25), 2.21 (3 H, 
s, H-14), 2.18 (1 H, m, H-24), 1.92 (1 H, m, H-24), 1.68 (1 H, m, H-16), 1.63 
(1 H, m, H-16), 1.51 (1 H, m, H-19 ), 1.45 (3 H, m, H-18, H-34), 1.32 (1 H, 
overlap, H-34), 1.31-1.23 (14 H, overlap, H-35─H-41), 0.97 (3 H, d, J = 6.9 
Hz, H-20), 0.95 (3 H, d, J = 6.9 Hz, H-21), 0.87 (3 H, t, J = 7.1 Hz, H-42); 
LRESIMS m/z 796.2, [M-H2O+H]
+ (Calcd for C42H62N5O10 796.4).  
Compound 24 (28): 1H NMR (600 MHz, MeOD-d4) δ 6.81 (1 H, s, 
H-4), 6.75 (1 H, t, J = 8.0 Hz, H-11), 6.66 (1 H, s, H-2), 6.43 (1 H, s, H-7), 
6.23 (1 H, d, J = 7.9 Hz, H-12), 6.07 (1 H, d, J = 7.9 Hz, H-10), 4.66 (1 H, t, 
J = 6.4 Hz, H-28), 4.46 (1 H, dd, J = 10.2, 3.7 Hz, H-17), 4.26 (1 H, dd, J = 
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9.6, 4.3 Hz, H-23), 3.95 (1 H, m, H-33), 2.80 (1 H, dd, J = 15.7, 6.4 Hz, H-
29), 2.71 (1 H, dd, J = 15.7, 6.4 Hz, H-29), 2.40 (1 H, dd, J = 14.2, 4.2 Hz, 
H-32), 2.31 (1 H, dd, J = 14.2, 8.3 Hz, H-32), 2.25 (2 H, overlap, H-32), 2.24 
(3 H, s, H-14), 2.13 (1 H, m, H-24), 1.80 (1 H, m, H-24), 1.62 (2 H, overlap, 
H-16), 1.45 (3 H, m, H-18, H-34), 1.39 (1 H, m, H-19 ), 1.31 (1 H, overlap, 
H-34), 1.31-1.23 (14 H, overlap, H-35─H-41), 0.94 (3 H, d, J = 6.9 Hz, H-
20), 0.93 (3 H, d, J = 6.9 Hz, H-21), 0.89 (3 H, t, J = 7.1 Hz, H-42); LRESIMS 
m/z 796.2, [M-H2O+H]
+ (Calcd for C42H62N5O10 796.4). 
15-ketone reduction of Compounds 21 and 22. Compound 21 (8.1 
mg) was dissolved in MeOH (2 ml) and NaBH4 (0.6 mg) was added to the 
solution in 0 oC. Then the reaction was kept in room temperature for 1 h and 
quenched by adding 1 N HCl to adjust PH = 7.0, the solution was purified by 
reverse-phase HPLC (YMC-ODS column, 4.6 × 250 mm; H2O‒MeCN, 70:30 
to 50:50, 0-20 min, 1.0 mL/min) to afford compounds 25 (2.1 mg) and 26 (2.2 
mg). Compounds 27 (2.5 mg) and 28 (2.4 mg) were prepared in the same 
procedure from compound 23 (8.2 mg). 
Compound 25 (29): 1H NMR (800 MHz, MeOD-d4) δ 6.77 (1 H, t, 
J = 8.0 Hz, H-11), 6.61 (1 H, s, H-2), 6.46 (1 H, s, H-4), 6.29 (1 H, s, H-7), 
6.24 (1 H, d, J = 8.0 Hz, H-12), 6.13 (1 H, d, J = 8.0 Hz, H-10), 5.52 (1 H, dd, 
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J = 9.2, 4.4, H-15), 4.64 (1 H, t, J = 6.4 Hz, H-28), 4.29 (1 H, dd, J = 10.0, 
4.1 Hz, H-23), 4.23 (1 H, dddd, J = 10.5, 7.3, 6.9, 4.0 Hz, H-17), 3.96 (1 H, 
m, H-33), 2.80 (1 H, dd, J = 15.8, 6.4 Hz, H-29), 2.75 (1 H, dd, J = 15.8, 6.4 
Hz, H-29), 2.45 (1 H, dd, J = 14.1, 4.3 Hz, H-32), 2.33 (2 H, m, H-25), 2.32 
(1 H, dd, J = 14.1, 6.8 Hz, H-32), 2.23 (1 H, m, H-24), 2.18 (3 H, s, H-14), 
2.02 (1 H, ddd, J = 14.1, 10.0, 6.9, H-16), 1.94 (1 H, m, H-24), 1.75 (1 H, ddd, 
J = 14.1, 7.3, 3.3, H-16), 1.50 (1 H, ddd, J = 14.1, 10.5, 4.5, H-18), 1.39 (1 H, 
ddd, J = 14.1, 9.7, 4.0, H-18), 1.45 (2 H, m, H-34), 1.29 (1 H, m, H-19), 1.31-
1.22 (14 H, overlap, H-35─H-41), 0.93 (3 H, t, J = 7.1 Hz, H-42), 0.88 (3 H, 
d, J = 6.9 Hz, H-20), 0.87 (3 H, d, J = 6.9 Hz, H-21); LRESIMS m/z 798.3, 
[M-H2O+H]
+ (Calcd for C42H64N5O10 798.4). 
Compound 26 (30): 1H NMR (900 MHz, MeOD-d4) δ 6.77 (1 H, t, 
J = 8.0 Hz, H-11), 6.63 (1 H, s, H-2), 6.45 (1 H, s, H-4), 6.27 (1 H, s, H-7), 
6.24 (1 H, d, J = 8.0 Hz, H-12), 6.11 (1 H, d, J = 8.0 Hz, H-10), 5.38 (1 H, dd, 
J = 10.6, 2.1, H-15), 4.65 (1 H, dd, J = 7.2, 6.3 Hz, H-28), 4.32 (1 H, dd, J = 
9.4, 4.3 Hz, H-23), 4.29 (1 H, dddd, J = 9.8, 9.8, 4.3, 4.3 Hz, H-17), 3.94 (1 
H, m, H-33), 2.79 (1 H, dd, J = 15.9, 7.2 Hz, H-29), 2.68 (1 H, dd, J = 15.9, 
6.3 Hz, H-29), 2.40 (1 H, dd, J = 14.4, 4.2 Hz, H-32), 2.39 (2 H, overlap, H-
25), 2.30 (1 H, dd, J = 14.4, 8.6 Hz, H-32), 2.23 (1 H, m, H-24), 2.18 (3 H, s, 
H-14), 2.03 (1 H, m, H-24), 1.94 (1 H, ddd, J = 14.3, 10.6, 4.3, H-16), 1.72 
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(1 H, ddd, J = 14.3, 9.8, 2.1, H-16), 1.66 (1 H, m, H-19), 1.54 (1 H, ddd, J = 
14.4, 10.4, 4.3, H-18), 1.41 (1 H, ddd, J = 14.4, 9.8, 4.4, H-18), 1.45 (2 H, m, 
H-34), 1.33-1.25 (14 H, overlap, H-35─H-41), 0.92 (3 H, d, J = 6.7 Hz, H-
20), 0.91 (3 H, d, J = 6.7 Hz, H-21), 0.89 (3 H, t, J = 7.2 Hz, H-42); LRESIMS 
m/z 798.3, [M-H2O+H]
+ (Calcd for C42H64N5O10 798.4). 
Compound 27 (31): 1H NMR (900 MHz, MeOD-d4) δ 6.77 (1 H, t, 
J = 8.0 Hz, H-11), 6.61 (1 H, s, H-2), 6.46 (1 H, s, H-4), 6.31 (1 H, s, H-7), 
6.24 (1 H, d, J = 8.0 Hz, H-12), 6.13 (1 H, d, J = 8.0 Hz, H-10), 5.50 (1 H, dd, 
J = 9.2, 4.4, H-15), 4.65 (1 H, t, J = 6.4 Hz, H-28), 4.26 (1 H, dd, J = 9.8, 4.2 
Hz, H-23), 4.15 (1 H, dddd, J = 10.1, 7.2, 6.8, 4.7 Hz, H-17), 3.98 (1 H, m, 
H-33), 2.79 (1 H, dd, J = 15.8, 6.4 Hz, H-29), 2.73 (1 H, dd, J = 15.8, 6.4 Hz, 
H-29), 2.44 (1 H, dd, J = 14.3, 4.1 Hz, H-32), 2.33 (1 H, dd, J = 14.3, 8.6 Hz, 
H-32), 2.31 (2 H, m, H-25), 2.19 (1 H, overlap, H-24), 2.18 (3 H, s, H-14), 
2.03 (1 H, ddd, J = 14.2, 9.2, 7.2, H-16), 1.91 (1 H, m, H-24), 1.81 (1 H, ddd, 
J = 14.2, 6.8, 4.4, H-16), 1.59 (1 H, m, H-19), 1.50 (1 H, overlap, H-18), 1.40 
(1 H, ddd, J = 13.7, 9.1, 4.7, H-18), 1.48 (1 H, m, H-34), 1.44 (1 H, m, H-34), 
1.35-1.25 (14 H, overlap, H-35─H-41), 0.89 (3 H, t, J = 6.5 Hz, H-42), 0.89 
(3 H, d, J = 6.5 Hz, H-20), 0.86 (3 H, d, J = 6.5 Hz, H-21); LRESIMS m/z 
798.2, [M-H2O+H]
+ (Calcd for C42H64N5O10 798.4). 
 
95 
Compound 28 (32): 1H NMR (900 MHz, MeOD-d4) δ 6.76 (1 H, t, 
J = 8.1 Hz, H-11), 6.60 (1 H, s, H-2), 6.45 (1 H, s, H-4), 6.28 (1 H, s, H-7), 
6.23 (1 H, d, J = 8.1 Hz, H-12), 6.18 (1 H, d, J = 8.1 Hz, H-10), 5.50 (1 H, dd, 
J = 10.7, 2.1, H-15), 4.66 (1 H, t, J = 6.4 Hz, H-28), 4.38 (1 H, dd, J = 10.2, 
3.6 Hz, H-23), 4.28 (1 H, dddd, J = 9.5, 9.4, 4.9, 4.2 Hz, H-17), 3.98 (1 H, m, 
H-33), 2.80 (1 H, dd, J = 15.7, 6.4 Hz, H-29), 2.74 (1 H, dd, J = 15.7, 6.4 Hz, 
H-29), 2.43 (1 H, dd, J = 14.3, 4.1 Hz, H-32), 2.33 (1 H, dd, J = 14.3, 8.6 Hz, 
H-32), 2.31 (2 H, m, H-25), 2.31 (1 H, overlap, H-24), 2.18 (3 H, s, H-14), 
1.97 (1 H, ddd, J = 14.7, 10.7, 4.2, H-16), 1.95 (1 H, m, H-24), 1.69 (1 H, ddd, 
J = 14.7, 9.4, 2.1, H-16), 1.68 (1 H, m, H-19), 1.64 (1 H, J = 14.2, 10.4, 4.9, 
H-18), 1.48 (2 H, m, H-34), 1.44 (1 H, ddd, J = 14.2, 9.5, 4.5, H-18), 1.35-
1.25 (14 H, overlap, H-35─H-41), 0.94 (3 H, d, J = 6.5 Hz, H-20), 0.91 (3 H, 
d, J = 6.5 Hz, H-21), 0.89 (3 H, t, J = 6.5 Hz, H-42); LRESIMS m/z 798.3, 
[M-H2O+H]
+ (Calcd for C42H64N5O10 798.4). 
Computational Analysis. The ground-state geometries were 
optimized with density functional theory (DFT) calculations using Turbomole 
6.5 with the basis set def-SV(P) for all atoms at the DFT level, using the 
B3LYP functional; the ground states were further confirmed by a harmonic 
frequency calculation. The calculated ECD data corresponding to the 
optimized structures were obtained using TDDFT with the basis set def2-
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TZVPP for all atoms at the DFT level, using the B3LYP functional. The ECD 
spectra were simulated by overlapping for each traction, where σ is the width 
of the band at 1/e height. ∆Ei and Ri are the excitation energies and rotatory 
strengths for transition i, respectively 
Biological assays. Five human cancer cell lines (A549, HCT116, 
SNU638, SK-HEP1, and MDA-MB231; 3.5 × 104 cells/mL) were treated 
with asperphenins A, B, and cycloasperhenins A, B, and other several 
reduction products of asperphenins A, B for 3 days. After treatment, cells 
were fixed with a 10% TCA solution, and cell viability was determined using 
a sulforhodamine B (SRB) assay. The results were expressed as percentages 
relative to solvent-treated control incubations, and IC50 values were 







Table 8. 13C and 1H NMR assignment for compound 17 in DMSO-d6
a
 
 Position δC δH   
 1 136.0, C  
 2 120.4, CH 7.21, s 
 3 138.5, C  
 4 120.2, CH 6.84, s 
 5 153.4, C  
 6 128.6, C  
 7 201.8, C  
 8 111.1, C  
 9 161.6, C  
 10 106.8, CH 6.19, d (8.3) 
 11 135.7, CH 7.15, t (8.3) 
 12 106.8, CH 6.19, d (8.3) 
 13 161.6, C  
 14 20.8, CH3 2.29, s  
 15 198.3, C  
 16 44.7, CH2 3.00, dd (16.5, 4.5); 2.85, dd (16.5, 8.7) 
 17 43.4, CH 4.13, m 
 17-NH  7.66, d (8.3) 
 18 42.4, CH2 1.28, m
b; 0.98, ddd (13.7, 9.4, 3.4) 
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 19 24.1, CH 1.45, m 
 20 21.3, CH3 0.66, d (6.7) 
 21 23.3, CH3 0.71, d (6.7) 
 22 170.2, C  
 23 52.6, CH 4.02, m 
 23-NH  7.92, d (7.7) 
 24 27.6, CH2 1.87, m; 1.65, m 
 25 31.4, CH2 2.02, t (7.9); 2.02, t (7.9) 
 26 173.9, C 
 26-NH2  7.14, brs; 6.70, brs 
 27 170.9, C 
 28 49.8, CH 4.44, m 
 28-NH  8.04, d (7.5) 
 29 36.9, CH2 2.40, m
b 
 30 171.8, C 
 30-NH2  7.39, brs; 6.91, brs 
 31 171.2, C 
 32 43.7, CH2 2.18, m
b 
 33 67.5, CH 3.75, m 
 33-OH  4.59, brs 
 34 37.0, CH2 1.30, m
b; 1.30, mb 
 35 25.1, CH2 1.19, m
b; 1.19, mb 
 36 31.3, CH2 1.19, m
b; 1.19, mb 
 37 29.1, CH2 1.19, m
b; 1.19, mb 
 38 29.1, CH2 1.19, m
b; 1.19, mb 
 39 29.0, CH2 1.19, m
b; 1.19, mb 
 40 28.7, CH2 1.19, m
b; 1.19, mb 
 41 22.1, CH2 1.21, m
b; 1.21, mb 
 42 13.9, CH3 0.81, t (7.0)    




Table 9. 13C and 1H NMR assignment for compound 18 in DMSO-d6
a
 
 Position δC δH   
 1 136.0, C  
 2 120.3, CH 7.21, s 
 3 138.6, C  
 4 120.5, CH 6.84, s 
 5 153.4, C  
 6 128.7, C  
 7 201.8, C  
 8 111.1, C  
 9 161.6, C  
 10 106.8, CH 6.19, d (8.1) 
 11 135.7, CH 7.15, t (8.1) 
 12 106.8, CH 6.19, d (8.1) 
 13 161.6, C  
 14 20.8, CH3 2.29, s  
 15 198.4, C  
 16 44.6, CH2 2.97, dd (16.4, 4.2); 2.85, dd (16.4, 8.5) 
 17 43.5, CH 4.13, brs 
 17-NH  7.63, d (8.2) 
 18 42.6, CH2 1.34, m
b; 1.01, mb 
 19 24.2, CH 1.46, m 
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 20 21.4, CH3 0.69, d (6.4) 
 21 23.4, CH3 0.74, d (6.4) 
 22 170.4, C  
 23 52.7, CH 4.02, brs 
 23-NH  8.03, d (8.4) 
 24 27.5, CH2 1.87, m; 1.65, m 
 25 31.5, CH2 2.02, m
b; 2.02, mb 
 26 174.1, C 
 26-NH2  7.16, brs; 6.74, brs 
 27 171.0, C 
 28 49.9, CH 4.46, ddd (6.9, 6.9, 5.1) 
 28-NH  8.05, d (7.5) 
 29 36.9, CH2 2.53, dd (15.6, 6.9); 2.42, dd (15.6, 6.9) 
 30 171.9, C 
 30-NH2  7.41, brs; 6.95, brs 
 31 171.3, C 
 32 43.7, CH2 2.18, m
b; 2.18, mb 
 33 67.5, CH 3.75, m 
 33-OH  4.60, brs 
 34 37.0, CH2 1.30, m
b; 1.30, mb 
 35 25.1, CH2 1.30, m
b; 1.19, mb 
 36 31.3, CH2 1.19, m
b; 1.19, mb 
 37 29.1, CH2 1.19, m
b; 1.19, mb 
 38 29.1, CH2 1.19, m
b; 1.19, mb 
 39 29.0, CH2 1.19, m
b; 1.19, mb 
 40 28.8, CH2 1.19, m
b; 1.19, mb 
 41 22.1, CH2 1.19, m
b; 1.19, mb 
 42 14.0, CH3 0.81, t (6.7)    




Table 10. Results of bioactivity tests (compounds 17-24, 26-28). 
>50 
IC50 
Gram (+) bacteria A549 HCT116 SNU638 SK-HEP1 MDA-MB231 
17 25.7 29.5 4.8 2.9 1.9 
18 38.7 2.2 8.0 3.5 4.3 
19 >50 >50 >50 >50 >50 
20 >50 35.0 35.0 31.5 42.4 
21 >50 29.5 39.3 36.9 45.4 
22 >50 48.2 48.6 41.4 >50 
23 >50 36.8 43.3 48.1 >50 
24 >50 >50 >50 >50 >50 
26 >50 >50 >50 >50 >50 
27 >50 >50 >50 >50 >50 
28 >50 >50 >50 >50 >50 













The purpose of this work is the investigation of new bioactive 
metabolites from marine-derived fungi. Based upon chemical analysis and 
bioassay, novel substances from marine-derived fungi have been isolated and 
demonstrated the biomedical potential as new drug candidates. 
LC-ESIMS analysis and bioactivity studies of selected two fungal 
strains lead to isolation of 9 novel compounds and 9 known compounds. 
These compounds have been structurally elucidated by combined 
spectroscopic methods and chemical analysis. The structures of these 18 
compounds are belonged to various structural classes and have been derived 
from various biogenetic origins. 
Diverse bioassay tests related to anticancer, antimicrobial, enzyme-
inhibitory, and quinone reductase activities have been performed. Some of the 
isolated compounds showed potent bioactivities anticancer and quinone 



















Traditional herbal medicines have been practiced to maintain health 
and treat diseases especially in the Asia communities for more than 2,000 
years. Herbal medicines are a comprehensive and holistic approach of 
medical practice with their own principles, diagnosis, and treatment system 
that balancing body function. They consider that human body is related to its 
own physical, natural and social environment.76 Recently, herbal medicines 
were used increasingly not only complement of conventional medical care 
but also functional food and dietary supplements in worldwide. According to 
U.S. national surveys conducted in 2002, over 75% of Asian-Americans and 
20% of adults had used herbal therapies in the past year.77  
Herbal medicines are prescribed alone for the treatment of various 
chronic diseases as well as in combination with other herbal ingredients in 
traditional herbal prescriptions.78 The combined use or processing of plants is 
thought to have favorable effects such as reduction of toxicity and side effects, 
potentiation of biological effects, alteration of properties or functions, 
microbiological prevention, correction of unpleasant tastes and an increase in 
purity by reduction of contaminants.79  
Increment of worldwide attention and concomitant pharmaceutical 
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research has made it essential to carry out the quality control measurement 
for the herbal medicines. However, serious hindrance has been attributed to 
the lack of recognition and regulation of professions, qualified practitioners, 
quality-controlled herbal medicines, and evidence-based clinical studies.80 
Thus it is urgently needed to establish a comprehensive qualified evaluation 
method that could accurately reflect the quality of herbal medicines. 
The purpose of this study is developing simultaneous analysis methods 
of bioactive compounds in herbal medicines. Two widely used herbal 
medicines, which are Kalopanacis Cortex (the dried stem bark of Kalopanax 
pictus) and semen Ziziphus jujuba were subjected to the current study. In herbal 
medicines, it is hard to consider that single or a few compounds would 
determine the overall pharmacological activities. Rather, it is more likely that 
multiple compounds act simultaneously and attribute to the therapeutic 
function of the herbal medicine. For this reason, every bioactive metabolites in 
the selected herbal medicines were analyzed and determined. In particular, 
three phenolics and nine hedergenin saponins were selected for the analysis of 
Kalopanacis Cortex. Moreover, one alkaloid, five flavonoid saponins and three 
jujuboside saponins from semen Ziziphus jujuba were also analyzed. 
The methods based on HPLC-DAD-ELSD-MS was established for 
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the quantitative and qualitative analysis of a selected folk medicines. Various 
validation parameters, such as linearity, limit of detection, limit of 
quantification, recovery, accuracy, and precision, were successfully obtained. 
In addition, the efficiencies of diverse extraction methods were compared for 
the development of a standard analytic method. The verified methods were 
successfully applied to the quantitative determination of representative 







II. Quantification and Identification of Bioactive Metabolites 
from Kalopanacis Cortex by HPLC with Evaporative Light 
Scattering Detection and ESI Quadrupole TOF MS  
A method based on HPLC-ELSD-Q-TOF-MS was established for the 
simultaneous determination of twelve bioactive metabolites from the 
Kalopanacis Cortex. Validation parameters, such as linearity, limit of 
detection, limit of quantification, recovery, accuracy, and precision, were 
successfully obtained. In addition, the efficiencies of diverse extraction 
methods were compared for the development of a standard analytic method. 
The verified method was successfully applied to the quantitative 
determination of twelve representative metabolites in sixty-one Kalopanacis 
Cortex samples from Korea and China. The quantitation results demonstrated 
that six compounds, coniferin (33), kalopanaxsaponin C (40), septemlosides 
II (38), III (36), C (39), and D (37), which exhibited distinct regional patterns 
in KC samples, could serve as marker compounds to distinguish KC from 
Korea and China.  
2-1. Introduction 
Kalopanax pictus, which belongs to the Araliaceae family, is a 
deciduous tree that is widely distributed in east Asian countries. Kalopanacis 
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Cortex, the dried stem bark of Kalopanax pictus, has been used as a traditional 
medicine to treat diverse conditions, such as diabetes mellitus, lumbago, 
neurotic pain, paralysis, and rheumatic arthritis.81,82  
Chemical investigations have revealed that the major constituents of 
this plant are triterpene saponins of the hederagenin class,83-85 with other 
constituents including phenolics 81 and lignans.86 
The crude extract of the stem bark of K. pictus has been reported to 
possess diverse bioactivities, such as antinociceptive,87,88 antidiabetic,89 anti-
inflammatory90-92 and cytotoxic activities.93,94 Kalopanaxsaponin B, a 
hederagenin bisdesmosidic saponin and one of the major constituents of KC, 
showed potent antimutagenic activity against aflatoxin.93 Kalopanaxsaponin 
A and I, monodesmosides, showed anti-inflammatory and anti-rheumatoidal 
activities.95 Additionally, the phenolic compounds such as liriodendrin and 
syringin exhibited significant hepatoprotective effect.96 
To date, diverse efforts have been reported to develop HPLC-UV 
methods to analyze these therapeutical constituents in KC. However, these 
methods have been restricted to limited marker compounds, such as one 
triterpene saponin 96 or only phenolic constituents.97,98 This is mainly 
attributed to the lack of chromophore in triterpene saponins, the major 
components of KC, which significantly hinders their analysis by UV 
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detection due to the high level of baseline noise and poor sensitivity. 
Furthermore, a complex mixture of many different compounds is responsible 
for all of the pharmacological activities in herbal medicines.99 Therefore, it is 
necessary to develop a new method for the simultaneous analysis of the 
overall chemical components of KC.  
The present study aimed to develop a simple and reliable HPLC 
method involving evaporative light scattering detector (ELSD) and 
electrospray ionization quadrupole time-of-flight (ESI-QTOF) mass detectors 
to quantify and identify triterpene saponins and phenolics in KC. ELSD was 
selected as the detector due to its capacity for the sensitive detection of 
nonvolatile analytes regardless of the presence of chromophores.100,101 
HPLC-ESI-QTOF-MS was also used to confirm peak identification by 
comparing the high resolution molecular mass and molecular formulas of the 
constituents.  
The efficiency of the developed HPLC-ELSD methods was 
successfully verified by diverse validation parameters such as the linearity, 
limits of detection and quantification, accuracy, precision, repeatability, and 
stability. In addition, the efficiencies of different extraction methods were 
compared. Using the developed methods, the contents of marker compounds 
in sixty-one commercial KC samples from Korea and China were 
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quantitatively analyzed and compared.  
During this study, one new hederagenin saponin, designated to be 
septemloside D, was isolated and included as one of the representative 
metabolites for the development of the analytical method. The structure of 
this compound was unambiguously elucidated by a combination of 
spectroscopic methods including IR, MS, and 1D and 2D NMR analyses.  
Significant differences between the concentrations of the phenolic 
compound coniferin, triterpene saponins septemlosides II and III, 
septemlosides C and D, and kalopanaxsaponin C from Korean and Chinese 
KC samples demonstrated their potential to serve as marker compounds for 
the quality control and geographical discrimination of KC samples upon the 
validation of their biological activities. 
2-2. Experimental section 
Plant materials - Sixty-one KC samples were collected and 
identified from various locations in Korea and China, and were provided by 
Prof. Je-Hyun Lee, Dongguk University, Korea thorough the National Center 
for Standardization of Herbal Medicine, Korea. Of the KC samples, eighteen 
(K-01~K-18) were collected from Korea, and forty-three (C-01~C-43) were 
collected from China. Voucher specimens of all of the KC samples were 
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deposited at the Natural Products Research Institute, Seoul National 
University (Table S1). 
Extraction, isolation, and structure determination - KC (C-16: 
280 g for extraction) was repeatedly extracted with methanol (1 L × 3). The 
crude extract was partitioned between H2O and n-BuOH. The n-BuOH extract 
was subjected to reverse-phase vacuum flash chromatography using 
sequential mixtures of H2O and MeOH (elution order: 50%, 40%, 30%, 20%, 
10% aqueous MeOH and 100% MeOH) and acetone as eluents. For the 
HPLC-ELSD analysis, the fractions that eluted with 50:50 H2O-MeOH and 
40:60 H2O-MeOH were chosen for separation. The 50:50 H2O-MeOH 
fraction was separated by semi-preparative reverse-phase HPLC (10 × 250 
mm, 5.0 μm) using H2O-MeOH (65:35) as the eluent followed by purification 
with reverse-phase HPLC (4.6 × 250 mm, 5.0 μm) using H2O-MeCN (85:15) 
to yield compound 33 (65.3 mg).  
The fraction that eluted with H2O-MeOH (40:60) was separated by 
semi-preparative reverse-phase HPLC (10 × 250 mm, 5.0 μm) using H2O-
MeOH (50:50) as the eluent to yield, in order of elution, compounds 34 (40.1 
mg), 35 (32.4 mg), 36 (20.6 mg) and 37 (21.3 mg). Comparison of the NMR 
and MS data with reported values led to the identification of the structures of 
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the known compounds 34, 36, 38, 39 as chlorogenic acid (34), septemloside 
III (36),102 septemloside II (38),103 
(http://www.dissertationtopic.net/doc/1588727), septemloside C (39),103 
respectively, while compound 37 was determined as a new hederagenin 
saponin.  
Compound 37 was obtained as a white, amorphous powder. The 
molecular formula was determined to be C74H120O38 from the 
pseudomolecular ion peak [M+H]+ at m/z 1616.7458 (calcd for C74H120O38, 
1616.7528) in the HR-ESI-QTOF-MS. The aglycone moiety of 37 was 
determined to be the same as in the other hedegrin triterpenoids by 2D NMR 
analyses as well as comparison of the spectroscopic data with literature 
data.103 The proton-proton COSY, HSQC and HMBC experiments 
successfully assigned all of the protons and carbons in the aglycone moiety 
(Table 11). 
The anomeric proton signals at δH 6.41 (1 H, d, J = 2.5 Hz), 6.28 (1 
H, br s), 6.09 (1 H, d, J = 8.5 Hz), 5.83 (1 H, s), 5.29 (1 H, d, J = 7.6 Hz), 
5.06 (1 H, d, J = 6.7 Hz), 4.98 (1 H, d, J = 8.2 Hz), and 4.84 (1 H, d, J = 7.8 
Hz) showed HMQC correlations with the carbon signals at δC 109.0, 101.5, 
94.4, 102.8, 107.2, 104.6, 104.8 and 103.8, respectively, indicating the 
presence of eight sugar units in 37. The downfield chemical shift of C-3 (δC 
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81.3) and upfield chemical shift of C-28 (δC 176.5) in the 
13C NMR spectrum 
of 37 (Table 11) indicated that this compound is a bisdesmosidic saponin.103  
However, the acid hydrolysis of 37 yielded a sugar mixture consisting 
of only four sugar residues D-xylose, D-glucose, L-rhamnose and L-
arabinose, which were identified by RP-HPLC-UV analysis using authentic 
samples as references. The peak intensity of each sugar unit in conjunction 
with the 1H and 13C-NMR analyses, indicated that the eight sugar units of 37 
were indeed consisted of each two four-sugar units. The protons of each of 
the monosaccharide residues were assigned starting with the anomeric 
protons via 1D and 2D TOCSY experiments. The presence of a 
furanoarabinose was determined from its distinct proton-proton coupling 
constants (2.4 Hz for H-1; 4.6 Hz and 2.4 Hz for H-2) and carbon chemical 
shifts (δC 109.0, 82.7, 77.9, 85.7, 62.8) (Table 11), while the remaining seven 
sugars contained the same pyranose backbone as in septemloside II.103 
Given this information, the bisdesmosidic nature of 37 as well as its 
full structure was determined by HMBC experiments. First, the sugar chain 
at C-3 was elucidated to be β-D-xylopyranosyl-(1→4)-β-D-xyloyranosyl-
(1→3)-α-L-rhamnopyranosyl-(1→2)-β-D-arabinopyranosyl from the 
following HMBC correlations: H-1 of xylose-II with C-4 of xylose-I, H-1 of 
xylose-I with C-3 of rhamnose-I, H-1 of rhamnose-I with C-2 of arabinose-I, 
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H-1 of arabinose-I with C-3 of the aglycone. Similarly, the sugar chain at C-
28 was also elucidated to be [α-L-arabinofuranosyl-(1→2)]-α-L-
rhamnopyranosyl-(1→4)-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl. 
The structure of α-L-arabinofuranose was also confirmed by the HMBC 
correlations of the H-1 anomeric proton with the C-4 carbon at δC 77.9 in the 




glucopyranosyl ester, and designated to be septemloside D.  
Acid hydrolysis and HPLC analysis of compound 37. A solution 
of 37 (2.0 mg) in 4 N TFA (0.5 mL) was stirred at 110 οC for 4 h. After it was 
cooled to room temperature, the solution was concentrated by rotary 
evaporation and kept under high vacuum for 12 h. The residue was dissolved 
in pyridine (0.5 mL) containing L-cysteine methyl ester hydrochloride (0.5 
mg) and heated at 60 οC for 1 h. A 0.1 mL solution of o-tolyl isothiocyanate 
(0.5 mg) in pyridine (0.5 mL) was added to the mixture, which was then 
heated at 60 οC for 1 h. The reaction mixture was directly analyzed by reverse-
phase HPLC.104 Peaks of hydrolysate derivatives were detected at 21.52, 
24.59, 25.57, and 38.19 min. The retention times of the authentic sugar 
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samples after treating simultaneously with L-cysteine methyl ester 
hydrochloride and o-tolyl isothiocyanate were 19.66 (L-glucose), 21.56 (D-
glucose), 23.75 (L-xylose), 24.55 (L-arabinose), 25.56 (D-xylose), 26.67 (D-
arabinose) and 38.15 (L-rhamnose) min. Co-injection of the hydrolysate 
derivatives with authentic samples of D-glucose, L-arabinose, D-xylose, and 
L-rhamnose gave single peaks at 21.54, 24.62, 25.54 and 38.23 min, 
respectively. 
Chemicals and reagents. Coniferin (33), liriodendrin (35), 
kalopanaxsaponin C (40), sieboldianoside A (41), kalopanaxsaponin B (42), 
cussonoside A (43), and kalopanaxsaponin A (44) were provided from the 
National Center for Standardization of Herbal Medicine, Korea. Chlorogenic 
acid (34), septemloside III (36), septemloside D (37), septemloside II (38), 
and septemloside C (39) were isolated and purified from KC using a series of 
chromatographic procedures. Glycyrrhizin was used as an internal standard 
compound and was obtained from Sigma-Aldrich (USA). Methanol, 
acetonitrile, and water were HPLC grade and purchased from Burdick & 
Jackson (USA), and analytical grade ethanol was purchased from Duksan 
(Korea).   
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Instrumentation and chromatographic conditions. The HPLC 
system consisted of Agilent 1200 series equipped with an autosampler, a 
column oven, a binary pump, an ELSD detector (Agilent Technologies, 1260 
Infinity), and a degasser (Agilent Technologies, Avondale, CA, USA). 
Separation was performed on an OptimaPak C18 (4.6 × 250 mm, 5.0 μm) 
analytical column. A gradient elution of A (water, 0.1% formic acid) and B 
(acetonitrile, 0.1% formic acid) was used (0 min, 15% B; 25 min, 25% B; 55 
min, 30% B; 60 min, 40% B; 65 min, 45% B; 75 min, 70% B; 80 min, 100% 
B in A v/v). The analytes were monitored with ELSD. Standard or sample 
solutions (10 μL) were directly injected to the HPLC system. The mobile 
phase flow rate was 0.3 mL/min and the column temperature was set to 25 οC. 
The ESI-QTOF-MS was performed with an Agilent 1260 series 
HPLC equipped with a binary pump (Agilent Technologies, 1290 Infinity) 
and coupled to an Accurate-Mass Q-TOF LC/MS (Agilent Technologies, 
6530). All of the mass data were obtained in positive ion mode [M + Na]+ 
with an ESI source and the mass range set to m/z 100 – 2000. The conditions 
of the ESI source were as follows: capillary voltage, 4000 V; nebulizing gas 
(N2) pressure, 30 psig; drying gas (N2) flow rate, 10.0 L/min; drying gas 
temperature, 350 οC; spectra rate, 1.03 Hz; sheath gas temperature, 350 οC; 
sheath gas flow 12 L/min. The operations and data analysis were performed 
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using the Agilent LC-MS-Q-TOF Mass Hunter Data Acquisition Software 
Ver. A.01.00 (Agilent Technologies) and the Agilent Mass Hunter Qualitative 
Analysis Software B.02.01, respectively. 
Preparation of standard solution. Stock solution (1 mg/mL) of the 
coniferin (33), chlorogenic acid (34), liriodendrin (35), septemloside III (36), 
septemloside D (37), septemloside II (38), septemloside C (39), 
kalopanaxsaponin C (40), sieboldianoside A (41), kalopanaxsaponin B (42), 
cussonoside A (43), and kalopanaxsaponin A (44) (Figure 27) isolated from 
KC were prepared individually in methanol. An appropriate amount of each 
standard solution was mixed and diluted to a series of concentrations as 
indicated for calibration. 
Preparation of test samples. 200 mg of KC and 1 mg of an internal 
standard compound were accurately weighed and extracted with 10 mL of 50% 
aqueous methanol by sonication at room temperature for 30 min. The solution 
was filtered through a 0.45 μm membrane filter prior to use. A 10 μL aliquot 
was injected for analysis. 
Calibration curves, limit of detection and limit of quantification. 
A methanol stock solution that contained the twelve analytes was prepared 
and diluted to a series of appropriate concentrations for the construction of 
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calibration curves. Mixed standard solutions at six different concentrations 
were loaded onto the HPLC in triplicate. The calibration function of each 
individual compound was calculated by plotting the logarithms of the peak 
areas versus the logarithms of the concentrations for each analyte. The limit 
of detection (LOD) and limit of quantification (LOQ) values under the 
chromatographic conditions used were determined separately at S/N values 
of 3 and 10, respectively. 
Precision, repeatability and stability. Intra- and inter-day variations 
were chosen to determine the precision of the developed method. Using three 
different concentrations of the twelve standard compounds, the intra-day 
precision was determined by performing the analysis three times within one 
day, while the inter-day precision was examined by performing the analysis 
on three consecutive days. To evaluate the repeatability of the developed 
method, five independently prepared KC samples were extracted and 
analyzed using identical conditions. The stability was tested by repeated 
analysis of KC samples every 4 h within a 24 h time period at room 
temperature. The relative standard deviation (RSD) was used as a measure of 
precision, repeatability and stability.  
Accuracy. Recovery was used to evaluate the accuracy of the method. 
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Standard addition was performed with a pre-analyzed standard solution. 
Three different standard mixtures were added to the KC sample. Spiked 
samples were prepared in triplicate and three determinations were performed. 
The recovery was determined according to the following formula: recovery 
(%) = (detected amount – original amount)/amount spiked × 100%. 
5-4. Results and discussion 
Optimization of HPLC conditions. The chromatographic 
conditions were first optimized for the simultaneous determination of 
representative KC metabolites belonging to two different chemical classes, 
phenolics and triterpene saponins. Various mixtures of acetonitrile, methanol 
and water were tested as the mobile phase. The mobile phase composed of 
acetonitrile (0.1% formic acid) and water (0.1% formic acid) achieved the 
best separation of the KC metabolites. To obtain the chromatographic benefit 
by suppressing silanol activity and provide an excess of cations in mass 
spectrometric analysis in positive mode, formic acid was added. The detection 
temperature was optimized by testing at 25, 30, 35, and 40 οC. The optimal 
detection temperature was determined to be 25 οC, where the baseline was 
stable and all of the compounds had good capacity factors, separation factors 
and resolutions. The ELSD parameters, such as the nebulizing gas flow rate 
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and drift tube temperature, were optimized to obtain the highest signals at the 
lowest nebulizer gas flow rate. The optimum ELSD parameters used to 
analyze the twelve compounds were as follows: drift tube temperature, 85 οC; 
nebulizing gas flow rate, 45 psig. As a result, a gradient system composed of 
acetonitrile (0.1% formic acid) – water (0.1% formic acid) solvent system 
gave the desired separation at 25 οC within a running time of 85 min (Figure 
28). 
Optimization of extraction conditions. To obtain a quantitative 
analytical method, the extraction conditions, including the extraction method, 
extraction solvent and extraction time, were optimized. Sonication, vortex 
and reflux extraction methods were compared for the selection of the optimal 
extraction method (Table S2) in 50% aqueous methanol as the solvent for 30 
min. Aqueous methanol or ethanol solutions were also texted as the extraction 
solvent (Table S3) using sonication for 30 min. The yields were also 
compared for the extraction time of 10, 20, 30, 60, and 90 min of sonication 
in 50% aqueous methanol to determine the optimal extraction time (Table S4). 
The results indicated that most of the marker compounds showed significantly 
higher yields with extraction in 50% aqueous methanol for 30 min of 
extraction by sonication than under any of the other tested conditions.  
 
121 
Validation of methodology. The calibration curves showed good 
linearity and the correlation coefficients were found to be in the range of 
0.996 – 0.999 for all of the tested compounds. The LODs and LOQs for the 
nine triterpene saponins were 2.5 – 4.6 and 8.5 – 15.7 μg/mL, respectively, 
whereas the LODs and LOQs for phenolics were 6.2 – 10.0 and 21.0 – 34.5 
μg/mL, respectively (Table 12). The relative standard deviation (RSD) was 
used as a measurement of precision. The RSD of the intra-day and inter-day 
variability was less than 3.80% (Table 13). The variations in overall stability 
over 24 h and repeatability variations were no more than 2.24% and 3.38%, 
respectively. The recoveries (Table 14) of the twelve analytes were in the 
range of 104.21% – 95.02%. Overall, these results demonstrate that the 
developed method has enough accuracy, precision and sensitivity for the 
simultaneously quantitative analysis of the twelve representative compounds 
in KC extract. 
HPLC-DAD-ELSD-QTOF-MS analysis of the metabolites. 
Because the identification of chromatographic peaks by retention time and 
ELSD spectrum alone may be ambiguous, HPLC-ESI-QTOF-MS was used 
to identify each compound by comparison of high resolution molecular mass 
and molecular formula in addition to the HPLC-ELSD analysis. The 
spectroscopic conditions were optimized in positive ion mode, and each 
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compound exhibited distinct quasi-molecular ions [M + Na]+ in this mode 
(Table 15). The molecular ion and molecular formula of each compound were 
well matched with the chemical structures in the HPLC-ESI-QTOF-MS 
spectra (Table 15). In summary, twelve bioactive compounds were identified 
in KC extract, and the identity of each peak as 33 – 44 was clearly 
demonstrated. 
Quantitative analysis. The developed method was applied for the 
measurement the concentration of marker compounds in the commercial KC 
samples. Sixty-one KC samples from various areas of Korea and China were 
prepared as described for the development of analytical method and analyzed 
in triplicate. The results are summarized in Table 16. Among the tested 
compounds, kalopanaxsaponin B, kalopanaxsaponin C, sieboldianoside A, 
and liriodendrin were detected in all of the KC samples, while the 
concentrations of the remaining eight compounds were variable and often 
below the detecting limits (10.0, 10.0, 3.2, 2.5, 3.4, 3.2, 3.5, and 3.4 μg/mL 
for chlorogenic acid, coniferin, cussonoside A, kalopanaxsaponin A, and 
septemlosides II, III, C and D, respectively). 
Among the triterpene saponins, kalopanaxsaponin B and 
sieboldianoside A showed significantly higher average content levels in 
 
123 
Korean KC samples (28.16 ± 10.04, 18.07 ± 14.03 mg/g, respectively) than 
in Chinese KC samples (6.88 ± 8.93, 7.49 ± 10.23 mg/g, respectively). In 
contrast, kalopanaxsaponin C showed a higher concentration in Chinese KC 
samples (37.23 ± 15.45 mg/g) than in Korean samples (0.78 ± 0.66 mg/g). 
Chinese samples also contained moderate concentrations of septemlosides II 
(38) (7.94 ± 4.68 mg/g), III (36) (7.57 ± 4.65 mg/g), C (39) (3.19 ± 1.61 
mg/g,), and D (37) (7.09 ± 3.66 mg/g), but these compounds were not detected 
in Korean samples. Finally, cussonoside A (43) and kalopanaxsaponin A (44) 
were detected at low concentration in both Korean (0.35 ± 0.20, 0.40 ± 0.22 
mg/g, respectively) and Chinese KC (0.31 ± 0.16, 0.36 ± 0.26 mg/g, 
respectively) samples. Among the phenolics, liriodendrin (35) was found at a 
higher concentration in Korean KC samples (12.08 ± 6.22 mg/g) than Chinese 
samples (5.65 ± 2.61 mg/g). In contrast, chlorogenic acid (34) was found at a 
higher concentration in Chinese KC samples (3.92 ± 3.36 mg/g) than in 
Korean samples (1.03 ± 2.01 mg/g). Coniferin (33), which was detectable in 
all Korean, but only in a few Chinese KC samples showed one order of 
magnitude difference between the Korean (1.55 ± 0.65 mg/g) and Chinese 
(0.16 ± 0.30 mg/g) KC samples. 
These results clearly demonstrated that the composition of 
metabolites differs significantly between the Korean and Chinese KC samples. 
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The variations may be due to their geographical environment. This type of 
trend has been widely observed in recent analyses of other herbal medicines, 
such as the roots of Scrophularia buergeriana105 and the seed of Cassia 
obtusifolia L.106 
The quantitation results demonstrated that six compounds, coniferin 
(33), kalopanaxsaponin C (40), septemlosides II (38), III (36), C (39), and D 
(37), which exhibited distinct regional patterns in KC samples, could serve as 
marker compounds to distinguish KC from Korea and China. In addition, 
these results clearly demonstrated that the developed HPLC-ELSD-ESI-
QTOF-MS method used for the quantification and identification of several 
standard compounds, including both triterpene saponins and phenolics, has 
potential as a valuable tool for the quality control of Kalopanacis Cortex and 





Figure 27. Chemical structures of representative compounds in KC and 













Table 11. 1H (600 MHz) and 13C (150 MHz) data for septemloside D (37) (in 
pyridine-d5) 
Position δC δH Position δC δH   
1 39.2, CH2 1.57, m; 1.08, m C-3   
2 28.7, CH2 2.19, m; 1.43, d (13.3) Ara-I-1 104.6, CH 5.06, d (6.3)  
3 81.3, CH 4.29, m 2 75.5, CH 4.56, t (7.4) 
4 43.7, C  3 75.1, CH 4.03, m  
5 48.3, CH 1.76, m 4 69.7, CH 4.14, m  
6 18.3, CH2 1.84, m; 1.31, m 5 66.1, CH2 4.26, m; 3.69, m  
7 32.3, CH2 1.89, m; 1.77, m Rha-I-1 101.5, CH 6.28, br s  
8 40.1, C  2 71.9, CH 4.87, br s  
9 47.8, CH 1.73, m 3 83.1, CH 4.72, m  
10 37.0, C  4 73.1, CH 4.47, t (9.3)  
11 23.9, CH2 1.97, m; 1.93, m 5 69.6, CH 4.70, m  
12 123.1, CH 5.43, br s 6 18.4, CH3 1.58, d (6.0)  
13 144.2, C  Xyl-I-1 107.2, CH 5.29, d (7.6)  
14 42.3, C  2 75.4, CH 4.03, m  
15 26.4, CH2 2.24, m; 2.03, m 3 76.0, CH 4.24, m  
16 23.4, CH2 1.98, m; 1.92, m 4 76.8, CH 4.14, m  
17 47.1, C  5 64.9, CH24.33, m; 3.60, m
  
18 41.9, CH 3.13, dd (13.6, 4.0) Xyl-II-1 103.8, CH 4.84, d (7.6)  
19 46.2, CH2 1.70, m; 1.20, m 2 74.0, CH 3.97, m  
20 30.7, C  3 78.0, CH 4.07, m 
21 34.1, CH2 1.29, m; 1.05, m 4 71.0, CH 4.14, m  
22 33.2, CH2 1.76, m; 1.69, m 5 67.4, CH24.28, m; 3.63, m
  
23 64.0, CH 4.23, m; 3.83, d (10.4) C-28    
24 14.1, CH3 1.08, s Glc-I-1 94.4, CH 6.09, d (8.0)  
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25 16.3, CH3 0.97, s 2 76.2, CH 4.31, m 
26 17.5, CH3 1.08, s 3 77.8, CH 4.07, m  
27 26.0, CH3 1.19, s 4 71.0, CH 4.21, m  
28 176.5, C  5 78.5, CH 4.38, m  
29 32.9, CH3 0.85, s 6 69.0, CH 4.61, d (10.6)  
30 23.8, CH3 1.19, s Glc-II-1 104.8, CH 4.98, d (8.2)  
   2 75.4, CH 3.94, m  
   3 76.6, CH 4.14, m  
   4 78.8, CH 4.38, m  
   5 77.2, CH 3.66, m  
   6 61.4, CH24.21, m; 4.08, m
  
   Rha-II-1 102.8, CH 5.83, s  
   2 72.6, CH 4.66, br s  
   3 72.8, CH 4.54,dd (8.9, 2.8) 
   4 73.9, CH 4.31, m  
   5 70.4, CH 4.93, dd (6.5, 2.8) 
   6 18.5, CH3 1.70, d (6.0)  
   Ara-II-1 109.0, CH 6.41, d (2.4)  
   2 82.7, CH 4.96,dd (4.6, 2.4) 
   3 77.9, CH 4.87, m  
   4 85.7, CH 4.81, m  
   5 62.8, CH2 4.41, m; 4.29, m 
a) Protons are overlapped, unless otherwise stated (s: singlet; d: 





Table 12. Calibration curves, LODs and LOQ of standard compounds 
Comp. Range (μg/mL)  Regression equation a) r2 b) LOD (μg) LOQ (μg)   
33 20-200 Y=1.63609X-3.73191 0.998 10.0 34.2 
34 20-200 Y=1.65378X-4.12177 0.998 10.0 34.5 
35 20-200 Y=1.56300X-3.56005 0.996 6.2 21.0 
36 20-200 Y=1.57909X-3.42611 0.999 3.2 10.4 
37 20-200 Y=1.61341X-3.52106 0.999 3.4 11.4 
38 20-200 Y=1.60897X-3.51462 0.998 3.4 11.6 
39 20-200 Y=1.66117X-3.68748 0.999 3.5 12.0 
40 20-200 Y=1.57408X-3.16422 0.998 4.3 14.5 
41 30-300 Y=1.51018X-2.99213 0.996 4.5 15.3 
42 20-200 Y=1.45481X-2.79906 0.998 4.6 15.7 
43 20-200 Y=1.45252X-2.86573 0.998 3.2 10.9 
44 20-200 Y=1.72059X-3.32448 0.996 2.5 8.5 
a) Y: logarithmic value of peak area, X: logarithmic value of 
concentration of the analyte (μg/mL) 










Table 13. Precision a), repeatability b) and stability b) of twelve analytes 
Comp. Spiked amount Intra-day  Inter-day Repeatability Stablility 
      
           (μg) Recovery (%) RSD (%) Recovery (%) RSD (%) RSD (%) RSD (%) 
33 20 97.49 0.39 97.51 1.04 2.30  1.35 
 40 99.74 0.75 99.92 0.25    
 80 99.79 0.44 100.46 0.63    
34 20 97.49 0.32 97.55 1.06 1.86  1.23 
 40 104.59 1.06 105.13 1.49    
 80 99.23 1.09 99.25 1.15    
35 20 95.09 2.58 95.11 0.95 2.23  1.06 
 40 100.05 0.67 99.65 1.74    
 80 98.85 1.08 96.19 2.43    
36 40 100.12 1.05 100.18 1.05 1.19  1.20 
 80 105.81 1.12 105.83 1.03    
 120 99.72 1.04 99.86 1.12    
37 40 100.36 0.22 100.66 0.75 1.50  0.93 
 80 105.75 1.14 106.21 1.40    
 120 101.36 0.90 101.38 1.23    
38 40 103.65 1.24 103.84 1.15 3.38  2.20 
 80 103.23 0.93 103.34 0.99    
 120 101.07 1.19 101.13 1.06    
39 40 101.79 1.51 102.53 0.62 1.31  1.21 
 80 101.38 1.15 101.42 1.10    
 120 98.21 1.17 98.39 1.17    
40 40 97.92 2.79 97.45 1.16 1.87  0.89 
 80 99.36 2.18 99.98 0.72    
 120 98.62 2.06 98.36 0.31    
41 40 99.88 1.89 100.47 1.07 1.59  2.24 
 80 97.36 1.22 97.38 0.94    
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 120 99.34 0.96 98.69 0.67    
42 40 101.39 1.18 101.13 0.46 2.34  1.11 
 80 97.92 2.34 97.83 0.64    
 120 99.59 1.19 100.51 0.79    
43 20 101.69 3.61 102.77 3.14 1.71  1.52 
 40 95.99 2.96 95.02 0.89    
 80 97.41 3.80 96.19 1.34    
44 20 99.54 1.96 98.96 0.55 1.40  2.01 
 40 99.09 1.50 99.15 1.07    
 80 98.18 1.23 98.91 0.68    
a) standard compounds 

















Table 14. Recovery assay of twelve analytes in KC (n=3, mean ± SD)  
Comp. Contained (μg) Added (μg) Found (μg) Recovery (%) RSD (%)  
33 69.07 ± 2.14 25.00 94.23 ± 1.18  100.64 1.25 
  50.00 119.03 ± 2.27 99.92 2.31 
  100.00 169.53 ± 2.61 100.46 1.54 
34 57.50 ± 0.71 25.00 82.00 ± 1.13 97.98 1.38 
  50.00 109.06 ± 2.06 103.13 1.89 
  100.00 156.75 ± 1.52 99.25 0.97 
35 366.22 ± 9.30 100.00 464.92 ± 4.93 98.71 1.06 
  150.00 515.70 ± 10.00 99.65 1.94 
  200.00 510.50 ± 15.37 96.19 3.01 
36 202.63 ± 4.01 100.00 305.01 ± 6.56 102.38 2.15 
  150.00 355.38 ± 3.52 101.83 0.99 
  200.00 402.34 ± 8.53 99.86 2.12 
37 301.80 ± 4.80 100.00 398.43 ± 3.79 96.63 0.95 
  150.00 458.12 ± 7.06 104.21 1.54 
  200.00 504.56 ± 11.15 101.38 2.21 
38 245.25 ± 5.15 100.00 348.79 ± 6.10 103.54 1.75 
  150.00 400.26 ± 7.96 103.34 1.99 
  200.00 447.51 ± 9.22 101.13 2.06 
39 230.01 ± 5.11 100.00 331.23 ± 5.37 101.22 1.62 
  150.00 382.15 ± 3.44 101.42 0.90 
  200.00 426.78 ± 3.71 98.39 0.87 
40 652.34 ± 13.11 100.00 750.69 ± 8.78 98.35 1.17 
  150.00 802.31 ± 21.82 99.98 2.72 
  300.00 947.41 ± 9.57 98.36 1.01 
41 305.32 ± 5.14 100.00 404.79 ± 4.29 99.47 1.06 
  150.00 451.38 ± 4.42 97.38 0.98 
  200.00 502.70 ± 4.22 98.69 0.84 
42 153.56 ± 1.89 100.00 254.29 ± 3.43 100.73 1.35 
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  150.00 300.31 ± 5.35 97.83 1.78 
  200.00 364.58 ± 6.53 100.51 1.79 
43 79.76 ± 1.01 25.00 105.07 ± 3.73 101.25 3.55 
  50.00 127.27 ± 2.41 95.02 1.89 
  100.00 175.95 ± 1.02 96.19 0.58 
44 106.55 ± 2.03 25.00 131.16 ± 1.11 98.45 0.85 
  50.00 156.13 ± 1.98 99.15 1.27 
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Table 15. HPLC-ESI-QTOF-MS Data of standard compounds 
Comp. tR (min) Identification Formula m/z  m/z Error  
    (calculated) (observed) (ppm) 
33 15.025 coniferin C16 H22 O8 342.1301 342.1315 -3.98 
34 18.925 chlorogenic acid C16 H18 O9 354.0924 354.0951 -7.48 
35 24.353 liriodendrin C34 H46 O18 742.2687 742.2684 0.31 
36 46.200 septemlosideIII C79 H128 O42 1748.8042 1748.7880 9.27 
37 48.409 septemloside D C74 H120 O38 1616.7528 1616.7458 4.37 
38 49.635 septemloside II C74 H120 O38 1616.7583 1616.7358 7.76 
39 56.267 septemloside C C69 H112 O34 1484.7103 1484.7035 4.59 
40 59.458 kalopanax saponin C C65 H106 O31 1382.6792 1382.6718 5.32 
41 61.913 sieboldianoside A C64 H104 O30 1352.6680 1352.6612 5.00 
42 64.613 kalopanax saponin B C59 H96 O26 1220.6239 1220.6190 4.05 
43 73.462 cussonoside A C48 H78 O18 942.5194 942.5188 0.64 




Table 16. The results of quantitative analysis of KC from Korea and China (mg/g, n=3, mean ± SD)  
             
NO. 29 30 31  32 33 34         35   36      37  38  39   40 
  
K-01 1.33 ± 0.05 0.15 ± 0.00 17.91 ± 0.56 N/D N/D N/D N/D 0.58 ± 0.00 29.55 ± 0.11 23.74 ± 0.09 0.54 ± 0.00 N/D 
K-02 1.17 ± 0.05 N/D 16.05 ± 0.10 N/D N/D N/D N/D 0.36 ± 0.00 0.50 ± 0.00 16.53 ± 0.02 0.42 ± 0.00 0.48 ± 0.00 
K-03 2.25 ± 0.04 N/D 23.19 ± 0.71 N/D N/D N/D N/D 0.59 ± 0.00 37.45 ± 0.09 30.81 ± 0.11 0.51 ± 0.00 0.48 ± 0.00 
K-04 0.67 ± 0.01 N/D 4.79 ± 0.01 N/D N/D N/D N/D 0.40 ± 0.00 19.45 ± 0.00 20.83 ± 0.01 0.45 ± 0.00 0.50 ± 0.00 
K-05 1.91 ± 0.03 N/D 11.18 ± 0.12 N/D N/D N/D N/D 0.69 ± 0.01 31.33 ± 1.56 35.03 ± 1.12 0.42 ± 0.00 0.51 ± 0.00 
K-06 1.93 ± 0.06 N/D 13.55 ± 0.23 N/D N/D N/D N/D 2.60 ± 0.01 0.84 ± 0.00 55.05 ± 1.23 N/D 0.51 ± 0.00 
K-07 1.68 ± 0.03 N/D 8.06 ± 0.32 N/D N/D N/D N/D 0.36 ± 0.00 1.79 ± 0.00 24.83 ± 1.03 0.42 ± 0.00 0.49 ± 0.00 
K-08 0.88 ± 0.01 N/D 4.75 ± 0.10 N/D N/D N/D N/D 0.47 ± 0.00 0.64 ± 0.00 28.18 ± 1.34 0.10 ± 0.00 0.49 ± 0.00 
K-09 0.86 ± 0.01 N/D 4.55 ± 0.20 N/D N/D N/D N/D 0.50 ± 0.00 0.99 ± 0.00 34.21 ± 1.45 0.41 ± 0.00 0.52 ± 0.00 
K-10 1.48 ± 0.02 N/D 17.54 ± 0.33 N/D N/D N/D N/D 0.42 ± 0.00 32.95 ± 1.06 19.26 ± 0.94 0.42 ± 0.00 N/D 
K-11 3.07 ± 0.05 N/D 18.64 ± 0.22 N/D N/D N/D N/D 0.66 ± 0.00 11.95 ± 0.92 23.87 ± 0.92 0.40 ± 0.00 N/D 
K-12 0.95 ± 0.00 5.89 ± 0.08 2.40 ± 0.04 N/D N/D N/D N/D 0.39 ± 0.00 14.97 ± 0.61 28.48 ± 0.83 N/D 0.49 ± 0.00 
K-13 0.81 ± 0.00 N/D 7.27 ± 0.35 N/D N/D N/D N/D 0.39 ± 0.00 19.23 ± 0.86 12.73 ± 0.89 0.47 ± 0.00 0.49 ± 0.00 
K-14 1.29 ± 0.04 N/D 11.37 ± 0.22 N/D N/D N/D N/D 0.60 ± 0.00 16.92 ± 0.75 27.74 ± 0.78 0.43 ± 0.00 0.53 ± 0.00 
K-15 2.47 ± 0.07 4.37 ± 0.09 8.12 ± 0.10 N/D N/D N/D N/D 2.11 ± 0.09 35.20 ± 1.05 17.00 ± 0.45 0.54 ± 0.00 0.50 ± 0.00 
K-16 2.17 ± 0.08 N/D 13.70 ± 0.52 N/D N/D N/D N/D 0.68 ± 0.00 6.04 ± 0.89 32.48 ± 1.33 0.39 ± 0.00 0.48 ± 0.00 
K-17 1.28 ± 0.05 3.88 ± 0.03 12.71 ± 0.69 N/D N/D N/D N/D 1.76 ± 0.08 27.49 ± 1.03 39.70 ± 2.03 0.42 ± 0.00 0.67 ± 0.00 
K-18 1.61 ± 0.08 4.35 ± 0.02 21.71 ± 0.51 N/D N/D N/D N/D 0.51 ± 0.00 37.95 ± 1.50 36.47 ± 1.89 N/D N/D 
C-01 N/D 3.54 ± 0.17 5.47 ± 0.05 7.95 ± 0.31 7.19 ± 0.09 7.58 ± 0.15 3.07 ± 0.16 6.88 ± 0.10 12.10 ± 0.61 0.33 ± 0.00 0.39 ± 0.00 0.50 ± 0.00 
C-02 0.63 ± 0.00 N/D 4.80 ± 0.12 6.61 ± 0.34 5.79 ± 0.05 7.29 ± 0.12 3.11 ± 0.13 18.86 ± 0.22 4.07 ± 0.45 11.07 ± 0.19 N/D 0.49 ± 0.00 
C-03 0.66 ± 0.00 N/D 7.26 ± 0.15 3.78 ± 0.40 4.41 ± 0.05 5.85 ± 0.12 2.60 ± 0.08 44.67 ± 1.02 2.48 ± 0.06 0.54 ± 0.00 0.39 ± 0.00 N/D 
C-04 0.63 ± 0.00 4.87 ± 0.10 6.00 ± 0.14 12.88 ± 0.45 11.77 ± 0.10 16.31 ± 0.42 4.55 ± 0.25 47.03 ± 1.09 3.20 ± 0.04 1.76 ± 0.00 0.39 ± 0.00 0.50 ± 0.00 
C-05 N/D 2.74 ± 0.05 4.78 ± 0.14 2.86 ± 0.05 3.38 ± 0.08 3.95 ± 0.09 2.45 ± 0.13 8.69 ± 0.27 2.10 ± 0.01 1.28 ± 0.03 0.39 ± 0.00 0.48 ± 0.00 
C-06 0.63 ± 0.00 N/D 5.61 ± 0.11 4.84 ± 0.12 6.01 ± 0.10 6.28 ± 0.11 2.89 ± 0.09 34.64 ± 0.33 3.61 ± 0.08 6.78 ± 0.22 0.39 ± 0.00 0.49 ± 0.00 
C-07 0.62 ± 0.00 2.42 ± 0.02 4.54 ± 0.12 5.19 ± 0.13 4.94 ± 0.07 4.20 ± 0.12 1.25 ± 0.07 48.64 ± 0.99 2.06 ± 0.06 1.44 ± 0.00 0.39 ± 0.00 0.48 ± 0.00 
C-08 N/D 2.20 ± 0.02 6.65 ± 0.20 5.00 ± 0.34 3.47 ± 0.04 4.36 ± 0.00 2.23 ± 0.04 47.85 ± 0.91 8.64 ± 0.14 3.46 ± 0.67 0.39 ± 0.00 0.10 ± 0.00 
C-09 N/D 1.95 ± 0.02 4.16 ± 0.10 9.79 ± 0.43 11.33 ± 0.24 16.04 ± 0.33 5.85 ± 0.22 39.86 ± 1.04 3.24 ± 0.07 2.48 ± 0.01 0.39 ± 0.01 0.55 ± 0.00 
C-10 N/D 2.21 ± 0.03 5.59 ± 0.15 6.82 ± 0.32 6.35 ± 0.02 8.77 ± 0.14 5.18 ± 0.14 43.21 ± 0.82 7.39 ± 0.11 2.27 ± 0.00 0.39 ± 0.00 N/D 
C-11 N/D 10.13 ± 0.52 7.78 ± 0.13 11.40 ± 0.51 6.28 ± 0.13 10.09 ± 0.23 3.27 ± 0.12 50.43 ± 1.45 4.62 ± 0.12 7.48 ± 0.11 0.39 ± 0.00 0.49 ± 0.00 
C-12 0.62 ± 0.00 5.54 ± 0.10 5.88 ± 0.14 9.82 ± 0.13 9.44 ± 0.23 11.01 ± 0.33 6.79 ± 0.26 27.94 ± 0.84 5.26 ± 0.09 5.12 ± 0.54 0.39 ± 0.00 0.78 ± 0.00 
C-13 N/D N/D 3.67 ± 0.10 18.99 ± 0.67 10.43 ± 0.15 9.65 ± 0.21 5.35 ± 0.10 50.94 ± 2.31 4.90 ± 0.10 38.06 ± 1.34 0.40 ± 0.00 0.57 ± 0.00 
C-14 0.61 ± 0.00 4.68 ± 0.08 3.59 ± 0.09 3.29 ± 0.09 3.41 ± 0.02 4.65 ± 0.04 1.41 ± 0.09 58.30 ± 0.99 5.91 ± 0.09 9.11 ± 0.58 0.38 ± 0.00 N/D 
C-15 N/D 1.89 ± 0.00 3.61 ± 0.11 13.63 ± 0.08 12.14 ± 0.14 16.79 ± 0.23 4.90 ± 0.20 47.06 ± 1.32 4.29 ± 0.09 2.68 ± 0.00 0.40 ± 0.00 0.61 ± 0.00 
C-16 N/D 10.42 ± 0.30 6.41 ± 0.18 26.13 ± 0.89 18.86 ± 0.23 16.76 ± 0.32 7.58 ± 0.32 42.77 ± 0.87 10.71 ± 0.11 21.28 ± 1.09 0.38 ± 0.00 0.49 ± 0.00 
C-17 N/D 3.15 ± 0.02 3.87 ± 0.09 20.59 ± 1.08 9.23 ± 0.90 5.35 ± 0.78 4.85 ± 0.89 16.68 ± 0.79 3.61 ± 0.09 12.65 ± 0.82 0.39 ± 0.00 0.50 ± 0.00 
C-18 0.86 ± 0.00 5.10 ± 0.09 5.16 ± 0.19 4.04 ± 0.04 3.75 ± 0.05 3.78 ± 0.01 1.31 ± 0.06 42.16 ± 1.14 3.44 ± 0.08 21.22 ± 0.99 N/D N/D 
C-19 N/D 2.11 ± 0.02 4.34 ± 0.11 7.51 ± 0.06 8.01 ± 0.13 8.42 ± 0.12 4.21 ± 0.14 46.42 ± 2.02 9.09 ± 0.11 13.81 ± 0.72 0.39 ± 0.00 0.57 ± 0.00 
C-20 N/D 1.95 ± 0.00 5.67 ± 0.08 5.44 ± 0.12 5.35 ± 0.12 7.36 ± 0.13 3.14 ± 0.10 44.74 ± 1.13 4.89 ± 0.21 4.42 ± 0.09 0.38 ± 0.00 0.50 ± 0.00 
C-21 N/D N/D 4.99 ± 0.12 6.13 ± 0.12 5.52 ± 0.12 5.67 ± 0.12 2.56 ± 0.07 26.11 ± 0.67 2.94 ± 0.08 2.16 ± 0.05 0.41 ± 0.00 0.68 ± 0.00 
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C-22 N/D 3.05 ± 0.09 4.02 ± 0.14 6.25 ± 0.23 4.37 ± 0.15 4.51 ± 0.19 1.15 ± 0.02 44.47 ± 0.82 5.20 ± 0.07 6.44 ± 0.06 0.39 ± 0.00 0.48 ± 0.00 
C-23 N/D 3.56 ± 0.02 4.57 ± 0.09 8.37 ± 0.54 8.95 ± 0.49 8.15 ± 0.89 3.20 ± 0.09 41.48 ± 0.83 4.47 ± 0.10 3.40 ± 0.01 0.40 ± 0.00 0.48 ± 0.00 
C-24 N/D 4.28 ± 0.02 3.52 ± 0.10 6.68 ± 0.23 7.52 ± 0.18 3.52 ± 0.04 3.86 ± 0.15 22.46 ± 0.71 3.77 ± 0.05 1.01 ± 0.00 N/D N/D 
C-25 N/D N/D 4.44 ± 0.07 5.20 ± 0.21 5.34 ± 0.04 6.25 ± 0.11 3.61 ± 0.14 18.85 ± 0.62 2.47 ± 0.04 6.50 ± 0.40 0.41 ± 0.00 0.48 ± 0.00 
C-26 N/D 2.05 ± 0.02 2.06 ± 0.02 9.83 ± 0.32 7.06 ± 0.09 8.82 ± 0.20 4.16 ± 0.21 48.76 ± 0.94 4.97 ± 0.02 6.70 ± 0.22 0.42 ± 0.00 0.49 ± 0.00 
C-27 N/D 3.43 ± 0.15 2.75 ± 0.08 5.37 ± 0.95 5.78 ± 1.01 6.98 ± 0.83 1.89 ± 0.07 51.60 ± 0.96 2.34 ± 0.01 0.94 ± 0.01 0.38 ± 0.00 0.49 ± 0.00 
C-28 N/D 6.32 ± 0.05 8.34 ± 0.20 6.84 ± 0.22 5.92 ± 0.13 8.31 ± 0.24 2.85 ± 0.05 19.78 ± 0.51 1.51 ± 0.00 1.03 ± 0.00 0.40 ± 0.00 N/D 
C-29 N/D 4.30 ± 0.02 5.66 ± 0.15 7.23 ± 0.24 8.46 ± 0.25 8.38 ± 0.26 3.89 ± 0.14 47.08 ± 0.73 7.42 ± 0.91 4.20 ± 0.51 0.40 ± 0.00 0.50 ± 0.00 
C-30 N/D 4.50 ± 0.02 5.88 ± 0.12 9.12 ± 0.31 12.79 ± 0.21 13.35 ± 0.47 5.39 ± 0.23 62.95 ± 1.65 14.45 ± 0.85 17.44 ± 0.99 N/D 0.49 ± 0.00 
C-31 N/D 4.75 ± 0.19 4.54 ± 0.11 5.01 ± 0.78 7.05 ± 0.89 6.74 ± 0.55 1.53 ± 0.09 56.42 ± 2.05 11.43 ± 0.79 24.24 ± 1.35 N/D 0.62 ± 0.00 
C-32 N/D 7.43 ± 0.05 8.74 ± 0.23 9.61 ± 0.29 9.02 ± 0.15 8.96 ± 0.22 3.46 ± 0.10 43.01 ± 1.05 3.23 ± 0.06 3.51 ± 0.01 0.39 ± 0.00 0.48 ± 0.00 
C-33 N/D 5.66 ± 0.05 8.45 ± 0.19 8.63 ± 0.24 7.91 ± 0.12 7.54 ± 0.34 3.30 ± 0.06 45.58 ± 2.01 3.68 ± 0.02 4.43 ± 0.06 0.41 ± 0.00 N/D 
C-34 N/D 3.46 ± 0.02 16.96 ± 0.50 5.34 ± 0.15 5.01 ± 0.12 4.64 ± 0.25 2.50 ± 0.04 23.00 ± 1.00 2.02 ± 0.01 0.74 ± 0.00 0.39 ± 0.00 N/D 
C-35 N/D N/D 5.17 ± 0.16 6.94 ± 0.11 4.23 ± 0.14 4.08 ± 0.09 2.07 ± 0.01 48.18 ± 0.73 6.31 ± 0.08 0.85 ± 0.00 0.39 ± 0.00 0.82 ± 0.00 
C-36 N/D 3.00 ± 0.02 3.72 ± 0.09 1.29 ± 0.05 1.56 ± 0.01 2.11 ± 0.02 1.28 ± 0.01 23.10 ± 0.53 1.65 ± 0.01 0.90 ± 0.00 N/D 0.49 ± 0.00 
C-37 N/D 13.86 ± 0.55 5.67 ± 0.09 10.99 ± 0.10 11.52 ± 0.22 16.12 ± 0.50 3.06 ± 0.07 38.50 ± 0.95 2.12 ± 0.04 0.49 ± 0.00 0.39 ± 0.00 N/D 
C-38 N/D 2.70 ± 0.07 8.36 ± 0.12 4.35 ± 0.46 3.05 ± 0.09   3.24 ± 0.07 1.30 ± 0.00 32.68 ± 0.86 4.36 ± 0.05 2.16 ± 0.01 N/D 0.49 ± 0.00 
C-39 0.92 ± 0.02 5.40 ± 0.08 6.13 ± 0.11 4.98 ± 0.14 6.47 ± 0.08 2.10 ± 0.00 0.53 ± 0.01 29.79 ± 0.51 8.25 ± 0.00 34.20 ± 1.22 0.41 ± 0.00 0.52 ± 0.00 
C-40 N/D 3.54 ± 0.05 5.47 ± 0.34 7.95 ± 0.37 7.19 ± 0.43 7.58 ± 0.58 3.07 ± 0.09 6.88 ± 0.32 12.10 ± 0.65 0.33 ± 0.00 0.39 ± 0.00 0.49 ± 0.00 
C-41 N/D N/D 4.04 ± 0.38 5.71 ± 0.28 5.61 ± 0.24 7.22 ± 0.46 2.26 ± 0.08 32.27 ± 1.59 3.26 ± 0.06 6.38 ± 0.88 N/D N/D 
C-42 N/D 13.57 ± 0.98 2.26 ± 0.08 1.99 ± 0.00  3.35 ± 0.18 4.85 ± 0.24 3.50 ± 0.12 5.86 ± 0.07 3.91 ± 0.07 0.52 ± 0.00 0.40 ± 0.00 N/D 
C-43 0.67 7.92 ± 0.56 12.22 ± 0.97 15.08 ± 0.79 15.54 ± 0.87 22.49 ± 1.08 4.86 ± 0.21 64.56 ± 2.08 12.89 ± 0.68 5.16 ± 0.50 N/D N/D 
Average K  
       1.55 ± 0.65 1.03 ± 2.01 12.08 ± 6.22 N/D N/D N/D N/D 0.78 ± 0.66 18.07 ± 14.03 28.16 ± 10.04 0.35 ± 0.20 0.40 ± 0.22 
Average C  
       0.16 ± 0.30 3.92 ± 3.36 5.65 ± 2.61 7.57 ± 4.65 7.09 ± 3.66 7.94 ± 4.68 3.19 ± 1.61 37.23 ± 15.45 7.49 ± 10.23 6.88 ± 8.93 0.31 ± 0.16 0.36 ± 0.26    
Average K: the average of Korean samples (K-01 ~ K18); Average C: the average of Chinese samples (C-01 ~ C43) 
N/D: Not detected 
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III. Simultaneous Analysis of Bioactive Metabolites from 
Ziziphus jujube byHPLC-DAD-ELSD-MS/MS   
A method based on HPLC-DAD-ELSD-MS/MS was established for the 
simultaneous determination of nine representative metabolites from semen 
Ziziphus jujuba. Validation parameters, such as linearity, limit of detection, 
limit of quantification, recovery, accuracy, and precision, were successfully 
obtained. In addition, the efficiencies of diverse extraction methods were 
compared for the development of a standard analytic method. The verified 
method was successfully applied to the quantitative determination of nine 
representative metabolites in twenty-four commercial samples of Z. jujuba 
var. spinosa and Z. mauritiana from different markets in Korea, China and 
Myanmar were analyzed and compared to each other. The analytical results 
showed that the contents of the nine analytes vary significantly with two 
different species.  
3-1. Introduction 
The dried seed of Ziziphus jujuba var. spinosa, which belongs to the 
Rhamnaceae, is listed in Korea and China Pharmacopeia. This plant is widely 
used as folk medicine for the treatment of insomnia and anxiety in clinical 
practice.107,108 However Ziziphus mauritiana, another species of this plant, not 
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listed in Pharmacopeia. But it is also used as herbal medicine. It is considered 
as counterfeit, because there are some differences in chemical constituent 
concentrations and pharmacological effects.109 
Many studies have demonstrated that semen Ziziphus jujuba 
processes multiple bioactivities such as nervine tonic, hypnotic-sedative, 
hypotensive, antihypoxia, antihyperlipidemia and hypothermic effects.107,108, 
110-112 Moreover, semen Ziziphus jujuba is beneficial to purify the blood, aid 
digestion and inhibit the inflammatory cells.113,114 
Up to now, there are many bioactive compounds have been reported 
such as cyclopeptide alkaloids, flavonoids,  saponins, fatty acids.115-119 From 
the prior researches, total saponins fraction including jujuboside A, 
jujuboside B, jujuboside D was the main pharmacological active compounds 
in the extracts of semen Ziziphus jujuba, which has been proved to prevent 
anoxemia of cardiac muscle, improve SOD activity,110 increase sleep time and 
lower hypelipemia,109 the cyclopeptide alkaloids, such as magnoflorine, has 
sedative activity,115 and flavonoids are responsible for the sedative activity.120-
123 In Chinese pharmacopeia, spinosin and jujuboside A were chosen as 
markers to estimate the quality of semen Ziziphus jujuba (Pharmacopeia 
Commission of PRC, 2010). However the curative effect of traditional herbal 
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medicine is an integrative result of a number of bioactive compounds. A 
single or a few compounds could not be responsible for the overall 
pharmacological activities. Simultaneous determination of multiple 
components is therefore a better strategy for the comprehensive quality 
evaluation. In present study, a HPLC-DAD-ELSD-MS/MS method was 
developed and validated for comparison of two species and simultaneous 
determination of nine bioactive components of semen Ziziphus jujuba, 
including one cyclopeptide alkaloid namely magnoflorine (45), five 
flavonoids namely isospinosin (46), spinosin (47), 6’’’-sinapoyl spinosin (48), 
6’’’-feruloyl spinosin (49), and 6’’’-coumaroyl spinosin (50), three 
triterpenoic saponins namely jujuboside A (51), jujuboside A2 (52), and 
jujuboside B (53) (Figure 30), The developed methods have been verified for 
their effectiveness against diverse validation parameters. In addition, the 
contents of bioactive compounds in twenty-four commercial samples of Z. 
jujuba var. spinosa and Z. mauritiana from different markets in Korea, China 
and Myanmar were analyzed and compared to each other. 
3-2. Experimental section 
Plant materials. Twenty-four samples of Ziziphus var. spinosa (Z-
1~Z-12) and Ziziphus mauritiana (Z-13~Z-24) grown in different regions 
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were provided by the National Center for Standardization of Herbal Medicine, 
such as Z-1 (Shandong, China), Z-2~Z-6 (unidentified area, China), Z-7 
(Hebei Province, Taiheng Mountain, China), Z-8 (Shanxi, China), Z-9 (Hebei, 
China), Z-10 ( Liaoning, China), Z-11~Z-12 (unidentified area, Korea), Z-
13~Z-16 (unidentified area, Korea), Z-17~Z-18 (unidentified area, China), 
and Z-19~Z-24 (unidentified area, Myanmar). 
Reagents, chemicals and samples - Magnoflorine (45), spinosin 
(46), isospinosin (47), 6’’’-sinapoyl spinosin (48), 6’’’-feruloyl spinosin (49), 
6’’’-coumaroyl spinosin (50), jujuboside A (51), jujuboside A2 (52), 
jujuboside B (53) isolated and purified from semen Ziziphus jujuba by a series 
of chromatographic procedures were provided  from National Center for 
Standardization of Herbal Medicine, Korea and the structures were elucidated 
by comparison of spectral data (UV, IR, MS, 1H-NMR, 13C-NMR) with the 
literature data.  The purities of these compounds were determined to be 
higher than 92 % by normalization of the peak area detection by HPLC-DAD-
ELSD analysis. Naringin as an internal standard compound was obtained 
from Sigma-Aldrich (USA).  
Methanol, acetonitrile, and water were HPLC grade purchased from 
Burdick & Jackson (USA) and ethanol (Duksan, Korea) was analytical grade. 
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Instrumentation and chromatographic conditions. The HPLC 
system was consisted of Agilent 1200 series equipped with an autosampler, a 
column oven, a binary pump, a diode array detector (Agilent Technologies, 
Waldbronn, Germany) , an ELSD detector (Agilent Technologies,1260 
Infinity) and a degasser (Agilent Technologies, Tokyo, Japan). The 
Chemstation software (Agilent Technologies, Avondale, CA, USA) was used 
to operate this HPLC-DAD-ELSD system. Separation was performed on a 
Shiseido CAPCELL PAK C18 5um (250 × 4.6 mm) analytical column. A 
gradient elution of A (water, 0.1% formic acid) and B (methanol, 0.1% formic 
acid) was used (0 min, 45% B; 25 min, 50% B; 40 min, 100% B; 50 min, 100% 
B; 55 min, 45% B in v/v). The analytes were monitored with DAD and ELSD. 
Standard or sample solutions of 10 µL were directly injected to the HPLC 
system and the mobile phase flow rate was 0.3 mL/min and the column 
temperature was set at 25 ℃. 
All ESI-MS and ESI-MSn spectra were acquired using a Finnigan 
MAT LCA ion-trap mass spectrometer (San Jose, CA, USA) equipped with a 
Finnigan electrospray source and capable of analyzing ions up to m/z 2000. 
Mass spectrometer conditions were firstly optimized using flow injection 
analysis of the standards without the HPLC column. The conditions were as 
follows: a sheath gas flow rate 60 arbitrary units, aux gas flow rate o arbitrary 
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units, capillary temperature 250 ℃, spray voltage 5kV, capillary voltage 39V, 
tube lens offset 55V. 
Preparation of test sample. In order to achieve quantitative 
extraction method, variables involved in the procedure such as extraction 
method, solvent, and extraction time were optimized. Ultrasonication, vortex 
and reflux methods were compared to each other for the selection of the 
optimal extraction method (Table 17) at 50 % aqueous methanol solvent for 
30 min. Aqueous methanol or ethanol solutions were tried as the extraction 
solvent (Table 18) using ultrasonication method at 30 min. Yields were also 
compared for the extraction times of 10, 20, 30, 60, and 90 min to determine 
the optimal extraction time (Table 19) using ultrasonication method at 50 % 
aqueous methanol. As a result, 50 % aqueous methanol for 30 min using 
ultrasonication was chosen for the best extraction condition for semen 
Ziziphus jujuba.  
Accurately weighed plant powder of 200 mg were extracted with 10 
mL of 50 % aqueous methanol, by means of sonication at room temperature 
for 30 min. After the filtration through 0.2 µm membrane filter, to an aliquot 
of 1 mL of the filtrate was added 10µg of internal standard compound, 




Calibration. Stock solution (1 mg/mL) of the magnoflorine (45), 
spinosin (46), isospinosin (47), 6’’’-sinapoyl spinosin (48), 6’’’-feruloyl 
spinosin (49), 6’’’-coumaroyl spinosin (50), jujuboside A (51), jujuboside A2 
(52), jujuboside B (53) isolated from semen Ziziphus jujuba were prepared 
individually in methanol, and different concentration (1,2, 4, 8, 15 and 20 
µg/mL) of these were loaded onto an HPLC for the preparation of the 
calibration function. The calibration function of individual compound was 
calculated with peak area (y), concentration (x, µg/mL), and mean values 
(n=3) ± standard deviation. 
3-3. Results and discussion 
For the simultaneously determination of nine bioactive compounds 
belonging to three kinds different chemical structures from alkaloid, 
flavonoid, and triterpenoid  in semen Ziziphus jujuba,  the  
chromatographic conditions were firstly investigated. Various mixtures of 
water, methanol and acetonitrile were tested as a mobile phase. The optimal 
wavelength for detection was tested at 210, 230, 250, 280, and 335 nm, 
respectively. Considering the significantly distinct UV maxima between the 
alkaloid and flavonoid chemical structure of analytes, optimum detection 
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wavelength was decided at 280 nm where of the six representative 
compounds showed relatively good absorptions. The parameters of ELSD 
such as nebulizing gas flow rate and drift tube temperature were optimized to 
obtain the best signals. In order to obtain highest signals at the lowest 
nebulizer gas flow rate, the optimized parameters of  ELSD used to analyse 
three triterpenoic saponin were as follows: drift tube temperature , 50℃; 
nebulizing gas flow rate, 39 psi. The temperature for detection was tested at 
25, 30, 35, 40, and 45℃. Optimum detection temperature was decided at 
25 ℃, where the baseline was stable and all of the compounds had good 
theoretical plate, capacity factor, separation factor, and resolution (Table 20). 
The presences of magnoflorine (45), spinosin (46), isospinosin (47), 6’’’-
sinapoyl spinosin (48), 6’’’-feruloyl spinosin (49), 6’’’-coumaroyl spinosin 
(50), jujuboside A (51), jujuboside A2 (52), jujuboside B (53) in semen 
Ziziphus jujuba were verified by comparing each retention time , UV and 
ELSD spectrum with those of each standard compound and spiking with 
authentic standards. As a result, a gradient methanol (0.1% formic acid) – 
water (0.1% formic acid) solvent system at 280 nm and 25 oC gave the desired 
separation within the running time of 50 min (Figure 31). 
A methanol stock solution, containing nine standard compounds, was 
prepared and diluted to a series of appropriate concentrations for the 
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construction of calibration curves. The curves showed good linearity and the 
correlation coefficients were found to be in the range of 0.995- 0.999 for all 
the compounds, over the concentration ranges 1 - 20 µg/mL. Limits of 
detection and limits of quantitation were determined by means of serial 
dilution based on a signal-to-noise (S/N) ratio of 3:1 and 10:1, respectively. 
LOD and LOQ were less than 0.895 and 2.712 µg/mL, respectively (Table 
21). 
The accuracy and precision tests were carried out by measurement of 
the intra-day and inter-day variability and recovery of these constituents. The 
measurement of intra-day and inter-day variability was utilized to determine 
the precision of this method. The intra-day variation was determined by 
analyzing in the triplicate same mixed standard methanol solution for three 
times within 1 day while for the inter-day variability test, the solution was 
examined in triplicate for consecutive 3 days. The average percentage 
recoveries were evaluated by calculating the ratio of detected amount versus 
the added amount and the mean recovery of each compound was 92.76 -
104.32 %. The relative standard deviation (RSD) was taken as a tool of 




Since the chromatographic peaks could not be identified 
unambiguously only by retention time and UV spectra in HPLC, HPLC - 
DAD - MS/MS was used as a supplement for confirmation of peak 
identification, by comparing the retention time, molecular ion and fragment 
pattern. In this experiment, mass spectral conditions were optimized in 
positive-ion mode and nine compounds exhibited distinct quasi-molecular 
ions ([M+Na+], [M+]) in this mode (Table 23). In HPLC-ESI- MS spectra, 
molecular ion and fragmentation pattern of each compound were well 
matched with chemical structures (Figure 32). Throughout these results, nine 
standard compounds were identified in the extract of Z. semen and the 
specificity of each peak for 45-53 was clearly demonstrated. 
 The developed method was applied for the measurement of 
concentration of standard components in commercial semen Ziziphus jujuba. 
Twelve samples of Ziziphus var. spinosa from various areas of China and 
Korea, and twelve samples of Ziziphus. mauritiana from China, Korea and 
Myanmar were analyzed. The test samples were prepared as described for the 
development of analytical method and injected in triplicate. The results are 
summarized in Table 24. It was found that contents of standard compounds in 
various regional samples vary significantly by sources. Jujuboside A2, which 
could be well detected in Z. var. spinosa (0.010 ± 0.006), could not be detected 
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in Z. mauritiana. The contents of magnoflorine (0.461 ± 0.183 %), jujuboside 
A (0.063 ± 0.033 %) and jujuboside B (0.043 ± 0.017 %) in Z. var. spinosa 
were much higher than magnoflorine (0.217 ± 0.023 %), jujuboside A (0.001 
± 0.004 %), and jujuboside B (0.015 ± 0.260 %) in Z. mauritiana. However, 
the contents of spinosin (0.146 ± 0.025 %), 6’’’-sinapoyl spinosin (0.006 ± 
0.009 %) and 6’’’-feruloyl spinosin (0.065 ± 0.015 %) in Z. var. spinosa were 
much lower than spinosin (0.210 ± 0.034 %), 6’’’-sinapoyl spinosin (0.029 ± 
0.030 %) and 6’’’-feruloyl spinosin (0.091 ± 0.021) in Z. mauritiana. The 
contents of isospinosin and 6’’’-coumaroyl spinosin from the two sources 
differentiated, but unremarkably. These results clearly demonstrated the 
significant differences in bioactive components between two different species. 
There was no big difference between Chinese and Korean regions from the 
same source. Overall, based on nine standard compounds, HPLC-DAD-
ELSD methods we developed can confirm two species easily and swiftly. 










Figure 31. HPLC chromatograms of extract of crude sample and standard 






Figure 32. Total ion chromatograms of semen Ziziphus jujuba in SIM mode 









Table 17. Comparison of effectiveness by extraction method (w/w, %, n=3) 
Compounds Vortex  Reflux Sonication 
45 0.611 ± 0.000 0.645 ± 0.002 0.678 ± 0.001 
46 0.025 ± 0.000 0.023 ± 0.000 0.025 ± 0.000 
47 0.151 ± 0.000 0.147 ± 0.000 0.146 ± 0.000 
48 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 
49 0.056 ± 0.000 0.051 ± 0.000 0.060 ± 0.000 
50 0.028 ± 0.000 0.028 ± 0.000 0.026 ± 0.000 
51 0.074 ± 0.000 0.085 ± 0.000 0.078 ± 0.003 
52 0.013 ± 0.000 0.013 ± 0.000 0.013 ± 0.000 
















Table 18. Comparison of effectiveness by extraction solvent (w/w, %, n=3) 
Compounds 70%Methanol 50%Methanol 70%Ethanol 50%Ethanol 
45 0.532 ± 0.000 0.678 ± 0.001 0.643 ± 0.001 0.505 ± 0.001 
46 0.023 ± 0.000 0.025 ± 0.000 0.022 ± 0.000 0.021 ± 0.000 
47 0.142 ± 0.000 0.146 ± 0.000 0.144 ± 0.000 0.134 ± 0.000 
48 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 
49 0.053 ± 0.000 0.060 ± 0.000 0.056 ± 0.000 0.054 ± 0.000 
50 0.027 ± 0.000 0.026 ± 0.000 0.028 ± 0.000 0.023 ± 0.000 
51 0.060 ± 0.001 0.078 ± 0.003 0.068 ± 0.002 0.073 ± 0.000 
52 0.011 ± 0.000 0.013 ± 0.000 0.012 ± 0.000 0.012 ± 0.000 













Table 19. Comparison of effectiveness by extraction time (w/w, %, n=3) 
Compounds 10 min 20 min 30 min 60 min 90 min 
45 0.594 ± 0.001 0.661 ± 0.001 0.676 ± 0.001 0.653 ± 0.001 0.594 ± 0.001 
46 0.022 ± 0.000 0.024 ± 0.000 0.025 ± 0.000 0.021 ± 0.000 0.022 ± 0.000 
47 0.140 ± 0.000 0.155 ± 0.000 0.145 ± 0.000 0.130 ± 0.000 0.140 ± 0.000 
48 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 0.002 ± 0.000 
49 0.055 ± 0.000 0.059 ± 0.000 0.055 ± 0.000 0.046 ± 0.000 0.055 ± 0.000 
50 0.022 ± 0.000 0.021 ± 0.000 0.025 ± 0.000 0.028 ± 0.000 0.022 ± 0.000 
51 0.067 ± 0.000 0.077 ± 0.001 0.075 ± 0.002 0.067 ± 0.003 0.067 ± 0.003 
52 0.012 ± 0.000 0.012 ± 0.000 0.013 ± 0.000 0.011 ± 0.000 0.012 ± 0.000 



















45 46 47 48 49  50 51      52 53 
Theoretical 
plates (N) 


































































































         
25 5.08±0.00 14.24±0.04 15.82±0.04 20.75±0.05 22.48±0.05 24.45±0.23 32.97±0.03 33.39±0.07 33.81±0.03 
30 5.01±0.06 13.36±0.25 14.70±0.28 19.22±0.27 20.77±0.28 22.37±0.26 32.77±0.00 33.17±0.00 33.61±0.00 
35 4.87±0.04 12.39±0.21 13.50±0.25 17.63±0.25 18.99±0.26 20.35±0.25 32.58±0.01 33.00±0.00 33.42±0.00 
40 4.76±0.03 11.57±0.20 12.48±0.23 16.25±0.25 17.45±0.26 19.17±0.34 32.40±0.01 32.84±0.02 33.26±0.01 
45 4.64±0.03 10.84±0.17 11.59±0.20 15.03±0.23 16.08±0.24 18.76±0.29 32.19±0.01 32.66±0.00 33.07±0.00 
Separation 
factor (α) 
         
25 - 2.80±0.01 1.11±0.00 1.16±0.01 1.08±0.00 1.08±0.00 1.85±0.01 1.01±0.00 1.01±0.00 
30 - 2.67±0.02 1.11±0.00 1.15±0.00 1.08±0.00 1.08±0.00 1.98±0.02 1.01±0.00 1.01±0.00 
35 - 2.54±0.02 1.09±0.00 1.14±0.00 1.08±0.00 1.09±0.00 2.13±0.02 1.01±0.00 1.01±0.00 
40 - 2.43±0.02 1.08±0.00 1.14±0.00 1.07±0.00 1.09±0.00 2.29±0.03 1.01±0.00 1.01±0.00 
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25 - 24.94±0.21 3.31±0.02 5.16±0.02 3.11±0.01 3.21±0.02 50.23±0.04 2.09±0.04 2.67±0.01 
30 - 25.39±0.72 3.14±0.07 5.01±0.06 3.04±0.03 3.19±0.04 58.94±0.02 2.23±0.04 2.40±0.04 
35 - 24.92±0.32 2.86±0.08 4.74±0.05 2.92±0.02 2.85±0.03 62.15±0.05 2.41±0.08 2.25±0.01 
40 - 24.12±0.48 2.56±0.08 4.47±0.05 2.75±0.03 2.69±0.02 72.65±0.02 2.42±0.01 2.36±0.03 
45 - 23.25±0.61 2.27±0.10 4.24±0.10 2.60±0.06 2.63±0.01 79.71±0.03 2.65±0.03 2.42±0.01 
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Regression equationa) r2 LOD b) (μg/ml) LOQc) (μg/ml) 
45 1~20 Y=0.02713X - 0.00701 0.9995 0.064 0.195 
46 1~20 Y=0.05764X - 0.00891 0.9999 0.046 0.141 
47 1~20 Y=0.06347X - 0.02215 0.9992 0.027 0.083 
48 1~20 Y=0.15388X - 0.03322 0.9997 0.019 0.059 
49 1~20 Y=0.07367X - 0.01395 0.9999 0.023 0.071 
50 1~20 Y=0.06247X - 0.02431 0.9994 0.030 0.092 
51 1~20 Y=0.33170X - 0.57136 0.996 0.895 2.712 
52 1~20 Y=0.33922X - 0.59272 0.995 0.787 2.383 
53 1~20 Y=0.29968X - 0.50443 0.996 0.833 2.526 
a )y: peak area, x: concentration of the analyte (µg/mL). 
b)LOD, limit of detection.  
















Intra-day (n = 3) Inter-day (n = 3) 
Recovery (%) RSD (%) Recovery (%) RSD (%) 
 10 97.77 0.37 98.07 1.30 
45 14 98.43 0.41 98.38 0.61 
 17 98.41 0.09 98.51 0.47 
 2 92.99 2.38 92.76 3.20 
46 4 95.11 0.82 94.41 0.31 
 8 95.48 0.34 95.63 0.75 
 4 98.42 0.10 98.35 0.61 
47 8 98.04 0.69 97.94 0.67 
 12 98.89 0.59 98.37 0.54 
 2 96.54 1.47 96.08 1.23 
48 4 95.89 0.84 96.73 0.96 
 8 96.21 0.35 96.53 0.52 
 2 102.44 1.55 100.35 1.11 
49 4 101.65 1.36 100.32 1.38 
 8 99.37 0.82 98.76 0.42 
 2 98.35 0.95 99.34 0.35 
50 4 96.43 0.56 98.12 0.55 
 8 99.23 0.43 94.19 0.47 
 20 99.29 2.66 100.59 1.48 
51 40 99.61 2.55 98.19 1.89 
 80 96.47 0.49 97.88 1.25 
 10 100.17 1.39 102.55 2.00 
52 20 102.17 2.64 100.09 1.80 
 40 104.32 1.68 103.03 1.13 
 10 98.93 0.77 102.39 3.03 
53 20 98.10 2.65 97.97 1.38 
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Table 23. HPLC-MS/MS Data of the nine standard compounds 
Peak No. MWa) MS (m/z) MS/MS (m/z) C.Eb) Ion mode Identification 
45 342 342 297 29 positive magnoflorine 
46 608 631 469 30 positive isospinosin 
47 608 631 469 33 positive spinosin 
48 814 837 451 33 positive 6'''-sinapoyl spinosin 
49 784 807 451 31.3 positive 6'''-feruloyl spinosin 
50 754 777 451 31.3 positive 6'''-coumaroyl spinosin 
51 1207 1230 757 33 positive jujuboside A 
52 1207 1230 757 33 positive jujuboside A2 
53 1045 1068 935 34 positive jujuboside B 
a) molecular weight. 




Table 24. Content of nine compounds in samples of twenty-four commercial products from diverse sources (w/w, %) 
sample 45 46 47 48 49 50 51 52 53 
Z-1 0.537 ± 0.001 0.020 ± 0.000 0.132 ± 0.000 0.002 ± 0.000 0.048 ± 0.000 0.009 ± 0.000 0.078 ± 0.003 0.013 ± 0.000 0.048 ± 0.001 
Z-2 0.601 ± 0.001 0.015 ± 0.000 0.136 ± 0.000 0.002 ± 0.000 0.079 ± 0.000 0.009 ± 0.000 0.085 ± 0.000 0.000 ± 0.000 0.042 ± 0.000 
Z-3 0.368 ± 0.000 0.034 ± 0.000 0.160 ± 0.000 0.002 ± 0.000 0.058 ± 0.000 0.011 ± 0.000 0.092 ± 0.000 0.014 ± 0.000 0.070 ± 0.000 
Z-4 0.296 ± 0.000 0.019 ± 0.000 0.160 ± 0.000 0.009 ± 0.000 0.067 ± 0.000 0.014 ± 0.000 0.045 ± 0.000 0.012 ± 0.000 0.035 ± 0.000 
Z-5 0.656 ± 0.001 0.016 ± 0.000 0.138 ± 0.000 0.002 ± 0.000 0.072 ± 0.000 0.010 ± 0.000 0.072 ± 0.000 0.012 ± 0.000 0.053 ± 0.000 
Z-6 0.098 ± 0.000 0.006 ± 0.000 0.140 ± 0.000 0.012 ± 0.000 0.036 ± 0.000 0.007 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.011 ± 0.000 
Z-7 0.452 ± 0.001 0.017 ± 0.000 0.127 ± 0.000 0.002 ± 0.000 0.063 ± 0.000 0.008 ± 0.000 0.053 ± 0.000 0.015 ± 0.000 0.036 ± 0.000 
Z-8 0.576 ± 0.001 0.020 ± 0.000 0.146 ± 0.000 0.002 ± 0.000 0.076 ± 0.000 0.015 ± 0.000 0.086 ± 0.000 0.013 ± 0.000 0.047 ± 0.000 
Z-9 0.191 ± 0.000 0.013 ± 0.000 0.219 ± 0.000 0.031 ± 0.000 0.092 ± 0.000 0.016 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.015 ± 0.000 
Z-10 0.556 ± 0.000 0.021 ± 0.000 0.128 ± 0.000 0.002 ± 0.000 0.056 ± 0.000 0.010 ± 0.000 0.090 ± 0.000 0.013 ± 0.000 0.061 ± 0.000 
Z-11 0.581± 0.001 0.027 ± 0.000 0.140 ± 0.000 0.002 ± 0.000 0.065 ± 0.000 0.011 ± 0.000 0.086 ± 0.002 0.015 ± 0.000 0.049 ± 0.002 
Z-12 0.623± 0.001 0.019 ± 0.000 0.131 ± 0.000 0.002 ± 0.000 0.064 ± 0.000 0.011 ± 0.000 0.072 ± 0.001 0.016 ± 0.000 0.044 ± 0.001 
Z-13 0.236 ± 0.001 0.013 ± 0.000 0.222 ± 0.000 0.028 ± 0.000 0.087 ± 0.000 0.016 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.014 ± 0.000 
Z-14 0.165 ± 0.000 0.014 ± 0.000 0.260 ± 0.001 0.036 ± 0.000 0.106 ± 0.000 0.018 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.015 ± 0.000 
Z-15 0.220 ± 0.000 0.013 ± 0.000 0.178 ± 0.000 0.025 ± 0.000 0.072 ± 0.000 0.011 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.015 ± 0.000 
Z-16 0.242 ± 0.000 0.020 ± 0.000 0.222 ± 0.000 0.028 ± 0.000 0.082 ± 0.000 0.014 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.014 ± 0.000 
Z-17 0.235 ± 0.000 0.012 ± 0.000 0.222 ± 0.000 0.031 ± 0.000 0.096 ± 0.000 0.018 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.014 ± 0.000 
Z-18 0.200 ± 0.000 0.008 ± 0.000 0.199 ± 0.000 0.023 ± 0.000 0.081 ± 0.000 0.012 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.013 ± 0.000 
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Z-19 0.201 ± 0.000 0.013 ± 0.000 0.175 ± 0.000 0.028 ± 0.000 0.094 ± 0.000 0.020 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.014 ± 0.000 
Z-20 0.229 ± 0.000 0.014 ± 0.000 0.178 ± 0.000 0.031 ± 0.000 0.085 ± 0.000 0.018 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.014 ± 0.000 
Z-21 0.234 ± 0.001 0.016 ± 0.000 0.234 ± 0.000 0.031 ± 0.000 0.107 ± 0.000 0.017 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.016 ± 0.000 
Z-22 0.232 ± 0.000 0.022 ± 0.000 0.211 ± 0.000 0.028 ± 0.000 0.096 ± 0.000 0.015 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.015 ± 0.000 
Z-23 0.210 ± 0.000 0.014 ± 0.000 0.218 ± 0.000 0.032 ± 0.000 0.094 ± 0.000 0.015 ± 0.000 0.000 ± 0.000 0.000 ± 0.000 0.015 ± 0.000 













The purpose of this work is the development of simultaneous analysis 
methods of all bioactive compounds in herbal medicines. The methods based 
on HPLC-DAD-ELSD-MS were established for the quantitative and 
qualitative analysis of two selected herbal medicines.  
Various validation parameters, such as linearity, limit of detection, 
limit of quantification, recovery, accuracy, and precision, were successfully 
obtained. In addition, the efficiencies of diverse extraction methods were 
compared for the development of a standard analytic method. The verified 
methods were successfully applied to the quantitative determination of 
representative metabolites in commercial samples from Korea, Myanmar, and 
China. 
These results have successfully demonstrated the potential of using 





During the four and half years of the Doctor of Philosophy studies, 
effort is focused on the study of isolation of secondary metabolites from 
marine-derived fungi and development of quantitative and qualitative 
analysis methods of herbal medicines.  
To achieve isolation and structure determination of novel substances 
from marine organisms, more than two hundred fungal strains were isolated 
from the sea sediments and marine organisms which collected from various 
locations of southern coast of Korea and two of them were selected for 
chemical investigation on the basis of LC-ESIMS analysis and bioactivity 
tests. From two selected marine-derived fungi, 18 compounds have been 
isolated and 9 new ones among these have been structurally elucidated by 
combined spectroscopic and chemical analysis. The structures of these 18 
compounds belonged to diverse structural classes with various biogenetic 
origins. Diverse bioassay tests related to anticancer, antimicrobial, and 
enzyme-inhibitory activities have been performed. Some of the isolated 
compounds showed potent bioactivities in quinone reductase and anticancer 
towards to HCT116, SNU638, SK-HEP1, MDA-MB231 cell lines. One of 
compound was studied vivo test on mice. Structure-activity relationships 
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were also deduced. 
In addition to chemical investigation of marine fungi, the standard 
methods based on HPLC-DAD-ELSD-MS was established for the 
simultaneous analysis of two selected herbal medicines. Based upon the prior 
researches, all standard compounds which have significant bioactivities and 
large contents were analyzed. Diverse validation parameters, such as linearity, 
limit of detection, limit of quantification, recovery, accuracy, and precision, 
were successfully obtained and the efficiencies of diverse extraction methods 
were compared. The developed methods were successfully applied to the 
quantitative determination of representative metabolites in commercial 
samples from Korea and China. 
1. Penicillipyrones A and B, Meroterpenoids from the Marine-derived 
Fungus Penicillium sp. 
Two novel meroterpenoids, Penicillipyrones A (1) and B (2), together 
with methyl 8-hydroxy-6-methyl-9-oxo-9H-xanthene-1-carboxylate (3) and 
coniochaetone B (4) were isolated from the marine-derived fungus 
Penicillium sp.. Based upon the results of combined spectroscopic analyses, 
these compounds were structurally elucidated to be triprenyl γ-lactones from 
a new skeletal class derived from a unique pattern of linkage between the 
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prenyl and pyrone moieties.  
The new compounds exhibited weak cytotoxicities against K562 and 
A549 cell lines. However, compounds 1 and 2 were inactive (MIC > 100 
μg/mL) against various Gram-positive and Gram-negative bacteria and 
pathogenic fungi. Compound 2 also elicited a significant induction of quinone 
reductase. Contrastingly, compound 1, which possessed the 3-hydroxy group, 
failed to show a noticeable induction in the given concentration, implying that 
the ketone moiety at C-3 of 2 plays a crucial role in its QR inducing activity. 
Therefore, the significant induction of penicillipyrone B (2) with significant 
induction of QR may be suggestive of a potential role in cancer prevention. 
2. Alkaloidal Metabolites from a Marine-Derived Aspergillus sp. Fungus 
Fumiquinazoline S (5), a new quinazoline-containing alkaloid, and 
the known fumiquinazolines F (10) and L (11) of the same structural class 
were isolated from the solid-substrate culture of an Aspergillus sp. fungus 
collected from marine-submerged wood. In addition, isochaetominines A-C 
(6-8) and 14-epi-isochaetominine C (9), new alkaloids possessing an unusual 
amino acid-based tetracyclic core framework related to the fumiquinazolines, 
and together with nidurufin (12), versiconol (13), sterigmatocystin (14), 7-
deoxysterigmatocystin (15), and isobenzofuranone (16) were isolated from 
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the same fungal strain. The structures of these compounds were determined 
by combined spectroscopic methods, and the absolute configurations were 
assigned by NOESY, ROESY and advanced Marfey’s analyses along with 
biogenetic considerations.  
The new compounds exhibited weak inhibition against Na+/K+-
ATPase. In our measurement of cytotoxicity, however, 5-11 were inactive (5-
9: IC50 > 13-50 μM, 10 and 11: IC50 > 100 μΜ) against the K562 and A549 
cell lines. In the antimicrobial activity tests against selected strains of Gram-
positive and Gram-negative bacteria and pathogenic fungi, only compound 
10 displayed weak inhibition (MIC 50 μΜ) against Bacillus subtilis. These 
alkaloids also exhibited a weak inhibition (IC50 were 34, 78, 20, 38, 57, 17, 
and 20 M for 5-11, respectively) against Na+/K+-ATPase. None of these 
compounds were active against the enzymes sortase A or isocitrate lyase. 
3. Asperphenins A and B, lipopeptides as anticancer agents from a 
Marine-Derived Aspergillus sp. Fungus 
Asperphenins A (17) and B (18), two new lipopeptide containing 
aromatic compounds were isolated from the marine-derived fungus 
Aapergillus sp.. Based upon the results of combined spectroscopic analyses, 
these compounds were structurally elucidated to be lipopeptide containing the 
 
168 
phenone function group, the first example of this type. 
 In our bioactivity measurement, compounds 17-28 were studied 
toward the A549, HCT116, SNU638, SK-HEP1, and MDA-MB 231. 
Asperphenins A (17) and B (18) were significantly ative against HCT116, 
moderately active toward the SNU638, SK-HEP1, and MDA-MB 231, and 
weak activity toward the A549. However, the cycloasperphenins A (19) and 
B (20) were inactive toward all the cell lines, and 7-ketone reduction of 
asperphenins A (21, 22) and B (23) were inactive toward the A549 and MDA-
MB 231, and weak toward HCT116, SNU638 and SK-HEP1. And 7-ketone 
reduction of asperphenin B (24) and 7,15-diketone reduction of asperphenins 
A (26) and B (27, 28) were inactive toward all the cell lines. The results 
implied that the 7-ketone and 15-ketone played the important role for 
activities against A549, HCT116, SNU638, SK-HEP1, and MDA-MB 231. 
Morever, the asperphenin B (18) was studied as the antitumor agent on RKO 
cell-implated xenografts. Asperphenin B exhibited significant inhibition of 
colon cancer. At a concentration of 8mg/kg, the inhibition rate was 68.7%, 
which was approached the inhibition rate of irinotecan with the 4 mg/kg. And 
the combination of asperphenin B and irinotecan improved the inhibition to 
86.9%. Therefore, the significant inhibition toward the colon cancer by 
asperphenin B may be suggestive of a potential role in anticancer drug. The 
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mechanism of anti-colon cancer of asperphenin B is futher being studied. 
4. Quantification and Identification of Bioactive Metabolites from 
Kalopanacis Cortex by HPLC with Evaporative Light Scattering 
Detection and ESI Quadrupole TOF MS 
A method based on HPLC-ELSD-Q-TOF-MS was established for the 
simultaneous determination of twelve bioactive metabolites from the 
Kalopanacis Cortex. Validation parameters, such as linearity, limit of 
detection, limit of quantification, recovery, accuracy, and precision, were 
successfully obtained. In addition, the efficiencies of diverse extraction 
methods were compared for the development of a standard analytic method. 
The verified method was successfully applied to the quantitative 
determination of twelve representative metabolites in sixty-one Kalopanacis 
Cortex samples from Korea and China. The quantitation results demonstrated 
that six compounds, coniferin (33), kalopanaxsaponin C (40), septemlosides 
II (38), III (36), C (39), and D (37), which exhibited distinct regional patterns 
in KC samples, could serve as marker compounds to distinguish KC from 




5. Simultaneous Analysis of Bioactive Metabolites from Ziziphus jujube 
by HPLC-DAD-ELSD-MS/MS 
A method based on HPLC-DAD-ELSD-MS/MS was established for 
the simultaneous determination of nine representative metabolites from 
semen Ziziphus jujuba. Validation parameters, such as linearity, limit of 
detection, limit of quantification, recovery, accuracy, and precision, were 
successfully obtained. In addition, the efficiencies of diverse extraction 
methods were compared for the development of a standard analytic method. 
The verified method was successfully applied to the quantitative 
determination of nine representative metabolites in twenty-four commercial 
samples of Z. jujuba var. spinosa and Z. mauritiana from different markets in 
Korea, China and Myanmar were analyzed and compared to each other. The 
analytical results showed that the contents of the nine analytes vary 
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B1. Biological Assays Methods 
Cytotoxicity assays, antimicrobial assays, and isocitrate lyase, 
sortase A, and Na+/K+-ATPase inhibition assays were performed as described 
previously.21, 42, 45, 47, 49 For the cytotoxicity test, an MTT viability assay was 
performed as previously described with slight modifications.47 MTT was first 
prepared as a stock solution of 5 mg/mL in phosphate buffered saline (PBS, 
pH 7.2) and was filtered. At the end of the treatment period (24 h, 48 h, and 
72 h), with three different test drug concentrations in triplicate, MTT solution 
(20 μL) was added to each well and then incubated for 4 h at 37 °C; then 
solubilizing buffer (10% sodium dodecyl sulfate dissolved in 0.01 N HCl, 100 
μL) was added to each well. After overnight incubation, the 96-well plate was 
read by an enzyme-linked immunosorbent assay (ELISA) reader at 570 nm 
for absorbance to determine the cell (A549 cell line and/or K562) viability. 
The viable cells produced a dark blue formazan product, whereas no such 
staining was formed by dead cells. The LC50 value was defined as the 
concentration that resulted in a 50% decrease in cell viability compared to 
that of control reactions in the absence of an inhibitor. The values (mean ± 
SD) were calculated from the dose–response curves of three concentrations 
of each test sample in three independent experiments (n = 3).  
Quinone reductase (QR) activity. Hepa 1c1c7 cells were purchased 
from American Type Culture Collection (ATCC CRL-2026) and were grown 
in alpha minimum essential medium without nucleosides, supplemented 
with 2 mM glutamine, 100 U/mL penicillin G, 100 μg/mL streptomycin and 
10% fetal bovine serum. Cultures were maintained at 37 oC in a 5% CO2/95% 
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air atmosphere. QR activities were determined spectrophotometrically 
according to the reported microtitre method with some modification. Hepa 
1c1c7 cells were plated at a density of 1.0 × 104 cells/mL and were grown 
for 24 h in a humidified incubator in a 5% CO2 at 37 
oC. The cells were 
exposed to test compounds, and then incubated for an additional 24 h. After 
the plates had been exposed to the test sample for 24 h, the media were 
decanted, and the cells were lysed by incubation at 37 oC for 10 min with 
250 μL in each well of a solution containing 10 mM Tris-HCl, pH 8.0, 140 
mM NaCl, 15 mM MgCl2, and 0.5% NP-40 (IGEPAL CA-630) (Sigma, St 
Louis, MO). The plates were then agitated on an orbital shaker for an 
additional 10 min at 25 oC, after which 1 mL of the complete reaction 
mixture was added to each well. The final assay mixture contained 10 mM 
Tris-HCl, pH 7.4, 0.5 mg/mL bovine serum albumin (BSA), 0.008% Tween-
20, 40 μM flavin adenine dinucleotide (FAD), 0.8 mM glucose-6-phosphate, 
2 U/mL glucose-6-phosphate dehydrogenase, 25 μM NADP, 40 μg/mL 3-
(4,5-dimethylthiazo-2-yl)-2,5-(diphenyltetrazolium bromide) (MTT), and 1 
mM menadione. A blue colour developed and the reaction was stopped after 
5 min by addition of 250 μL of a solution containing 0.3 mM dicoumarol in 
0.5% pyridine and 5 mM potassium phosphate, pH 7.4. The rate of the 
NADPH-dependent, menadiol-mediated reduction of MTT was measured at 
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610 nm. Protein was determined by crystal violet staining of an identical set 
of test plates. The specific activity (SA) of quinone reductase (nmol/min/mg 
of protein) was calculated from the equation: 
SA = [MTTabs/CVabs] × 3,345 
where MTTabs is the absorbance change of MTT per min; CVabs is the 
absorbance of crystal violet; and 3,345 is the ratio of the proportionality 
constant determined for crystal violet and the extinction coefficient of MTT, 














B2. Computational Calculation of Compounds 5, 6, and 9. 
Computational analysis. The groud-state geometries were optimized with 
density functional theory (DFT) calculations, using Turbomole 6.5 at the 
basis set def-SV(P) for all atoms and functional B3LYP/DFT level, the 
ground states were further confirmed by the harmonic frequency calculation. 
Lowest energy conformations were calculated for the structures of 
compounds 5 with 3S, 14R, 17R, 18R, and 20S configurations, 6 with 2R, 3R, 
11S, and 14R configurations, and 9 with 2R, 3R, 11S, and 14S configurations. 
The DFT settings (functional B3-LYP/Gridsize M3) and geometry 
optimization options (energy 10-6 hartree, gradient norm │dE / dxyz│ = 10-3 
hartree/bohr) were used. 






Compound 5 (3S, 14R, 17R, 18R, and 20S configurations) 
total energy      =  -1579.61023575168 
------------------------------------------------------ 
kinetic energy    =   1564.99522787312 
potential energy  =  -3144.60546362481 
 
The result of DFT calculation of compound 6 (left) and 9 (right). 
   
Left; compound 6 (2R, 3R, 11S, and 14R configurations) 
total energy      =  -1367.31823420808 
----------------------------------------------------- 
kinetic energy    =   1354.91548967183 
potential energy  =  -2722.23372387990 
 
Right; compound 9 (2R, 3R, 11S, and 14S configurations) 




kinetic energy    =   1432.44233243421 
potential energy  =  -2878.29551976129 
 





















































K-01 10H1001 C-04 10H3025 C-25 10H2029 
K-02 10H1007 C-05 10H2024 C-26 10H2030 
K-03 10H1026 C-06 10H2002 C-27 10H2034 
K-04 10H1027 C-07 10H2003 C-28 10H2035 
K-05 10H1031 C-08 10H2008 C-29 10H2036 
K-06 10H1032 C-09 10H2010 C-30 10H2037 
K-07 10H1039 C-10 10H2011 C-31 10H2038 
K-08 10H2005 C-11 10H2012 C-32 10H2043 
K-09 10H2006 C-12 10H2013 C-33 10H2044 
K-10 10H2007 C-13 10H2014 C-34 10H2045 
K-11 10H2009 C-14 10H2015 C-35 10H2046 
K-12 10H2032 C-15 10H2017 C-36 10H2049 
K-13 10H2033 C-16 10H2018 C-37 10H2054 
K-14 10H2053 C-17 10H2019 C-38 10H2039 
K-15 10H2052 C-18 10H2020 C-39 10H2004 
K-16 10H2001 C-19 10H2021 C-40 10H2016 
K-17 10H2040 C-20 10H2022 C-41 10H2041 
K-18 10H2042 C-21 10H2023 C-42 10H2050 
C-01 10H2016 C-22 10H2025 C-43 10H2051 
C-02 10H3023 C-23 10H2027   





Table S2. Comparison of effectiveness of KC metabolites by extraction 
method (mg/g, n = 3). 
Compounds Sonication Vortex Reflux 
33 0.92 ± 0.02 0.73 ± 0.01 0.89 ± 0.02 
34 5.40 ± 0.08 5.41 ± 0.07 5.15 ± 0.07 
35 6.13 ± 0.11 5.93 ± 0.11 6.23 ± 0.10 
36 4.98 ± 0.14 4.32 ± 0.12 5.03 ± 0.10 
37 6.47 ± 0.08 6.15 ± 0.09 6.27 ± 0.10 
38 2.10 ± 0.00 2.00 ± 0.01 1.90 ± 0.01 
39 0.53 ± 0.01 0.54 ± 0.01 0.51 ± 0.00 
40 29.79 ± 0.51 29.34 ± 0.49 29.42 ± 0.55 
41 8.25 ± 0.00 8.14 ± 0.09 8.20 ± 0.10 
42 34.20 ± 1.22 34.01 ± 1.25 34.00 ± 1.01 
43 0.41 ± 0.00 0.42 ± 0.00 0.41 ± 0.00 



















Table S3. Comparison of effectiveness of KC metabolites by extraction 
solvent (mg/g, n = 3). 
Compounds 70% MeOH 50% MeOH 70% EtOH 50% EtOH 
33 0.88 ± 0.02 0.92 ± 0.02 0.79 ± 0.03 0.82 ± 0.05 
34 5.38 ± 0.10 5.40 ± 0.08 5.14 ± 0.12 5.30 ± 0.18 
35 6.02 ± 0.09 6.13 ± 0.11 5.93 ± 0.08 6.10 ± 0.16 
36 4.57 ± 0.15 4.98 ± 0.14 4.59 ± 0.11 4.97 ± 0.09 
37 6.45 ± 0.13 6.47 ± 0.08 6.21 ± 0.18 6.10 ± 0.21 
38 2.02 ± 0.01 2.10 ± 0.00 2.10 ± 0.02 2.15 ± 0.02 
39 0.53 ± 0.01 0.53 ± 0.01 0.51 ± 0.01 0.48 ± 0.01 
40 29.22 ± 0.49 29.79 ± 0.51 29.24 ± 0.62 29.39 ± 0.58 
41 8.37 ± 0.08 8.25 ± 0.00 8.20 ± 0.10 8.32 ± 0.10 
42 33.94 ± 1.34 34.20 ± 1.22 34.34 ± 1.32 34.25 ± 1.03 
43 0.39 ± 0.01 0.41 ± 0.00 0.40 ± 0.00 0.38 ± 0.02 



















Table S4. Comparison of effectiveness of KC metabolites by extraction time 
(mg/g, n = 3). 
Compounds 10 min 20 min 30 min 60 min 90 min 
33 0.72 ± 0.02 0.81 ± 0.02 0.92 ± 0.02 0.92 ± 0.02 0.87 ± 0.04 
34 4.87 ± 0.07 5.33 ± 0.08 5.40 ± 0.08 5.39 ± 0.05 5.23 ± 0.10 
35 5.67 ± 0.09 5.94 ± 0.11 6.13 ± 0.11 6.07 ± 0.07 6.07 ± 0.13 
36 4.17 ± 0.08 4.75 ± 0.14 4.98 ± 0.14 4.89 ± 0.09 4.68 ± 0.09 
37 6.02 ± 1.00 6.23 ± 0.08 6.47 ± 0.08 6.38 ± 0.11 6.24 ± 0.11 
38 1.90 ± 0.01 2.00 ± 0.01 2.10 ± 0.00 2.11 ± 0.01 2.02 ± 0.00 
39 0.50 ± 0.01 0.53 ± 0.01 0.53 ± 0.01 0.50 ± 0.01 0.43 ± 0.01 
40 29.00 ± 0.57 29.46 ± 0.65 29.79 ± 0.51 29.67 ± 0.76 29.54 ± 0.71 
41 7.39 ± 0.08 7.95 ± 0.10 8.25 ± 0.00 8.20 ± 0.02 8.25 ± 0.10 
42 34.01 ± 1.01 34.18 ± 1.20 34.20 ± 1.22 34.25 ± 1.34 33.87 ± 1.45 
43 0.32 ± 0.01 0.41 ± 0.01 0.41 ± 0.00 0.40 ± 0.01 0.31 ± 0.00 












1. “Comparative Analyses of Bioactive Constituents from Forsythia suspensa 
and Forsythia viridissima by HPLC-DAD” Won, T. H.; Liao, L.; Lee, S. 
H.; Son, J. K.; Shin, J. Nat. Prod. Sci. 2011, 17, 328-336. 
2. “Simultaneous Analysis of Bioactive Metabolites from Ziziphus jujuba by 
HPLC-DAD-ELSD-MS/MS” Liao, L.; Won, T. H.; Kang, S. S.; Shin, J. 
J. Pharm. Investig. 2012, 42, 21-31.  
3. “New Polyaromatic Metabolites from a Marine-Derived Fungus 
Penicillium sp.” Julianti, E.; Lee, J.-H.; Liao, L.; Park, W.; Park, S.; Oh, 
D.-C.; Oh, K.-B.; Shin, J. Org. Lett. 2013, 15, 1286-1289. 
4. “Simultaneous Analysis of Furfural Metabolites from Rehmanniae Radix 
Preparata by HPLC-DAD-ESI-MS” Won, T. H.; Liao, L.; Kang, S. S.; 
Shin, J. Food Chem. 2014, 142, 107-113. 
5. “Cytotoxic Diterpenoid Pseudodimers from the Korean Sponge Phorbas 
gukulensis” Jeon, J.-e.; Liao, L.; Kim, H.; Sim, C. J.; Oh, D.-C.; Oh, K.-
B.; Shin, J. J. Nat. Prod. 2013, 76, 1679-1685. 
 
214 
6. “Penicillipyrones A and B, Meroterpenoids from a Marine-Derived 
Penicillium sp. Fungus” Liao, L.; Lee, J.-H.; You, M.; Choi, T. J.; Park, 
W.; Lee, S. K.; Oh, D.-C.; Oh, K.-B.; Shin, J. J. Nat. Prod. 2014, 77, 406-
410.  
7. “Quantification and Identification of Bioactive Metabolites from 
Kalopanacis Cortex by HPLC with Evaporative Light Scattering 
Detection and ESI Quadrupole TOF MS” Liao, L.; Won, T. H.; Kim, Y. 
H.; Shin, J. J. Sep. Sci. 2014, 37, 505-514. 
8. “Alkaloidal Metabolites from a Marine-Derived Aspergillus sp. Fungus” 
Liao, L.; You, M.; Chung, B. K.; Oh, D.-C.; Oh, K.-B.; Shin, J. J. Nat. 
Prod. 2015, 78, 349-354. 
9. “Lumazine Peptides from the Marine-Derived Fungus Aspergillus terreus” 
You, M.; Liao, L.; Hong, S. H.; Park, W.; Kwon, D. I.; Lee, J.; Noh, M.; 







I would like to thank all who in one way or another helped me during 
my four and a half years Ph.D study in Seoul National University and 
contributed in the completion of this thesis. 
First and foremost the deepest gratitude must go to my advisor 
Professor Jongheon Shin for his guidance, caring, patience, encouragement, 
immense knowledge, and financial supportment during my research to finish 
the thesis. I could not have imagined having a better advisor and mentor for 
my Ph.D study. 
I would also like to express the gratitude to the Professor Ki-Bong 
Oh, who provided the biological assays and the identification of fungi strains 
for my thesis.  
And I would like to thank Professor Dong-Chan Oh, whose valuable 
guidance on the fungi strains’ selection based on his professional knowledge 
and the LC-EISMS data interptation and encouragement when I was in 
difficulties.  
Thanks will also go to Professor Sang-Jip Nam and Professor Sung 
Won Kwon for their best suggestions as committee on my defense.  
 
216 
I wish I can express my sincere gratitude to Professor Sang Kook Lee 
for his biological assays and Professor Yeong Shik Kim for his excellent and 
deep lectures.  
I want to express my warm and deep gratitude to all the lab members 
for their friendships and assistances: Song Jueun, Oh Ikhoon, Elin Julianti, 
Jeon Ju-eun, Won Tae Hyung, Lee Jung-Ho, Oh Hana, Lee Sooryun, Lee 
Yoonyeong, Song Jinhaeng, Riswanto, Kim Chang-Kwon, Song Inn-Hye, 
Woo Jung-Kyun, You Minjung, Kim Hyung Joong, Cho Hyun Joo, Ryu Yeon 
Hwa, Kwon O Seok, Woo Yeon Soo, Yun Jung-Ho, and Hwang Ji Yeon. 
I wish to extend my warmest thanks to all the NMR and IR/MS 
operators in the College of Pharmacy and National Center for Inter-University 
Research Facilities for their providing data for all the tested samples. 
I especially appreciate my husband (for his encouragement and 
financial supportment), my lovely baby (she is my motivation and the source 
of enthusium), my parents (for their encouragement and well undserstanding), 
my mother-in-law (for her kindness and help me care the baby), my elder 
sister and young brother (for their encouragement).   
